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Abstract 
Background: Two-thirds of Canadian adults currently do not receive the annual influenza 
vaccine. Vaccine hesitancy (VH), the voluntary delay or refusal of vaccination services despite 
availability is a significant contributor to the poor uptake of several vaccines including the 
influenza vaccine. The overarching intent of this thesis was to gain a nuanced understanding of 
the community pharmacists’ experiences with influenza VH and explore means to best address it. 
Methods: This thesis is comprised of three studies. The first study was a quantitative descriptive 
analysis of an exploratory cross-sectional online survey of 885 pharmacists. This study aimed to 
provide an overview of pharmacists’ perceived knowledge, attitudes and practices pertaining to 
influenza VH. The second study was a qualitative interpretive analysis of in-depth semi-
structured interviews with 22 pharmacists. An implementation science lens was then used to 
examine the results from the first two studies to guide the selection of a behavioural target and 
inform intervention design. Based on these findings, the third study included a cost-utility 
analysis of a novel remunerated community pharmacist consultation service on influenza 
vaccination for Ontario seniors from a provincial payer perspective. 
Results: Pharmacists’ self-reported knowledge of influenza vaccine and disease, their 
confidence and ability to identify and address influenza VH was generally high. Pharmacists’ 
engagement with patients on the influenza vaccine was found to be modulated by a complex and 
mutually reinforcing constellation of attitudes and behaviours which included: a binary (pro-
vaccine or anti-vaccine) perception of patient vaccination decisions; a conflation of those 
expressing hesitancy with those that are anti-vaccine; and a passive approach to patient 
  v 
engagement. Despite possessing the requisite knowledge and skills, workflow barriers such as 
limited time, inadequate staffing, and poor remuneration were found to restrict optimal patient 
engagement on influenza vaccinations. Offering pharmacists a CAD $15 consultation fee to 
engage with seniors on the influenza vaccine was estimated to be both cost-effective and 
clinically effective. 
Conclusion: Facilitating optimal practice scope for pharmacists, and capitalizing the additional 
convenience and accessibility offered through the community pharmacy setting presents a 
promising means to address influenza VH. Conventional tools to aid health professionals in 
addressing influenza VH rely on augmenting the vaccine provider’s knowledge and skills; 
however, our analysis suggests that reorienting efforts to enhance the provider’s motivation and 
opportunity to engage with patients on influenza vaccine conversations are likely to be more 
effective in the community pharmacy setting. 
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 Chapter 1 
Introduction 
The worldwide success of vaccination programs and the consequent decline in outbreaks of 
devastating vaccine preventable diseases (VPDs) are amongst the foremost achievements in 
public health.1 Vaccination programs have resulted in the global eradication of diseases such as 
smallpox and have averted significant morbidity and mortality from several others.2 However, 
the continued sustenance of these achievements relies on a high public acceptance and uptake of 
vaccines and vaccination services. In recent times, the clustered outbreaks of VPDs suggest a rise 
in a concerning trend, termed ‘vaccine hesitancy’ (VH). VH refers to the voluntary delay or 
refusal of vaccination services despite availability.3-5 Consequently, the World Health 
Organization (WHO) in 2019 identified VH among the top 10 threats to global health.4 
Influenza, commonly referred to as flu, is a vaccine preventable infectious disease of the 
respiratory system. It is estimated that 10-20% of the world’s population is infected with the 
influenza virus every year.6,7 Among the leading causes of death, annual influenza outbreaks 
result in over 3,500 deaths and 12,000 hospitalizations across Canada.8-10 In addition to the 
immense clinical burden, influenza is also associated with a significant social burden and indirect 
costs through lost productivity.11 A 2018 study estimated the indirect costs of seasonal influenza 
in the United States to be USD $8.0 billion, more than twice the estimated costs of direct medical 
care.12 The prime preventive measure against influenza, the influenza vaccine, is available to all 
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Ontarians free of charge from a variety of healthcare providers including pharmacists,13,14 yet, 
vaccination rates remain suboptimal.15  
Vaccines are widely recognized by healthcare authorities throughout the world as an effective 
way to combat vaccine preventable infectious diseases. They are effective both at the individual 
level through direct protection and at the community level through herd immunity.16,17 A 
Cochrane meta-analysis conferred a 73% (95% CI, 54% to 84%) risk reduction in the 
development of influenza amongst vaccinated individuals as compared to those unvaccinated.18 
The protective efficacy of the influenza vaccine depends upon the closeness of the match 
between strains in the vaccine and those circulating in the community. Influenza viruses mutate 
their antigenic properties that result in susceptibility of the population to viruses containing novel 
antigens. Additionally, vaccine induced effects wane over the year following immunization. 
Therefore, annual immunization with influenza vaccine is an important public health measure in 
controlling influenza outbreaks.6 
Regardless of the wealth of scientific evidence that supports and promotes vaccination as the 
prime preventative measure against VPDs, conflicting information invariably makes its way to 
the public. Such information often disputes the scientific concord on the safety and effectiveness 
of some or all vaccines on a number of grounds, ranging from moral, to religious and pseudo-
scientific factors.19 Additionally, acceptance of vaccines in a timely manner is further 
compounded by issues such as complacency, a low perceived susceptibility and severity of a 
VPD, contradicting scientific notions and negative messaging from vaccine related controversies, 
and wide distribution of content critical of vaccines through social media.20 Perhaps, it is only 
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understandable that some individuals become ‘hesitant’ about their decision to vaccinate. While 
the majority of the population worldwide accepts routine vaccination, a small fraction decline 
vaccines entirely, delay them or accept them, without being entirely convinced doing so.3  
VH, public mistrust of immunization services and outright refusal of vaccines are global issues 
that threaten to undermine decades of progress in public health.19 The WHO recognizing the 
same established the Strategic Advisory Group of Experts (SAGE) on VH in March 2012. The 
working group submitted its final report on VH in October 2014, defining the phenomenon as, 
‘[a]delay in acceptance or refusal of vaccines despite availability of vaccination services. 
Vaccine hesitancy is complex and context specific, varying across time, place and vaccines. It is 
influenced by factors such as complacency, convenience and confidence’3,21 
 
Figure 1-1 The continuum of VH3 
VH may be a consequence of the growth of ‘consumerism’ in healthcare, that involves a focus 
on lifestyle and individual action and involvement in health decisions. The rise of the informed 
patient has shifted the traditional locus of power from physicians as sole directors of patient care 
to shared decision making between healthcare professionals and patients who want to be active 
participants in the decision-making process concerning their health.22 Questions regarding the 
benefits, safety and the very need of vaccines may be put forth by those expressing hesitancy.23,24 
Hesitancy to certain aspects of vaccination may be harbored even in individuals who are 
 
 
Accept all vaccines   Accept some, delay some, refuse some   Refuse all vaccines 
                  [Accept but unsure - - - Undecided - - - Refuse but unsure] 
Vaccine hesitancy continuum 
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vaccinated.20 While not exhaustive, the list of 21 unique determinants identified by the WHO 
working group on VH that range from historical influences, to politics, and beliefs and attitudes 
about health and prevention, underscore the complexity of this phenomenon.3,21 In addition to an 
increase in the rate of an unvaccinated subpopulation in the community, long term concerns of 
VH also include a risk of deficit in herd immunity and a possibility of VPD outbreak.25 The 
recent outbreak of measles in 2014, resulted in confirmed cases across the USA, Canada and 
Mexico.5,26 Among most reported cases, patients were either unvaccinated or had undocumented 
vaccination status.26 This multi-nation public health incident was all linked to one sick teenage 
tourist.27 This incident serves to highlight the highly contagious nature of VPDs, the importance 
of vaccination, and the very real threat of VPD resurgence.  
Therefore, improving vaccine uptake by untangling the barriers to immunization is paramount to 
preventing such occurrences and improving and sustaining vaccine coverage of the community. 
However, the complex, context specific, and dynamic nature of VH makes designing a single 
intervention to address hesitancy difficult to achieve.23,25,28 Traditionally socio-economic factors 
have direct associations with health behaviours, however, factors such as education, higher 
economic status, higher health literacy have all been identified as both promoters and barriers to 
vaccination based on the region, and the prevailing context.21 Despite this complexity, healthcare 
providers remain the most trusted advisors and influencers of patient vaccination decisions.29-32  
The provision of information is a primary tool adopted by healthcare providers when 
communicating with patients. Fundamental information on the need, benefits and risks of 
receiving the vaccine often form the basis of an individual’s decision-making process.28 The 
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impact of physician, nurse, and pharmacist recommendations on vaccine uptake has been well 
documented.33-40 Provider recommendation is a strong motivator to receive a vaccine. For 
example, 87.5% of children were immunized against influenza when their parents received a 
provider recommendation, compared to 10.6% in the absence of any recommendation.41 
Similarly, a randomized controlled trial evaluating the impact of pharmacist administered 
education and advocacy on influenza vaccine for seniors, determined an 8.7% increase in the 
vaccine uptake over one season.35 Indeed, healthcare provider recommendations, education, and 
advocacy form the current best predictors of positive patient vaccine uptake.29-32 Therefore, 
provider-patient interactions on vaccinations are important opportunities where patient concerns 
may be discussed and resolved, paving the way for vaccine recommendations and 
administrations to occur.  
Pharmacists in Ontario have been authorized to administer influenza vaccinations since 2012,42 
with the rationale that community pharmacy-based influenza immunization services would 
increase the capacity of provincial immunization efforts and increase patient access and 
convenience. Community pharmacies are accessible with extended work hours (i.e., evenings 
and weekends), and often vaccinations are offered on a walk-in basis.43-45 Indeed, the inclusion 
of pharmacists in the immunization workforce has resulted in a net increase of almost 500,000 
influenza vaccinations in Ontario in just over two seasons since pharmacist delivered influenza 
immunizations first became available.11 In a survey of pharmacy patrons conducted in Toronto, 
Ontario, 7% of the respondents reported being first-time vaccine recipients, and about a third 
responded that they would not have been vaccinated that year if pharmacy vaccination services 
were unavailable.45 Such data provides a glimpse of the impact pharmacists have had on 
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influenza vaccination in Ontario. By virtue of their standing in the community and opportunity 
for frequent patient contact, pharmacists are ideally positioned to address influenza VH; 
however, ensuring optimal utilization of this opportunity requires preparing and enabling 
pharmacists to best address the challenge of VH. 
To ensure a healthy uptake of vaccination services, the needs of the public and the gaps in the 
service must be explored. VH is complex and multifactorial, comprising emotional, cultural, 
cognitive, and political factors that make it difficult to characterize. Therefore, an important first 
step towards managing VH lies in understanding the time, context and vaccine specific nature of 
this phenomenon. Influenza VH in the community pharmacy is a unique dynamic involving the 
vaccine hesitant individual, pharmacy as the healthcare delivery setting and the pharmacists’ 
skills including their knowledge of VH, awareness of existing tools to address VH, and attitudes 
towards personal and patient vaccine uptake. This body of work aims to explore and understand 
the community pharmacy context of the experience of influenza VH, current practices used by 
pharmacists to overcome influenza VH, and explore potential gaps and opportunities in the 
pharmacists’ management of those expressing hesitancy. 
1.1  Statement of problem 
The emergence of VH as a global health threat calls for research to better understand, and 
thereby, address this phenomenon. Given the extensive individual and societal benefits of 
influenza vaccination, its sub-optimal utilization in a country like Canada, where it is readily 
available and accessible is an avoidable tragedy.  
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The addition of pharmacists to the immunizing work force in Ontario has resulted in improved 
accessibility and convenience. Pharmacists have long been recognized amongst the most 
trustworthy professionals and are often the first point of contact for many health-related concerns 
in the general population.46-48 Unsurprisingly, pharmacists have become an integral part of the 
immunization workforce, with community pharmacies becoming the leading destination to 
receive an influenza vaccination in Canada.49  
Existing research in the domain of VH has predominantly explored childhood immunizations, 
parental hesitancy and patient perspectives on vaccinations. 32,38,50-57 From a provider’s 
standpoint, research has also been conducted to understand the experiences of general 
practitioners, pediatricians, nurses, and midwives on vaccinations.58-63 However, to the best of 
our knowledge, little is known about community pharmacists’ experiences of influenza VH, their 
perceived preparedness, and current practices when dealing with those expressing hesitancy. 
As such, there is a distinct lack of evidence to inform the design of effective interventions 
specifically tailored to the pharmacy setting. This ongoing predicament motivates the focus of 
our research to understand the manifestation of influenza VH in the community pharmacy setting 
from a practicing pharmacist’s perspective; and, employ this nuanced understanding to identify 
means to best address the challenges of influenza VH in the community pharmacy context.  
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1.2 Thesis objectives 
The overarching intent of this thesis is to understand the community pharmacists’ experience of 
influenza VH, including their perceived preparedness and explore means to best address 
influenza VH in community pharmacy practice. In doing so, the objectives are to: 
1. Explore community pharmacists’ self-reported knowledge and practices related to 
influenza vaccination and influenza VH. 
2. Understand community pharmacists’ perspectives of, and experiences with influenza VH 
in routine practice. 
3. Understand the modulators of pharmacists’ engagement with individuals expressing 
hesitancy to receive the influenza vaccine in community pharmacy. 
4. Estimate the cost-effectiveness of a novel remunerated community pharmacist 
consultation service on influenza vaccination for seniors in Ontario, Canada from a 
provincial public-payer perspective. 
1.3 Thesis outline 
This thesis adopts a sandwich style, wherein individual research chapters (Chapters 3-5) have 
been written as independent, self-contained manuscripts. 
Chapter 2 – A review of pertinent literature. 
Chapter 3 – A quantitative descriptive analysis of a cross-sectional survey of community 
pharmacists.  
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Exploring influenza vaccine hesitancy in community pharmacies: Descriptive analysis of 
knowledge, attitudes and practices of community pharmacists in Ontario, Canada. 
Chapter 4 – A qualitative interpretive analysis of semi-structured interviews with community 
pharmacists. 
Shades of gray in vaccination decisions - Understanding community pharmacists’ 
perspectives of, and experiences with, influenza vaccine hesitancy in Ontario, Canada. 
Chapter 5 – A pharmacoeconomic analysis of a novel intervention. This chapter includes a brief 
prologue, setting the stage and rationale for the selection and design of the intervention. 
Cost-utility analysis of offering a novel remunerated community pharmacist consultation 
service on influenza vaccination for seniors in Ontario, Canada. 
Chapter 6 – Overall summary, practice and policy implications and conclusion.  
Appendices – Survey questionnaire; Semi-structured interview guide and coding scheme; 
Survey and interviews - Participant recruitment materials and informed consent forms. 
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 Chapter 2  
Review of literature 
2.1 Burden of Influenza 
Influenza is an infectious disease of the respiratory system caused by Influenza A or B viruses, 
belonging to the Orthomyxoviridae family.64 Epidemics and outbreaks of influenza occur in 
varying patterns depending on the region in the world. In Canada, influenza generally occurs 
each year in the late fall and winter months.65,66 It is characterized by sudden onset of headache, 
chills, cough, fever, loss of appetite, myalgia, sneezing, rhinitis, fatigue, throat irritation and 
watery eyes. Nausea, vomiting and diarrhea may also occur, especially in children. 
Seasonal influenza is primarily transmitted through direct or indirect contact with infected 
respiratory secretions.65 The incubation period is usually two days, but can range from one to 
fourteen days.65 Additionally, adults may continue to shed the virus a day before the onset to 
approximately five days after resolution of symptoms.65 Most individuals recover from influenza 
within a week to ten days, however some – including individuals aged 65 and above, and adults 
and children with chronic conditions are at an elevated risk of potentially fatal complications 
such as pneumonia.66  
Among the leading causes of death in Canada, influenza is estimated to affect 10-20% of the 
Canadian population, resulting in approximately 12,200 hospitalizations and 3,500 deaths each 
year.66 Unfortunately, these numbers do not depict the complete picture as laboratory 
confirmation is seldom performed and clinical diagnosis often takes precedence in practice. 
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Additionally, patients that present to hospital with complications of influenza such as 
pneumonia, after viral shedding has ceased, are difficult to identify and are not captured in the 
numbers above. Rates of infection are highest in children aged 5-9 years, but serious illness and 
death are highest in children aged below two and elderly aged over 65 years and individuals with 
underlying medical conditions.65,66  
The national economic burden associated with the direct medical care costs of influenza adjusted 
for inflation (2019 CAD) is estimated to be $71 million. 65,66 In addition to the immense 
economic and clinical burden, influenza is also associated with significant social burden and 
indirect costs through lost productivity.11 A 2018 study estimated the indirect costs of seasonal 
influenza in the United States to be USD $8.0 billion, more than twice the estimated costs of 
direct medical care.12 
2.2  Influenza vaccination – An effective countermeasure 
Annual influenza vaccination is an important public health countermeasure against influenza.16,17 
The influenza virus, a single-stranded, helically shaped RNA virus has three basic antigen types 
A, B and C.64,65 Subtypes of Influenza A are determined by the surface proteins hemagglutinin 
(A) and neuraminidase (N).65 The protection provided by a typical influenza vaccine is 
dependent on the induction of virus neutralizing antibodies, primarily against the viral 
hemagglutinin.65  
Hemagglutinin and neuraminidase periodically change, which is attributed to point mutations in 
a gene segment, this phenomenon is referred to as the antigenic drift. In addition, at irregular 
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intervals of 10 to >40 years, major antigenic differences may occur as a result of genetic 
recombination between Influenza A viruses that affect humans and/or animals, referred to as 
antigenic shift. Antigenic shift may result in worldwide pandemic if the virus is efficiently 
transmitted. The 2009 Influenza A (H1N1) outbreak is the last recorded instance of such 
phenomenon.67 This represented the first pandemic of the 21st century, affecting individuals 
across the globe, including 214 countries, territories and communities.67,68 An estimated 60 
million individuals were affected causing 270,000 hospitalizations and 12,500 deaths in the 
United States alone.67,69  
The protective efficacy of the influenza vaccine is determined by the closeness of match between 
the strains in the vaccine and the viruses that circulate in the outbreak.65 Influenza vaccines have 
traditionally been produced in embryonated chicken eggs that take approximately nine months to 
manufacture, and as such contain antigens from strains that circulated the previous season.65 
During the 2004-2005 influenza season, the estimated strain match was only 5% as compared to 
91% in 2006-2007, translating into vaccine effectiveness of 10% (95% CI, -36% to 40%) and 
52% (95% CI, 22% to 70%) respectively.70 Annual immunization is necessary even if one or 
more of the circulating strain was part of the previous vaccine due to waning of vaccine-induced 
antibody during the year following vaccination.65 Regardless of vaccine match, the National 
Advisory Committee on Immunization (NACI) appointed by the Public Health Agency of 
Canada (PHAC) strongly recommends annual influenza vaccination for all individuals aged 6 
months and above as vaccinated individuals are still more likely to be protected compared to 
those who are unvaccinated.65 
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The vaccine effectiveness depends on several factors that include inter-individual variations such 
as age, presence of chronic conditions, medications and other factors, the match between the 
vaccine and circulating strain, the definition of disease used (laboratory confirmed versus 
influenza like illness – ILI) and the vaccine itself. The vaccine is available in a number of forms, 
including Inactivated Influenza Vaccine (IIV), Live Attenuated Influenza Vaccine (LAIV), high 
dose vaccine, and standard dose vaccine. In those over the age of 65 years, the high dose IIV has 
been demonstrated to offer better protection against ILI and improved clinical outcomes such as 
lower rate of hospitalization and mortality compared to standard dose IIV.71 A Cochrane 
systematic review looking at published evidence through July 2017 estimated the risk reduction 
offered by the IIV for healthy adults to be 0.41 (95% CI, 0.36 to 0.47) against laboratory-
confirmed influenza and, 0.84 (95% CI, 0.75 to 0.95) against ILI.65,72,73 A 2012 meta-analysis 
that included eight randomized controlled trials of the IIV in adults aged between 18 and 64 over 
nine influenza seasons attributed a vaccine efficacy of 59% (95% CI, 51% to 67%) in preventing 
laboratory-confirmed influenza.74 Given the moderate overall effectiveness of the influenza 
vaccine, infection may occur in some individuals despite vaccination. This limitation of vaccine 
effectiveness often forms an underpinning of hesitant and anti-vaccine behaviour.  
2.2.1  Cost-effectiveness 
The cost-effectiveness of the influenza vaccine has been extensively evaluated in several 
studies.75-78 In the high risk elderly population, the medical care costs saved by preventing 
influenza associated complications provided compelling rationale to endorse the annual influenza 
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vaccination.78 Further, the indirect benefits such as prevention of suffering, incapacity and lost 
wages offset the cost of immunization in healthy adults and non-high risk elderly patients.11,78  
A cost-effectiveness analysis based on 10 years of surveillance data from the World Health 
Organization (WHO) among healthy working adults was conducted in 2005. The study 
accounted for inter seasonal variability in effectiveness of the influenza vaccine. A cost of 234 
USD per person per year for anti-viral therapy without vaccination and 239 USD per person per 
year for annual vaccination was estimated. However, sensitivity analyses of the data that 
incorporated the lower cost of the vaccine, high annual probability of influenza and higher 
number of work-days lost to influenza made influenza vaccination more cost-effective than 
treatment.77 An economic appraisal of the Ontario Universal Influenza Immunization Program 
(UIIP) compared to the previous targeted immunization program found the UIIP reduced 
mortality by 28% and overall cases of influenza by 61%.79 Another study also found a reduction 
in the number of antibiotic prescriptions during periods of peak influenza activity since the 
implementation of UIIP.80  
2.2.2  Adverse reactions 
The IIV is generally well tolerated. Most side effects are mild and transient such as soreness at 
the injection site (64% incidence).81 Healthy adults receiving the IIV did not display an increase 
in the frequency of febrile illness or other systemic symptoms compared to placebo. 65  
The multi-dose formulations of IIV authorized for use in Canada contain Thiomersal82, a 
preservative. Large cohort studies of health-databases have demonstrated no relationship 
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between Thiomersal and neurodevelopmental disorders such as Autism.82,83 However, all single 
dose formulations of  Trivalent Inactivated Vaccine (TIV) and LAIV are Thiomersal free.  
Influenza vaccination has been on occasions linked to an increased risk of Guillain-Barre` 
Syndrome (GBS).84,85 A self-matched case series study conducted in Ontario identified 1601 
hospitalized cases of GBS of which 269 were diagnosed within 43 weeks of vaccine 
administration. The estimated relative incidence of GBS during the primary risk interval (weeks 
2-7) as compared to control interval (week 20-43) was 1.45 (95% CI, 1.05–1.99).85 However, a 
separate time-series analysis showed no statistically significant increase in hospitalization for 
GBS after introduction of the universal influenza vaccination program.85 
Occulorespiratory Syndrome, characterized by bilateral red eyes, cough, wheeze, chest tightness, 
dyspnea, dysphagia, hoarseness, sore throat and/or facial swelling within a day of influenza 
immunization was reported following receipt of TIV supplied by one manufacturer during 2000-
2001 influenza season in British Columbia. 86 However, after changes in the manufacturing 
process to the vaccine formulation, the incidence dropped substantially.  
In summary, the influenza vaccine is differentiated from other vaccines through the need for 
annual re-immunization and the inter-seasonal variation in its efficacy and clinical effectiveness. 
It is rarely associated with serious side-effects and is generally safe. Despite some limitations, 
vaccination against influenza remains the current best measure to protect individuals and the 
community at large, from the vast clinical, societal, and economic burden of influenza disease. 
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2.2.3  Influenza vaccinations in Ontario and Canada 
In Ontario, the influenza vaccine is provided through the Ministry of Health and Long-Term 
Care (MOHLTC) in form of the annual UIIP. The UIIP is a first of its kind publicly funded 
program that was started in the fall of 2000.87 Through the program, the influenza vaccine is 
available free of charge to all individuals over 6 months of age living, working or attending 
schools in Ontario.88 The service is accessible through participating pharmacies (that utilize 
pharmacists authorized to administer injections or other trained professionals); public health 
units; on-site clinics; long-term care homes; nurse practitioners; or physician offices. The 
program recommends the prioritization of high-risk groups such as seniors aged 65 years and 
over, pregnant women, individuals with chronic cardiac or pulmonary disorders and individuals 
with immune compromising conditions. Additionally, UIIP provides the ‘Flu consult kit’ for 
vaccine providers that includes fact-sheets, posters and other promotional and targeted 
material.89  
The introduction of the UIIP in Ontario was associated with an increase in vaccine uptake, 
reduction in mortality (RR=0.26), hospitalization (RR=0.25) and physician office visits 
(RR=0.21).90 However, the initial increase in influenza vaccine uptake was followed by a decline 
and subsequent plateauing of vaccination rate. For example, the vaccination rates dropped over a 
period of 10 years; from 38% in 2003 to 34% in 2013-14.91 However, the current vaccination 
rates in Canada have again seen an upward trend, rising from 34.3% in 2015-16 to 38.3% in 
2017-18.66 The vaccination rates remain the highest among seniors aged 65 years and over at 
70.7% (2017-18), yet, fall short of the NACI advised national target of 80%.49,66 Interestingly, 
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the majority of individuals that did not receive the influenza vaccine in 2017/18 felt it was either 
unnecessary (22.4%) or did not believe in the efficacy of the influenza vaccine (20.2%).66 Such 
data suggests that there are underlying issues of influenza vaccine hesitancy (VH) in Canada. 
2.3  Pharmacists as immunizers 
Amongst several other strategies to improve influenza vaccination rates, allowing pharmacists to 
immunize forms one.43,92 As of July 2019, nine provinces in Canada including Ontario have 
passed regulations that allow a pharmacist to administer the influenza vaccine with one province 
awaiting legislation for implementation.93 Pharmacists are ideally placed professionals who are 
well trained and accessible to the community.43,94 They are respected sources of health 
information for patients, with potential to positively influence the influenza vaccine 
acceptance.95 Community pharmacies have the advantage of extended work hours and 
convenient locations, and they typically do not require appointments for consultation.44,94 This 
added convenience is possibly reflected through the 2017/18 national influenza immunization 
coverage survey data, which described pharmacies to be the primary place of influenza 
vaccination (34.2%) for Canadians, surpassing physician offices (30.4%) and vaccine clinics 
(11.4%).49 
In a survey of pharmacy patrons conducted in Toronto, Ontario, 92% of the respondents 
receiving the influenza vaccination in the pharmacy were very satisfied with the service and 99% 
reported that they would recommend pharmacy vaccination services to friends and family. 
Interestingly, 7% of the respondents were first-time vaccine recipients and about a third 
responded that they would not have been vaccinated that year if pharmacy vaccination services 
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were unavailable.45 With pharmacists having rapidly become an integral part of the 
immunization work force, the roadmap to their future in immunization must include preparation 
for challenges such as VH.  
2.4  VH – A complex and multidimensional issue 
Vaccinations are undoubtedly amongst the foremost achievements in the upkeep of public health. 
Vaccination programs have reduced the morbidity and mortality of several infectious diseases 
and global vaccination programs continue to be the most successful and cost-effective 
intervention in improving health outcomes.2 Mass immunization programs have been credited 
with the worldwide eradication of smallpox and the elimination of polio in several countries 
including North America. Vaccines are effective at both the individual level through direct 
protection and the community level through herd immunity.96,97 The continued success of 
immunization programs in reducing the incidence and prevalence of vaccine preventable disease 
(VPD) relies upon attaining and sustaining high vaccine uptake rates.20 
Despite the wealth of extensive scientific evidence that supports and promotes vaccination as the 
primary preventive measure against VPD, conflicting information often makes its way to the 
public, that, disputes the scientific concord on the safety and effectiveness of some or all 
vaccines on a number of grounds, from religious to cultural and political factors.19 Additionally, 
acceptance of the recommended vaccination in a timely manner is challenged by many issues, 
such as complacency when the risk of contracting a VPD has dropped due to high rates of 
immunization, declining trust in government, contradicting scientific notions and the negative 
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influence of vaccine related controversies in the media, including the wider diffusion of vaccine 
critical content on social media.20 
The proliferation of such information and the ease with which misinformation can amplify – 
both, through traditional and new media channels has resulted in a confusing context to 
individuals seeking to gain information about the risks and benefits of vaccines. It is therefore 
understandable that some individuals have become ‘hesitant’ about their decision to vaccinate. 
Dube et al. (2015) estimate that up to a third of individuals might have doubts and uncertainties 
that might result in refusing certain vaccines but agreeing to others or accepting the 
recommendations with reluctance.98 VH and outright refusal of vaccines are global issues that 
threaten the sanctity of public health.19 The WHO, recognizing the same, established the 
Strategic Advisory Group of Experts (SAGE) on VH in March 2012. The working group 
submitted its final report on the issue in October 2014, defining VH as, ‘[a]delay in acceptance 
or refusal of vaccines despite availability of vaccination services. Vaccine hesitancy is complex 
and context specific, varying across time, place and vaccines. It is influenced by factors such as 
complacency, convenience and confidence’21 
2.4.1  Understanding VH 
While the majority of the population worldwide accept vaccination, a smaller fraction decline 
entirely, delay them, or accept them while not being entirely sure while doing so.3,99 Hesitancy, 
is thus situated in the space between those who receive vaccinations with no doubts and those 
who refuse vaccines without doubts.3 (Figure 2-1) 
  20 
 
Figure 2-1 The continuum of VH between full acceptance and outright refusal of all vaccine 3 
A ‘3C’ model was put forward to facilitate an easy comprehension of the term VH. 21 It 
categorizes the reasons for VH into three primary domains: 
Confidence - (i.e., trust) In the safety and efficacy of the vaccine itself, trust in the system that 
delivers it, competence and reliability of the health care professionals administering them and the 
motives of the policy-makers pressing on the needs for vaccination.3,21  
Complacency - Occurs when the perceived risk of contracting a vaccine preventable illness is 
low and thereby vaccination is deemed unnecessary. Immunization programs have become 
victims of their own success. Individuals tend to disregard the need for vaccines as a necessary 
preventive measure when the perceived risk of VPDs decrease. Further, individuals may weigh 
the odds of contracting a VPD to be less than the risks associated with the vaccine itself, thereby 
contributing to hesitancy.3,21 
Convenience - Factors such as availability, accessibility, affordability and willingness to pay, 
health literacy and the appeal of immunization services affect the uptake of immunization 
services significantly. The quality of the service and the extent of the aforementioned factors 
may affect the decision of an individual to get vaccinated, thereby paving way to hesitancy.3,21 
 
 
Refuse all vaccines   Refuse some, delay some, accept some  Accept all vaccines 
                  [Refuse but unsure - - - Undecided - - - Accept but unsure] 
 
Vaccine hesitancy continuum 
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Beyond the WHO, VH has increasingly been a subject of interest for immunization researchers 
worldwide and extensions and alternatives to the WHO ‘3C’ model and definition to better 
understand the phenomenon have since been proposed.58,96,100-102 Researchers have criticized the 
current definition of VH for its inability to incorporate attributes that extend beyond the mere 
behavioural outcomes of vaccine acceptance, delay, and refusal.  
Alternatives to the WHO definition have described VH as:  
1. A ‘motivational state’ of being conflicted about or opposed to receiving a vaccine. This 
definition takes a psychological perspective to the phenomenon, and describes VH as a 
challenge relating to motivation. The authors further classify the gamut of motivations that an 
individual may exhibit towards vaccination into those: a) asking to be immunized, 
independent of a provider raising the issue; b) being open to immunization when presented 
with the opportunity; c) displaying passive hesitancy; d) initially resistant to receive 
immunization but open to persuasion and; e) absolutely opposed to some or all 
vaccines.100,102,103  
2. A decision-making process (of how/why people come to accept, refuse or delay vaccination) 
that is influenced by contextual (historical, social, cultural, political) factors, resulting in a 
variety of behavioural outcomes. Further, the authors suggest that perhaps those who are 
hesitant may face difficulty in this process of decision making compared to those who are 
pro- or anti-vaccine, as polarized individuals likely hold strong convictions about the 
vaccine, and their decision making process is practically automatic.96 
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3. ‘A reluctance to receive recommended vaccination because of concerns and doubts about 
vaccines that may or may not lead to delayed vaccination or refusal of one, many or all 
vaccines.’ This definition was conceived through a consultation with vaccine providers and 
researchers, and accounts for attitudes and beliefs (ex. doubts, concerns) extending beyond 
binary behavioural outcomes of accepting or rejecting a vaccine.58 
Indeed, the myriad definitions and descriptions of VH speak to the complexity of this 
phenomenon. In addition to these definitions, alternative models to better understand vaccination 
behaviour and VH have also been proposed. Betsch et al. (2018) used empirical and theoretical 
modeling to propose, assess and validate an alternate ‘5C’ model to better understand the 
psychological antecedents of vaccination behaviour.101 In addition to: a.) ‘Complacency’, a low 
perceived risk of acquiring VPDs, and b.) ‘Confidence’ (or lack thereof), in vaccine and the 
system delivering/advocating vaccines; the authors include, c.) ‘Calculation’, an active process 
of weighing and deliberating the risks and benefits of accepting and/or refusing a vaccine, d.) 
‘Collective responsibility’, involving herd immunity and social protection, and modify 
‘Convenience’ (as described in the WHO 3C model of VH3) to e.) ‘Constraints’ as the authors 
argue the choice of convenience as placing the onus of vaccination on an individual regardless of 
systemic barriers that may hinder access to vaccination services.  
2.4.2  Potential causes of VH 
Concluding from a systematic review of the existing literature,3,104 models of VH, the WHO 
immunization managers’ survey on hesitancy,3,105 experiences of the immunization experts and 
researchers working in the area, a total of 21 unique determinants of VH were identified. These 
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determinants were further formulated into a ‘determinants matrix’ and grouped into three 
categories: contextual, individual and group influences and vaccine/vaccination specific issues 
(Presented in Table 2-1).21  
Unlike the social determinants of health, VH determinants such as socio-economic status and 
education do not affect the outcome in a single direction. Additionally, each determinant may 
have different effect on vaccine uptake in different geographical settings. Studies from China,106 
Lebanon,107 Israel,108 Bangladesh109 and USA110 identified higher education as a potential 
barrier, whereas studies from Greece,111 Netherlands,112 Nigeria113 and Pakistan114,115 identified 
the same as a promoter. Furthermore, lower education had different effects in different countries. 
In India,116 lower education was associated with lower health-knowledge but not anti-vaccination 
attitudes, whereas in Nigeria the same was associated with higher anti-vaccination attitudes.21,104 
Thus, the findings of these studies serve to reinforce the necessity to consider multiple influences 
and importance of context when estimating the cause for hesitancy.21,104 
Contextual influences 
Influences arising due to historic, socio-cultural, 
environmental, health system/institutional, economic or 
political factors 
a. Communication and media environment 
b. Influential leaders, immunization program 
gatekeepers and anti- or pro-vaccination lobbies 
c. Historical influences 
d. Religion/culture/gender/socio-economic 
e. Politics/policies 
f. Geographic barriers 
g. Perception of the pharmaceutical industry 
Individual and group influences 
Influences arising from personal perception of the 
vaccine or influences of the social/peer environment 
a. Personal, family and/or community members’ 
experience with vaccination, including pain 
b. Beliefs, attitudes about health and prevention 
c. Knowledge/awareness 
  24 
d. Health system and providers – trust and personal 
experience 
e. Risk/benefit (perceived, heuristic) 
f. Immunization as a social norm vs. not 
needed/harmful 
Vaccine/vaccination – specific issues 
Directly related to vaccine or vaccination 
a. Risk/benefit (epidemiological and scientific 
evidence) 
b. Introduction of a new vaccine or new formulation or 
a new recommendation for an existing vaccine 
c. Mode of administration 
d. Design of vaccination program/Mode of delivery 
(e.g., routine program or mass vaccination campaign) 
e. Reliability and/or source of supply of vaccine and/or 
vaccination equipment 
f. Vaccination schedule 
g. Costs 
h. The strength of the recommendation and/or 
knowledge base and/or attitude of healthcare 
professionals 
Table 2-1 VH determinant matrix3 
2.4.3  Significance of historical, political and socio-cultural context 
Several sociocultural changes contribute to VH. Social science research suggests that vaccine 
uptake is to be understood in a broad socio-cultural context, wherein a decision to vaccinate is 
not a simple preventive-health measure but one that has its ambiguities and is influenced by 
several factors such as, controversies surrounding the particular vaccine at a given time, selecting 
between potentially competing risks (disease versus vaccine or one vaccine versus another), 
traction between the idea of private and public good, socio-economic status and education 
amongst several others.104,117 Vaccination has been described as part of the wider social world 
wherein, factors such as previous experiences with immunization services, conversations with 
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friends, or simply the order of one’s priorities may play a role in an individual’s decision to get 
vaccinated.118 
Since their inception, vaccinations have been subject to several controversies. In the 1990’s the 
universal vaccination program in France was suspended due to associations between the 
hepatitis-B vaccine and development of multiple sclerosis despite evidence that stated otherwise. 
In recent times, the false link between MMR (measles, mumps and rubella) vaccine and autism is 
well known and reported to-day as a reason for concern.119,120 This scare caused the vaccination 
rates to drop significantly in the United Kingdom and parts of Europe, however, it had negligible 
impact in Canada where it was equally well publicized.121 Such evidence further underscores the 
non-linear and context specific nature of VH.  
2.4.4  Media and communication  
Despite strong evidence of the safety and effectiveness of vaccines, media controversies impart a 
negative influence on vaccine uptake.122,123 A 2011 study conducted in Quebec determined that 
exposure to negative stories on vaccination through mass media acted as a barrier to vaccine 
uptake.124 
The advent of the internet has facilitated easy access to information surrounding health and 
vaccination. Although health professionals remain the primary and most trusted source for health 
information, easy access and convenience of the internet has rapidly made it an essential source 
for all sorts of information including on vaccinations.125 However, the unregulated nature of 
content on online sources leads individuals to information of variable quality that is often 
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inexact, and predominantly negative.123,126,127 A study simulating a lay persons’ search on a 
popular internet search engine for advice on the relationship between autism and MMR vaccine 
resulted in 59% of the results supporting the incorrect relationship. Betsch et al. (2010) 
conducted an experimental study with 325 participants to identify the nature of the relationship 
between exposure to anti-vaccine websites and the decision to vaccinate one’s child. The study 
concluded that surfing anti-vaccination websites for 5-10 minutes resulted in a negative outlook 
towards vaccination, decreasing the perception of risk of omitting vaccines and increasing the 
perception of risks associated with vaccines.128 Further demonstrating the wide-reaching impact 
of social media, a study evaluating 300,000 Twitter messages concerning H1N1 vaccine found a 
strong correlation (r=0.52) between the prevailing sentiment (positive or negative) in a 
geographical region and vaccine uptake.129 
Interestingly, social and psychological theories indicate that people cluster in physical and social 
spaces on the basis of similarities, and that these similarities spread through networks, 
phenomena referred to as homophily and contagion.102,130,131 Implications of these phenomena on 
vaccine conversations in the online space and social media include amplification and polarization 
of views.102 Indeed, a study analyzing user comments on influenza vaccine related news reports 
on the Canadian Broadcasting Corporation’s (CBC) website, observed extreme polarization of 
vaccine positions in the online space.132 The authors indicate that such overwhelming presence of 
strong beliefs likely serves to foster polarization rather than promote consideration of contrasting 
views.132 More importantly, the implications of these observations include the likely dissolution 
of space for individuals between the two extremes of the vaccine continuum, rendering 
individuals with vaccine hesitancy as mere spectators in online vaccination debates.132 
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2.4.5  Vaccine policies and public health 
Public health organizations need to adequately communicate with the population.123 Despite the 
presence of stringent regulatory requirements and surveillance systems that ensure the safety and 
reliability of vaccines on an ongoing basis, the lack of effective communication regarding the 
same results in misinterpretation and dissemination of false beliefs.123,133,134 However, health 
interventions to improve vaccine uptake based on education and information alone have not been 
successful.135 Blanket interventions including broad educational attempts that rely on supplying 
probabilistic information on the benefits and risks of vaccines may only impact a very small 
subsection of those expressing hesitancy and may not be as effective as targeted and tailored 
strategies.28 Researchers have described messaging from official sources as being dry, factual 
and forgettable in comparison to vaccine critical content that tend to include first-person 
testimonies and stories which tend to be more relatable.102,136,137 As such, public health 
communicators must design their messaging to target those hesitant and proactively 
communicate to promote vaccinations, contain and prevent the spread of vaccine 
misinformation, and counter vaccine critical content.138 
Mandatory vaccination of certain vaccines has been initiated in some countries to encourage 
higher vaccine uptake.139 A study in the USA suggested an increasing opposition to compulsory 
vaccination. Unsurprisingly, such individuals were significantly more likely to hold negative 
beliefs towards the safety and utility of vaccines.140 Mandatory vaccination policies such as 
vaccinate or mask policies have been increasingly used to promote vaccine uptake of health care 
providers in institutional settings.141-144 While effective in increasing the vaccine uptake, such 
  28 
measures have been criticized on legal, moral and ethical grounds and remain controversial. 141-
146  
2.4.6 Knowledge and attitudes about vaccination  
Patient vaccination decisions are often associated with a perceived self-sufficiency of 
information on the need, advantages and disadvantages of vaccination.123 Interestingly, studies 
suggest that generally, people getting vaccinated have limited knowledge on vaccination and 
VPDs as compared to individuals who refuse vaccines, indicating that dissemination of 
misrepresented information often outweighs correct or no information.147,148 Perceiving 
vaccinations as a social-norm has been identified as a potent promoter of vaccination.24 
Individuals may perceive it to be their social responsibility to obtain a vaccine to maintain herd-
immunity. However, qualitative studies have determined that while ‘benefit to others’ is a 
motivator, the decision to immunize oneself is largely based on perceived benefit to self.56,149 
2.5 Health care professionals and hesitancy to personal immunization  
The interaction between recipient and provider is the foundation of maintaining belief in 
vaccination.123 The attitude and knowledge of healthcare professionals towards vaccines is 
determinant of their own vaccine uptake as well as the strength of recommendation to their 
patients. Although most healthcare professionals are supporters of vaccination, a hesitant attitude 
may be present in some. A study conducted amongst nurses illustrated a reluctance to receive the 
influenza vaccine despite freely available vaccines and strong recommendations supporting 
immunization.150,151 To assess the vaccination attitudes and practices of general practitioners in 
France, Verger et al. performed a nation-wide cross-sectional survey that looked at the self-
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reported frequency of recommendation of six specific vaccines. The study found that up to 43% 
of certain vaccines were never recommended in the target populations Additionally, although the 
majority of surveyed physicians were confident in their ability to explain the safety and utility of 
vaccine, many also held negative beliefs regarding immunization. The authors conclude the 
above findings as an indicator of the practitioners’ own VH.152 Other studies further establish a 
strong association between the attitudes and beliefs of healthcare professionals, their 
recommendation of vaccines to their patients and the eventual uptake of vaccines by their 
patients.153,154 
2.6  Factors involved in vaccine decision making 
2.6.1  Previous experience with vaccination service 
Negative encounters with immunization providers can influence decisions regarding future 
vaccinations. Fear of needles and pain also contributes to VH and refusal.57 Additionally, 
personal experiences including those of friends and acquaintances may affect an individual’s 
decision to vaccinate. 
2.6.2  Perceived necessity of vaccination for maintaining health 
Studies establish the perceived redundancy of vaccination as a barrier to improving 
coverage.123,148 Individuals believe that by maintaining good hygiene and habits, VPDs may be 
avoided or that their immunity is sufficient to ward off a VPD.123 While a good immunity or 
hygiene practice may be beneficial to a certain extent, the air borne nature of influenza and rapid 
mutation of the influenza virus comprehensively undermine those beneficial effects.151,155 
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2.6.3  Risk perception 
Risk in vaccination is a cumulative measure of an individual’s perceived susceptibility to a VPD 
and perceived intensity of consequence if the disease were to occur.156 A perceived risk of a 
VPD can improve the uptake of a vaccine, whereas the perceived risk from a vaccine can 
contribute to refusal. The prophylactic nature of vaccines, wherein the intended recipients are 
healthy individuals, may also result in a relative inflation of perceived vaccine associated risks 
compared to any benefits, which may not be immediately tangible.157 Further, many individuals 
tend to be risk-averse preferring a consequence of inaction (i.e., not taking vaccine) than getting 
an ‘unsafe’ vaccine.123,158 
2.6.4  Trust 
Lack of trust may encompass several factors such as the vaccine, its provider, the health care 
system, the government or even the pharmaceutical industry.99,123,148 A sociological study on 
trust and vaccination concludes that trust is not just based on knowledge, but also on a ‘leap of 
faith’ that arises from several accountable and unaccountable parameters including relationship 
with the provider and opinion gathered through various sources of information that may include 
friends, family or media.159 
2.6.5  Moral and religious beliefs 
Vaccine refusal has often been linked to philosophical beliefs and moral convictions regarding 
immunity and health. Strong religious tenets have been associated with refusal of vaccines. A 
well-known example is the refusal of HPV vaccine in adolescent girls in several countries. In 
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Calgary, Bishop Fredrick Henry issued an edict that withheld the free HPV vaccination in 
Catholic schools on religious grounds. The belief that chastity and abstinence were the ‘holistic’ 
means to prevent sexually transmitted diseases and that the vaccine promoted promiscuity 
resulted in thousands of young children not being vaccinated.160,161 McRee et al. performed a 
state wide study of health care workers in Minnesota, USA to assess HPV VH. The study 
determined that only 76% of the health professionals routinely recommended the vaccine to the 
target population, citing parent’s belief of sexual inactivity of their child among other reasons.162  
In conclusion, despite identifying a host of factors associated with VH and vaccination 
behaviour, individual decision-making regarding vaccination is complex and cannot be 
predicted. It involves cultural, social, emotional, spiritual and political factors to the same extent 
as cognitive factors.123 Additionally, in recent times ‘changing scientific, cultural, medico-legal 
and media environments’ have resulted in heightened hesitancy.22 Further research is needed to 
understand individual vaccine decision-making processes.24 
2.7  Measuring hesitancy towards influenza immunization 
A challenge associated with VH is determining the extent of its presence in society. Although 
assessing vaccine uptake through immunization registries and health care authorities may 
provide an ‘estimate’ of influenza vaccine uptake in a given area, the dynamic nature of any 
population and the availability of vaccine from multiple providers and sites prevents one from 
obtaining an absolute value of the coverage.163,164 Vaccine uptake serves as an indirect measure 
of hesitancy, yet, distinguishing the degree of vaccine avoiders and those ambivalent within a 
sub-group not covered by vaccine is difficult to determine. Further, coverage rates encompass 
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non-hesitancy aspects such as vaccine shortages and program delivery obstacles. The problem is 
further compounded by the fact that many individuals although vaccinated may delay their 
vaccination. Such individuals may be counted for as vaccinated, but, by definition, are hesitant.  
Therefore, determining extent of VH calls for specific and targeted tools. It has been estimated 
that VH occurs in pockets and subgroups within the general population.20,165 The Tailoring 
Immunization Programmes (TIP) for seasonal influenza guide published in 2015 is an adaptation 
of the original guide to TIP, which was published in April 2013 by the WHO regional office for 
Europe that aimed to increase and maintain parental participation in child vaccinations. The TIP 
guide is based upon evidence from behavioural economics, medical humanities, psychology and 
neuroscience, and is an example of a tool that may be used to identify and prioritize vaccine 
hesitant populations and subgroups. The TIP Flu guide provides a model in-depth semi-
structured interview guide, and a survey to identify the presence and determinants of 
hesitancy.21,166 
The WHO/UNICEF Joint Reporting Form (JRF) questionnaire, intended to be answered by the 
national immunization managers is another monitoring tool that can capture hesitancy on a 
routine basis. In 2012, the JRF introduced two questions to assess the level of hesitancy and 
determine the reasons for hesitancy within the member nations.166 These questions were revised 
in 2013 to widen the scope of VH to not just include confidence but also complacency and 
convenience, to align with the WHO SAGE definition of VH.166 Further, initiatives at the WHO 
are currently underway to develop a validated measure to identify vaccine hesitant subgroups in 
the population and understand the drivers of their hesitancy. The WHO Working Group on VH 
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has established a universal compendium of validated survey questions in this regard. The 
generated information can be used to tailor targeted interventions to resolve hesitancy and 
increase vaccine acceptance. The use of a standardized compendium of questions further enables 
comparison of VH determinants across population subgroups, socio-cultural and geographical 
contexts, providing a nuanced understanding of the phenomenon.167 
2.8  Interventions to address influenza VH 
Hesitancy being a complex, context specific and dynamic phenomenon that varies across time, 
place and vaccine25, makes designing a single intervention strategy to address all causes of 
hesitancy hard to achieve.23,28 The traditional knowledge-deficit approach that assumes hesitancy 
can be overcome by provision of knowledge, is not effective.123,168 Thus, understanding the 
nature of hesitancy within a sub-population or a country is an essential first step, followed by 
identification and implementation of customized strategies backed by evidence to eliminate the 
root cause of hesitancy.169 
The Centers for Disease Control and Prevention (CDC) has published evidence-based 
recommendations to improve the uptake of vaccination delivery. The interventions have been 
categorized into three groups based on the outcome they attempt to influence: (1) interventions to 
increase community demand for vaccinations; (2) interventions that enhance access to 
vaccinations and (3) provider based interventions.28,135 
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2.8.1  Interventions to increase community demand for vaccinations 
Client or family incentive rewards have been demonstrated to be effective in improving the 
uptake of vaccination service. These may include food vouchers, lottery prizes, gift cards etc. 
Reminder and recall interventions have strong evidence of effectiveness in varying settings of 
practice and communities. Quasi-obligation of immunization service through policies, such as 
compulsory immunization for attendance to school or workplace have been used in certain 
communities to enhance vaccine uptake but have faced criticism. Community based 
interventions are often implemented in combination to increase effectiveness.28 
2.8.2  Interventions to enhance access to vaccinations 
The definition of VH considers a voluntary delay or refusal of vaccination services despite their 
availability.3 It is of value however, to differentiate availability and accessibility, as one may not 
imply the other. Interventions that enhance public accessibility to vaccinations have resulted in a 
positive impact on vaccine uptake. For example, the addition of pharmacists to the Ontario 
immunization work-force has improved influenza vaccine accessibility and convenience, 
resulting in a net increase of approximately half a million doses administered over two seasons 
since pharmacist administered influenza immunizations first became available.45 While not 
quantifiable, a portion of this increase may be attributed to those who were previously hesitant. 
2.8.3  Provider or system based interventions 
Health care professionals are the primary and most trusted sources of information on vaccines. 
They play an important role in providing the community they serve with clear, factual 
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information regarding influenza and its vaccine.170-172 Their recommendations, advocacy and 
education form an effective intervention to positively impact uptake of all vaccines.32,34,35,40,102,170 
Two studies conducted with pediatricians in Canada concluded that confidence in personal 
knowledge, training in vaccination and perceived severity of a VPD were promoters of vaccine 
recommendations.60,61 On the flipside, Kempe et al. (2009) note that a less severe VPD was a 
barrier to vaccine recommendation.173 Studies demonstrate that greater provider knowledge on 
vaccines and VPDs is associated with a greater likelihood of them recommending vaccines to 
their patients.40 Important areas of knowledge pertaining to the influenza vaccine include its 
safety and effectiveness, and the severity and prevalence of influenza and its complications.  
To ensure an optimum response to a provider’s vaccine recommendation it is important that they 
tailor their communication to address specific concerns and doubts while maintaining a 
trustworthy relationship.123 As such, several interventions and communication frameworks have 
been designed to augment the provider’s knowledge and help them steer vaccine conversations 
with patients. These tools have been developed to understand a patient’s reason for hesitancy and 
provide tailored information. Some examples include the Ontario, MOHLTC’s ‘Flu consult 
kit’174, Immunize BC’s ‘ASK approach’175 and the PHAC’s ‘Canadian Immunization Guide’.66 
However, the relative naivety of these tools has meant that their adoption, applicability and 
effectiveness across providers and settings remains unexplored.  
Other recommendations from researchers include pain mitigation and promotional 
communication as an effective tool to positively change knowledge, attitudes and behaviours of 
individuals towards immunization.176 Emphasizing the importance of right communication, 
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UNICEF’s Benjamin Hickler, contends (that) “The best approach tends to be to identify those 
people who are looking for information and make sure that they get the correct information in a 
clear and compelling way, so they aren’t swayed by some of the more outlandish stuff.”19 
Reviews evaluating interventions to improve vaccine uptake conclude that health-care provider 
recommendations, one-on-one education, household visits, information campaigns, 
communication using multiple means of mass media and using social media as a tool to promote 
vaccinations are most effective in improving vaccine uptake and addressing hesitancy.28,32,102 
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3.1 Overview 
Background: Vaccine hesitancy (VH) continues to remain a prime contributor to poor influenza 
vaccine uptake. This study seeks to explore the knowledge, attitudes and practices of community 
pharmacists towards influenza VH, including their personal influenza immunization attitudes and 
behaviours. 
Methods: A web-based cross-sectional survey questionnaire was designed and administered to 
community pharmacists practicing in Ontario, Canada. The survey tool comprised of 38 
questions exploring five domains including pharmacists’ personal attitudes and behaviour 
towards influenza immunization, their self-reported knowledge of influenza, its vaccine and 
vaccine hesitancy, and their attitudes, practices and experiences with influenza VH at the 
community pharmacy. The data was analyzed descriptively.  
Results: A total of 5,530 survey invitations were e-mailed and 885 responses were collected 
(response rate 16%). Two-thirds (n=568, 65.7%) of the respondents reported receiving the 
influenza vaccine in the preceding season. The most frequent reasons for personal influenza 
immunization were prevention of disease transmission to patients, friends and family, and 
contribution to herd immunity. In addition to their confidence and perceived ability to identify 
and address influenza VH, respondents’ self-reported knowledge across a 15 item Likert 
questionnaire was high. Respondents reported coming across an average of 16 (SD 28) 
individuals hesitant to receive the influenza vaccine each week. Regular workload (n=419, 
65.6%), and insufficient time (n=406, 65.3%) were reported as the most limiting barriers to 
optimal engagement in influenza vaccine conversations. 
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Conclusion: Facilitating optimal practice scope for pharmacists, and capitalizing the additional 
convenience and accessibility offered through the community pharmacy setting presents a 
promising means to address influenza VH. However, barriers to pharmacist-initiated engagement 
on influenza vaccine must be explored and addressed. 
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3.2 Introduction 
Irrefutably, vaccinations remain the most effective way to combat vaccine preventable infectious 
diseases. They are effective both at the individual level through direct protection, and at the 
community level through herd immunity.17,177 Despite extensive scientific evidence backing the 
safety, efficacy, and overall benefits of all vaccines66,74,85,178-182, achieving and sustaining high 
vaccine uptake remains a challenge. Vaccine hesitancy (VH), defined as the voluntary delay or 
refusal of vaccinations despite availability is an increasingly prevalent phenomenon with 
potential to undo decades of public health progress.3,183 Consequently, the World Health 
Organization (WHO) in 2019 identified VH as a threat to global health.4  
VH challenges the traditional dichotomous notion of vaccination decisions and outcomes as 
strictly acceptance or refusal of the vaccine. Instead, it recognizes vaccine decision making as a 
complex, context specific, and dynamic process, wherein individuals may display an array of 
attitudes or behaviours as they transition across a spectrum of possibilities in response to a 
variety of influences between complete acceptance and refusal.96,104,123 While VH can be specific 
to one or all vaccines, influenza VH is of unique interest due to the need for annual re-
immunization, seasonal variations in vaccine effectiveness, and the existence of influenza 
vaccine specific myths such as, ‘influenza vaccination causes influenza’ among others.32,184 
While reasons for non-vaccination among people are varied and complex, health care providers 
remain the most trusted advisors and influencers of vaccination decisions.30-32 Experiences of 
general practitioners, pediatricians, nurses, and midwives on vaccinations have been studied 
before.58-63 Previous literature has established that greater knowledge on vaccines, beliefs 
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aligning with scientific evidence and favorable attitudes toward vaccination are associated with a 
greater intention to recommend and administer vaccines.40 While most healthcare providers are 
generally strong supporters of vaccinations, research suggests that vaccine hesitant attitudes and 
beliefs may exist in some, impacting their personal vaccine uptake, and, their likelihood to 
recommend vaccinations to their patients.40,185-187 
Proven to increase vaccination rates, pharmacists’ recommendation, education, and advocacy on 
the influenza vaccine are valuable tools in promoting positive vaccine outcomes.35,36 Their 
standing within the community as trusted sources of health information, coupled with an 
opportunity for frequent patient contact by means of easy accessibility and convenient hours of 
service of community pharmacies, makes pharmacists well-positioned to address influenza VH.33 
Pharmacists have fast become an integral part of the immunization workforce, with community 
pharmacies being the choice destination for influenza vaccine administration in Canada;49 yet, 
the experience of influenza VH in this setting remains unexplored. The current study aims to 
help bridge this gap by exploring community pharmacists’ personal knowledge and practices 
related to influenza vaccination, and their experiences with influenza VH in practice. 
3.3 Methods 
3.3.1 Study design and population 
A cross-sectional, anonymous online survey was administered in English to community 
pharmacists practicing in Ontario, Canada. The survey was distributed by email to pharmacists 
listed in the Part A of the Ontario College of Pharmacists (OCP) membership database who had 
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previously provided consent to be contacted for research purposes. To ensure participation form 
pharmacists who primarily practiced in community settings, the source database was filtered to 
only include pharmacists whose primary workplace was listed as a community setting, and, a 
screening questioning regarding place of practice was included at the beginning of the survey. 
Approval for the study was obtained through the Office of Research Ethics, University of 
Waterloo (ORE#21648). 
3.3.2 Survey development and distribution 
The survey was designed using a knowledge, attitudes, and practices (KAP) approach, which 
describes the behaviour of an individual in a given context as a linear function of their 
underpinning knowledge and attitude.188 The KAP framework is widely used in health research 
to elicit context-specific dynamics describing, identifying, and exploring barriers to optimal 
behaviour in a health care setting.189-191 The survey questionnaire was built and refined through 
an iterative process, using existing literature, clinical expertise of the research team, and 
discussions with collaborating immunization researchers from other institutions across Canada.  
The survey consisted of 38 questions exploring five domains relating to the pharmacists’: 1) 
Professional characteristics; 2) Personal attitudes and behaviour towards influenza 
immunization; 3) Self-reported knowledge of influenza, its vaccine, and other vaccination-
related issues; 4) Attitudes and behaviour with regards to influenza vaccinations at the 
community pharmacy; and 5) Experiences with seasonal influenza VH at the community 
pharmacy. (See Appendix A for survey instrument). Likert questions followed a 1-5 scale, with 1 
representing a negative/disagreement score and 5 representing a positive/agreement score. 
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Face validity of content was assessed by eight registered pharmacists, six immunization 
researchers, and four pharmacy practice researchers. Survey flow, functionality and language 
were refined through a pilot with ten individuals who were not part of the research team. The 
survey was distributed using the online survey platform, Qualtrics® (Qualtrics Labs, Inc., 2016, 
Provo, UT, USA). The initial request for participation was followed by reminder emails to non-
responders at weeks 2, 3, and 4. No incentives were provided for participation in the study. 
3.3.3 Survey analysis 
Descriptive analysis of the survey data was performed using IBM SPSS®, version 22.0 (IBM 
Corp, 2015, Armonk, NY, USA). Free text comments were assessed qualitatively and coded into 
existing quantitative variables as appropriate or used to identify new themes by GRP, and cross 
checked by RV to improve accuracy. To aid interpretation, responses to five-point Likert 
questions were categorized as positive (scores of 4 or 5), neutral (score of 3), or negative (score 
of 1 or 2). 
Internal consistency of multi-item Likert questions was measured by calculating Cronbach’s 
alpha coefficient. A value of ≥ 0.9 was considered excellent and a value between 0.9 and 0.8 was 
considered good.192 
3.4 Results 
3.4.1  Sample demographics  
A total of 5,530 electronic survey invitations were sent and 885 responses were collected 
(response rate 16%). Most respondents were authorized to administer injections (n=753, 86.6%), 
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held a baccalaureate degree in pharmacy (n=765, 87.0%), and practiced in pharmacies that 
offered influenza immunizations (n=739, 85.0%). Around half the respondents were female 
(n=452, 51.5%), and practiced in urban locations (n=467, 53.9%). A third of the respondents 
worked as full-time staff pharmacists (n=289, 33.0%), and a quarter worked in independent 
pharmacies (n=219, 25%). On average 217 prescriptions were dispensed daily at the respondent 
practice sites, and respondents authorized to administer injections reported administering an 
average of 158 influenza vaccines in the preceding influenza season. Complete demographic 
details are presented in Table 3-1. 
Table 3-1 Participant demographics 
Characteristics Number (%) 
Gender (n=878) 
Man 
Woman 
Other 
 
425 (48.4%) 
452 (51.5%) 
1 (.1%) 
Education* (n=879) 
BSc Pharmacy 
Post-baccalaureate PharmD 
Entry-to-practice PharmD 
Master’s in pharmacy 
PhD in Pharmacy 
Residency 
Fellowship 
Other(s) 
 
765 (87.0%) 
19 (2.2%) 
26 (3.0%) 
71 (8.1%) 
19 (2.2%) 
21 (2.4%) 
2 (0.2%) 
71 (8.1%) 
Experience (n=877) 
Less than 5 years 
5-10 years 
11-15 years 
16-20 years 
More than 20 years 
 
169 (19.3) 
164 (18.7) 
94 (10.7) 
74 (8.4) 
376 (42.9) 
Authorized to administer injections (n=870) 
Yes 
 
753 (86.6%) 
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No 117 (13.4%) 
Position at primary place of practice* (n=875) 
Pharmacist - Manager 
Staff pharmacist – Full time 
Staff pharmacist - Part-time 
Pharmacy owner 
Relief pharmacist 
Other(s) 
 
244 (27.9%) 
289 (33.0%) 
158 (18.1%) 
178 (20.3%) 
83 (9.5%) 
8 (0.9%) 
Type of pharmacy (n=876) 
Chain (more than 6 stores with one owner) 
Independent (one owner up to 6 stores) 
Franchise 
Banner 
Mass merchandiser/Food store 
Other 
 
175 (20.0) 
219 (25) 
176 (20.1) 
144 (16.4) 
138 (15.8) 
24 (2.7) 
Location 
Rural (population <1000 individuals) 
Small population centre (1000 to 29,999 individuals) 
Medium population centre (30,000 to 99,000 individuals) 
Large urban population centre (>100,000 individuals) 
 
25 (2.9) 
205 (23.7) 
169 (19.5) 
467 (53.9) 
Involvement with influenza immunization (n=869) 
Yes, pharmacist(s) administer the vaccine 
Yes, nurses/nursing agencies contracted by the pharmacy administer the 
vaccine 
No current involvement, but planning to participate in the future 
No current involvement and no immediate plans for involvement in the future 
 
731 (84.1) 
8 (.9) 
52 (6.0) 
78 (9.0) 
 Mean (SD) 
Average prescriptions volume per day (n=847) 
Influenza vaccines administered in the preceding season (2015-16) 
(n=738) 
217 (147.3) 
158 (100) 
 
3.4.2  Pharmacists’ personal attitudes and behaviour related to influenza immunization 
Two-thirds (n=568, 65.7%) of survey respondents reported receiving the influenza vaccine in the 
preceding season. The most frequent reasons for receiving the influenza vaccine were preventing 
disease transmission to patients (n=476, 70.4%) or to family and friends (n=460, 68%), 
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contributing to herd immunity (n=434, 64.2%), and to ensure personal protection (n=434, 
64.2%). The most frequent reasons reported by respondents that did not receive the influenza 
vaccine in any of the preceding three seasons (n=189, 21.4%) were skepticism on the 
effectiveness of the vaccine (n=42, 22.2%), and absence of prior personal experience with 
seasonal influenza illness (n=38, 20.1%). 
3.4.3  Pharmacists’ self-reported knowledge 
Fifteen items exploring the respondents’ self-reported knowledge on various aspects of influenza 
vaccination, including influenza, its vaccine and administration, and other vaccination-related 
issues demonstrated consistently high scores (Table 3-2). The knowledge areas most frequently 
rated high (scores 4 or 5 on a 5-point Likert scale) across all respondents were adverse reactions 
to the influenza vaccine (n=679, 81.2%), and its dosing and indications (n=677, 81.0%). Among 
pharmacists who were authorized to administer injections, knowledge on influenza vaccine 
administration technique (n=655, 91.4%) was most frequently rated to be high. Knowledge areas 
least frequently rated high were annual influenza vaccine updates, such as updates on circulating 
strains and vaccine match, (n=409, 49.0%), composition of the influenza vaccine (n=424, 50.8%) 
and vaccine communication frameworks (n=438, 52.6%).  
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Table 3-2 Pharmacists’ self-reported knowledge 
Knowledge Item Median Frequency of Responses§ 
  Low (n (%)) Average (n (%)) High (n (%)) 
Influenza disease:     
Pathophysiology 4 49 (5.8%) 300 (35.8) 488 (58.3%) 
Pharmacotherapy 4 23 (2.8%) 210 (25.1%) 603 (72.1%) 
Influenza vaccine:     
Dosing and indications 4 43 (5.1%) 116 (13.9%) 677 (81.0%) 
Formulations 4 86 (10.3%) 213 (25.5%) 537 (64.2%) 
Composition 4 119 (14.3%) 292 (35.0%) 424 (50.8%) 
Interactions 4 55 (6.6%) 221 (26.5%) 558 (66.9%) 
Pharmacology 4 53 (6.4%) 222 (26.6%) 559 (67.0%) 
Adverse reactions 4 20 (2.4%) 137 (16.4%) 679 (81.2%) 
Contraindications 4 29 (3.5%) 147 (17.7%) 656 (78.8%) 
Influenza vaccine administration*:     
Administration technique 4 8 (1.1%) 54 (7.5%) 655 (91.4%) 
Management of anaphylaxis 4 39 (4.7%) 168 (20.3%) 621 (75.0%) 
Other vaccination-related issues:     
Vaccines and autism 4 112 (13.4%) 210 (25.2%) 511 (61.3%) 
Vaccine hesitancy 4 66 (7.9%) 264 (31.7%) 502 (60.3%) 
Annual influenza vaccine updates 3 94 (11.3%) 331 (39.7%) 409 (49.0%) 
Vaccine communication frameworks 4 94 (11.3%) 300 (36.1%) 438 (52.6%) 
§Row totals may not add to n=885 due to non-response to any of these items.   
*These questions were only provided to pharmacists authorized to administer injections. 
Cronbach’s alpha (15 items) = 0.919  
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3.4.4  Influenza vaccine and the community pharmacist: Attitudes and behaviour 
Most respondents (n=494, 59.5%) reported recommending the influenza vaccine to at least half 
of all patrons accessing their pharmacy. Two thirds (n=800, 66.2%) of all vaccine 
recommendations were described as being made specifically to patrons at high risk of influenza 
and its complications. Respondents authorized to administer injections estimated that at least two 
out of three (n=465, 66.3%) individuals getting the influenza vaccine at their pharmacy made an 
active request for it. Most (n=507, 61.7%) believed that at least seven out of ten individuals 
receiving the vaccine had made their decision prior to discussing with a healthcare provider. 
Interestingly, almost half the respondents (n=371, 44.8%) did not consider their ability to 
influence patrons’ vaccination decisions to be high.  
3.4.5  Influenza VH at the community pharmacy 
Pharmacists’ description of VH 
Survey respondents most frequently described individuals expressing hesitancy as those that did 
not trust the vaccine and immunization services (n=576, 69.1%), or as those that received the 
vaccine without being completely convinced of its benefits (n=399, 47.9%) (Table 3-3). 
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Table 3-3 Pharmacists’ description of individuals expressing VH (n=833) 
Someone is vaccine hesitant when*: n % 
They do not trust the vaccine and immunization services 576 69.1 
They are accepting of a vaccine while not being entirely convinced of its 
benefits 
399 47.9 
They’ve had negative experiences with immunizations in the past 376 45.1 
They refuse a vaccine 373 44.8 
They’ve had an uncomfortable and/or inconvenient vaccination experience 338 40.6 
They believe they have a low risk of contracting a vaccine-preventable 
disease 
334 40.1 
They delay receiving the vaccine 331 39.7 
They cannot get the vaccine due to an insufficient vaccine supply and/or lack 
of trained personnel to administer the vaccine 
8 1.0 
*Respondents were asked to select all applicable options. 
Reasons for influenza VH expressed to community pharmacists 
Respondents reported that the most frequent reasons for delay or refusal of influenza vaccination 
at the pharmacy were related to misinformation (n=485, 60.5%) and poor patient perception of 
influenza vaccine’s risks and benefits (n=467, 58.4%). Reasons reported least frequently 
included concerns about the community pharmacy as a vaccination setting (n=26, 3.3%), and 
community pharmacist as the immunizer (n=26, 3.3%) (Figure 3-1). 
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Figure 3-1 Patrons’ reported reasons for delay or refusal of influenza vaccination 
 
Cronbach’s alpha (19 items) = 0.872  
3.4.6  Pharmacists’ experiences with and attitudes towards influenza VH 
On average, respondents reported encountering 16 (SD 28.2) individuals hesitant to receive the 
influenza vaccine each week in the preceding influenza season. Most respondents considered 
engagement with these individuals on the importance of vaccination as either ‘very’ or 
‘extremely’ important (n=643, 78.3%). However, 84.2% (n=507) of pharmacists authorized to 
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administer injections estimated that upon engaging, less than half of the individuals expressing 
hesitancy ultimately received the vaccine at their pharmacy.  
Self-reported confidence in addressing patron queries on issues of influenza vaccine safety 
(n=619, 82.3%), and efficacy (n=619, 82.3%) was generally high, with the lowest levels of 
confidence reported for addressing questions involving conspiracy theories (n=338, 47.7%), and 
hidden ties to pharmaceutical organizations (n=406, 54.2%). Most respondents also reported 
their ability to identify hesitant individuals (n=745, 65.5%), determine the cause of their 
hesitancy (n=741, 60.1%), engage in conversation (n=741, 59%), and respond to their concerns 
(n=740, 64.7%) as high.  
3.4.7 Addressing influenza VH at the community pharmacy  
Among 13 approaches identified in the literature to address influenza VH, respondents reported 
that the most effective strategies included the provision of information on safety (n=388, 54.4%) 
and efficacy (n=353, 54.4%), and educating patients on the risks of non-vaccination and the 
benefits of vaccination (n=373, 54.4%). Specialized vaccine communication tools (such as the 
ASK tool175 and recommendations from the NACI guidelines66) were rated the least effective 
(n=367, 25.3%) (Figure 3-2). 
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Figure 3-2 Effectiveness of current practices in addressing VH 
 
Cronbach’s alpha (13 items) = 0.903 
5.5 Barriers to optimal immunization service delivery 
Respondents rated regular workflow (n=419, 65.6%), and insufficient time (n=406, 65.3%) as 
the most limiting barriers to optimal immunization service delivery. In contrast, items such as the 
quality of immunization training received (n=56, 8.8%), privacy (n=100, 11.3%), and space 
(n=115, 17.9%) were infrequently reported to be barriers (Figure 3-3).  
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Figure 3-3 Barriers to optimal immunization service delivery reported by respondents 
authorized to administer injections (n=753) 
Cronbach’s alpha (8 items) = 0.780 
3.5 Discussion 
Our study is the first to investigate pharmacists’ experiences with influenza VH in the 
community pharmacy setting using a large provincial sample. Our findings indicate that 
influenza VH is frequently encountered in community pharmacy practice. Pharmacists’ self-
reported scientific knowledge of influenza and its vaccine were high; however, the perceived 
effectiveness of communication tools to structure discussions with individuals expressing 
hesitancy appeared to be low. Further, pharmacists’ engagement in discussions with those 
expressing hesitancy appeared to be limited in nature and compounded by barriers relating to the 
available time, and regular workload in community practice. 
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Personal influenza immunization rates reported among pharmacists in our sample (65.7%) were 
higher than those reported in other Canadian health professionals such as nurses (57%), dentists 
(44%) and specialist physicians (59%), but were lower than that of general practitioners 
(72%).193 Reasons pharmacists cited to be vaccinated such as prevention of disease transmission 
to patients, family, and friends were consistent with those expressed by other health providers.58 
Despite the relatively high vaccination rates, one in five responding pharmacists did not receive 
the influenza vaccine in any of the three previous influenza seasons, suggesting the presence of 
influenza VH in some pharmacists. Reasons for not receiving the vaccine, assessed through the 
5C scale of psychological antecedents of vaccination behaviour (confidence, complacency, 
constraints, calculation, collective responsibility),101 revealed confidence (skepticism on vaccine 
effectiveness), and complacency (not suffering from seasonal influenza before) as the prime 
domains shaping behaviour in vaccine hesitant pharmacists. Interventions aiming to improve 
personal influenza vaccine uptake among community pharmacists should therefore focus on 
these domains.  
Self-reported measures have been used previously to gauge knowledge and competence of 
healthcare providers in other settings.194-198 Our results illustrate pharmacists’ self-reported 
knowledge of influenza disease and its vaccine, and their confidence and ability to identify, 
assess and address patient vaccine concerns to be generally high. These results align with 
previous Canadian literature reporting high perceived preparedness among general practitioners 
and nurses when dealing with hesitant individuals.58 Interestingly, communication frameworks 
exclusively designed to assist health professionals in steering vaccine conversations were ranked 
as being the least effective strategy in addressing influenza VH. However, it is unclear whether 
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this ranking actually reflects low perceived effectiveness or is rather a reflection of the 
respondents’ unfamiliarity with such tools. Future programs should focus on improving 
awareness of vaccine communication tools among pharmacists and assessing their utility in the 
community pharmacy setting. 
With accessible locations and convenient hours, community pharmacies provide frequent 
opportunities for pharmacist-patient interaction.33 Yet, our results suggest that most vaccinations 
administered at the pharmacy are done upon patient request, suggesting that provider-patient 
engagement on influenza vaccination at the pharmacy is primarily passive and ‘patient-driven’. 
The phenomenon of VH recognizes vaccination attitudes and beliefs across a dynamic 
continuum of possibilities.3 However, given the lower likelihood that individuals who are 
ambiguous or complacent about influenza vaccination will initiate vaccine conversations, this 
approach to influenza vaccine conversations likely results in missed opportunities to identify and 
positively nudge vaccine hesitant patients along this continuum.  
The passive approach to vaccine conversations is also reflected through a low reported frequency 
of encounters with those expressing influenza VH, relative to: a) A low population uptake of 
influenza vaccine;49 b) Literature describing those refusing all vaccines without doubt as only a 
small fraction of the overall population;3,98 and c) The high prescription volume at respondents’ 
practice sites. While the overarching stressors of limited resources such as inadequate time and 
insufficient staffing contribute to pharmacists’ passive approach to patient engagement on 
vaccinations, further research is imperative to understand other determinants of this behaviour 
and strategies to best address it. 
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3.6 Limitations 
The use of convenience sampling and a response rate of 16% may result in selection bias. As 
such, the results described in our study may not be representative of all Ontario pharmacists. A 
contrast of the participants’ demographic characteristics in relation to the Ontario pharmacists at 
large is available in Appendix B. Inherent to the nature of voluntary participation surveys, non-
response bias cannot be evaluated. The use of subjective, self-reported measures may also result 
in recall bias and information bias. Finally, the use of a primarily quantitative survey and 
analysis does not allow us to further explore contextual factors and personal beliefs impacting 
the responses observed. Future research will use the results of this survey as a framework to 
further explore pharmacists’ experiences with VH in practice through qualitative methods. 
3.7 Conclusion 
Pharmacists self-reported knowledge, confidence, and ability to address influenza VH at the 
community pharmacy was high. Facilitating optimal practice scope for pharmacists and 
capitalizing on the convenience and accessibility offered through the community pharmacy 
setting presents a promising means to address influenza VH. In addition to addressing 
environmental barriers to pharmacist-led initiation of vaccine conversations, future programs to 
assist pharmacists must explore strategies that encourage active pharmacist-patient engagement 
on influenza immunizations. 
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4.1 Overview 
Background and objectives: Vaccine hesitancy (VH) has been increasingly recognized as a 
global threat to public health. Yet, limited research exists exploring healthcare providers’ 
experience of this phenomenon. Our study aims to understand community pharmacists’ attitudes 
towards, and experiences with, influenza VH, and explore factors affecting their engagement 
with patients on the influenza vaccine.  
Methods: A semi-structured interview guide was developed, and interviews were conducted to 
saturation with community pharmacists practicing in Ontario, Canada. Interview data were 
transcribed verbatim and analyzed using a thematic content analysis framework. The analysis 
yielded 110 unique codes, which were merged into five major themes and 15 subthemes.  
Results: A total of 22 pharmacists were interviewed to achieve saturation. Most pharmacists 
were authorized to administer injections (n=20, 90.9%) and practiced for >20 years (n=16, 
72.7%). Pharmacists’ engagement with patients on the influenza vaccine were found to be 
modulated by a complex and mutually reinforcing constellation of attitudes and behaviours 
which included: a binary (pro-vaccine or anti-vaccine) perception of patient vaccination 
decisions; a conflation of those expressing hesitancy with those that were anti-vaccine; and a 
passive approach to patient engagement, wherein patients were found to be the primary initiators 
of vaccine conversations. Although pharmacists recognized the importance of educating patients 
and addressing their vaccine-related concerns, barriers such as limited time, inadequate staffing, 
and poor remuneration were found to restrict optimal patient engagement on influenza 
vaccinations. 
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Conclusion: While pharmacists hold the potential to effectively address influenza VH within 
their communities, future interventions must aim to break the loop of passive patient engagement 
and enable proactive pharmacist-patient interactions on influenza vaccinations in this setting. 
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4.2 Introduction 
Successful vaccination initiatives and the resulting decline in devastating vaccine-preventable 
disease outbreaks are among the most notable achievements in public health.2 However, the 
continued success of vaccination programs has been jeopardized in recent times through the 
voluntary delay or refusal of vaccines despite their availability, an increasingly prevalent 
phenomenon, referred to as ‘vaccine hesitancy’ (VH).3,4 Subsequently, VH has been recognized 
as one of the top ten threats to global health in 2019 by the World Health Organization (WHO).4 
VH challenges existing perceptions of vaccination attitudes and behaviours as a dichotomous 
outcome of merely accepting or rejecting a vaccine. Rather, it proposes vaccine decision making 
as an ongoing, complex and multifactorial process, wherein individuals dynamically transition 
across a continuum of possibilities, displaying varying beliefs, attitudes, and behaviours toward a 
vaccine in response to new information and influences.3,32,104,123 While not exhaustive, the list of 
21 unique determinants identified by the WHO working group on VH highlights the complexity 
of this phenomenon.3 Interestingly, these determinants have a bi-directional influence on an 
individual’s decision to vaccinate depending on the extrinsic context, for example, the prevailing 
outlook towards a vaccine in news and social media at a given time, and an individual’s response 
to these factors.3,98,120,123,148 
Despite such complexity, healthcare providers – through their standing as trusted sources of 
health information – remain the strongest influencers of vaccination decisions.29-32 The effect of 
physician, nurse, and pharmacist recommendations on vaccine uptake has been well 
documented.33-40 Provider-patient engagement on vaccinations is an important opportunity where 
  61 
patient concerns about a vaccine can be expressed and resolved, allowing vaccine 
recommendations or administration to occur. While existing research has focused on the patient 
experiences of VH,32,50-53 little is known about the provider’s perceptions and experiences. Prior 
research suggests that pharmacists may not fully engage with those expressing hesitancy as a 
result of a complex interplay of multiple personal, pharmacy, and non-pharmacy specific factors 
such as workload and time among others.199  
While hesitancy may be expressed towards one or all vaccines, influenza VH is of particular 
interest to immunization researchers for a number of reasons: 1) The need for annual re-
vaccination of the entire population; 2) Seasonal variation in the vaccine’s efficacy; 3) Low 
perceived severity of influenza as a disease among the public; and 4) The prevalence of influenza 
vaccine-specific myths, including that vaccination against influenza causes the illness.32,184,200 
Despite offering a Universal Influenza Immunization Program (UIIP) that provides influenza 
vaccination at no charge to all residents of Ontario through multiple providers, and the addition 
of pharmacists to the immunizing workforce (which has resulted in a net increase in influenza 
vaccines administered), overall vaccination rates remain below target.11,201  
Although Ontario pharmacists have been able to provide influenza immunizations since 2012, 
influenza VH in the community pharmacy setting remains unexplored. The current study aims to 
understand community pharmacists’ attitudes towards, and experiences with, influenza VH in 
practice, and factors impacting pharmacists’ engagement with their patients about the influenza 
vaccine.  
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4.3 Methods 
4.3.1 Study design, population, and recruitment 
This study adopted a qualitative interpretive approach to gain an in-depth understanding of 
Ontario community pharmacists’ experiences with influenza VH. Semi-structured interviews 
were conducted with pharmacists who were licensed in Ontario, practiced in community 
pharmacies, and indicated interest in participating in a one-time interview following the 
completion of a survey on the same topic. The study was approved by the Office of Research 
Ethics at the University of Waterloo (#21648). 
4.3.2 Interview guide 
A semi-structured interview guide was designed using existing literature, expertise of the 
research group, and exploratory findings from a survey examining community pharmacists’ 
knowledge, attitudes and practices towards influenza VH.199 The interview aimed to elicit 
pharmacists’ attitudes towards influenza VH, their perceived role in vaccination and VH, and 
their experiences when engaging with those expressing hesitancy to receive the influenza 
vaccine.  
The interview guide was assessed for face validity through review by three practicing 
pharmacists and two pharmacy practice researchers. Interview questions were screened for 
sensitive content through a pilot conducted with two pharmacists not part of the research group. 
Following these, the interview guide was refined and interview probes developed. (See Appendix 
C for interview guide).  
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4.3.3 Data collection 
All interviews were conducted by telephone and data were recorded using interviewer field notes 
and audio recording. To ensure consistency, all interviews were conducted by GRP and data 
collection was performed to saturation (defined as three interviews past the point where novel 
information could no longer be discerned). An iterative approach was taken to data collection, 
wherein, data analysis was performed concurrently, and emerging themes were used to inform 
questioning in future interviews. All interviews were conducted between September 2016 and 
December 2016. No incentives were provided for participation in the study. 
4.3.4 Data analysis 
Audio recordings were transcribed verbatim by a professional transcriber and checked for 
accuracy by GRP. Data saturation was assessed through concurrent analysis of the data. The 
organization and analysis of data was performed using NVivo 12 (QSR international, Burlington, 
Massachusetts, USA). The data was analyzed using Braun and Clarke’s guide for thematic data 
analysis to identify, analyze and describe themes.202 The coding framework adopted deductive 
(pre-determined concepts underpinning the research questions) and inductive (prominent and 
recurring themes identified within the data) forms of coding, as the use of such ‘hybrid approach’ 
is known to improve rigor in qualitative research.203  
GRP and RV independently coded the interview transcripts and coding discrepancies were 
resolved through consensus. Consultation with a third researcher (NW who was not part of the 
initial analysis) was done when consensus could not be reached. Through repeated evaluation 
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and comparison, overlapping codes were then grouped into appropriate themes reflective of the 
content patterns. 
4.4 Results 
Of the 42 survey respondents expressing interest in being interviewed, twelve did not respond to 
follow-up through emails or phone calls, and one withdrew interest. A total of 22 pharmacists 
were interviewed to achieve saturation. Of these, all but two were authorized to administer 
injections, almost three-quarters practiced pharmacy for >20 years, and half currently practiced 
in urban locations. The interview length ranged from 15-64 minutes (average: 31 minutes). 
Complete participant demographics are presented in Table 1.  
From the transcribed interviews, 710 significant statements were extracted and grouped into 110 
unique codes (See Appendix D for code list). These codes were further merged into five major 
themes and 15 subthemes as described below.  
4.4.1 Theme 1: Pharmacists and immunization services 
Degree of support for pharmacist’s role in influenza immunization 
Most participants were supportive of their role in administering immunizations, emphasizing 
their ability to provide accessible and convenient services to patients who otherwise may not 
receive the influenza vaccine. Participants also identified this service as an opportunity to build 
and enhance ongoing pharmacist-patient relationships, contribute to the province’s pandemic 
preparedness plans, and provide other vaccinations.  
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“I think that our basic role as a pharmacist is to promote the healthcare and well-being 
of all our patients and vaccination is an essential component of that.” PH13 
Those who were critical of this service identified challenges with workflow and remuneration, as 
discussed in detail in other themes. 
Integration of vaccinations into pharmacy workflow 
In general, requests for vaccinations were processed like regular prescriptions within the 
pharmacy’s workflow. Interestingly, participants did not comment on organizing specialized 
influenza clinics, instead, highlighting the walk-in nature of the service. 
4.4.2 Theme 2: Pharmacists’ attitudes towards influenza vaccine and VH 
Attitudes towards personal influenza immunization 
Participants described personally receiving the influenza vaccine primarily to prevent disease 
transmission to family and patients. Revealing one’s own personal immunization status was also 
used as a strategy to promote vaccination to patients. Participants who did not receive the 
influenza vaccine themselves expressed poor efficacy of the vaccine and no prior experience of 
influenza as the reasons for refusal.  
Perceived role in VH 
The participants perceived their role in VH primarily as educators and advocates of the vaccine, 
by resolving concerns and fulfilling patient information needs. This role was contextualized with 
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an appreciation of the greater contact-time and opportunity for patient engagement in the 
pharmacy setting as compared to other healthcare settings.  
“We have so much direct contact with patients that I think we are able to mostly address 
the issue than a lot of doctors because doctors only see their patients when they are ill, so 
[at] the time of the vaccine season, especially the flu vaccine, they may not necessarily 
see their patients.” PH11 
Attitudes towards VH and those expressing hesitancy 
Two participants referred to VH as a complex but modifiable issue, encompassing a variety of 
reasons resulting in the delay or refusal of a vaccine. However, most pharmacists interviewed 
perceived those expressing hesitancy as difficult to convince and strongly opinionated against the 
vaccine. In these scenarios, the participants emphasized the importance of providing information 
and supporting individual autonomy on the eventual vaccination decision.  
“People have preconceived notions, you know you can think that perhaps they have been 
brain washed, but then on the other hand they think that you have been brain washed. So, 
you cannot convince them otherwise, and all that you do is present them with evidence 
and hope that they see the light.” PH22 
Conflation of VH with binary vaccination decisions 
Most participants described those expressing hesitancy as ‘adamant’ and ‘close-minded’ 
individuals, who had made a decision to not receive the vaccine and were unlikely to change. 
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This description is consistent with a binary outlook to vaccination decisions, wherein patients 
either received (pro-vaccine) or refused (anti-vaccine) the influenza vaccine. This results in a 
compression of the VH continuum, and the reduction of vaccination decisions to a static binary 
of yes/no, rather than a dynamic space of possibilities.  
“I just have this recollection of people being adamant that they are not getting the 
vaccine, and nothing I could do could change their mind and they make me sad, this is 
what it did, it made me sad.” PH8 
Interestingly, one participant acknowledged this misclassification; however, described difficulty 
distinguishing those hesitant from those that are anti-vaccine in practice. 
“I do think there is a significant difference between the anti-vaccine and vaccine 
hesitancy… I am not sure I can do that, I am not sure that I have the insight or the 
experience to tell.” PH14 
Despite the conflation, some participants recognized that individuals may re-think their initial 
vaccination decision over time as a result of multiple influences and interactions, passively 
acknowledging the dynamic nature of vaccination decisions. 
“I feel it is just about planting the seed, and if you have several people planting seeds, 
something might grow. So, my job is not really to force people into getting it, but just to 
make them think about it in a different way.” PH13 
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4.4.3 Theme 3: Pharmacists’ experiences with influenza VH and those expressing hesitancy 
Frequency of VH experiences 
Most pharmacists described the frequency of coming across those hesitant to receive the 
influenza vaccine as a minor proportion of their patient population over the influenza season.  
“I am sure there are lot of them, but I did not really come across them in my practice 
places, not really, no.” PH1 
“Fortunately, not too often, I would say, in a flu season may be twice a week” PH17 
One pharmacist described frequent encounters with those hesitant; however, the availability of 
time to proactively engage with patients on vaccinations was highlighted.  
“It is quite often because prior to where I am right now, where I worked it was a slower 
pace pharmacy and I had quite a bit of time at my hand to engage customers walking to 
the store and it was quite often.” PH20 
Reasons for patient influenza VH 
The participants described the most frequent reasons for influenza VH expressed in the 
pharmacy as being rooted in misinformation, specifically, patients believing influenza vaccine 
leads to influenza. This was followed by complacency, wherein patients did not feel the necessity 
to be vaccinated. Other reasons expressed included fear of needles, and religious reasons.  
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“It is usually that every time they get the flu vaccine, they get sick, regardless of the fact 
that you can explain that it is not a live vaccine…” PH14 
Perceived influence on individuals expressing hesitancy 
The participants described most individuals they come across as having already made a 
vaccination decision to either receive or not receive the vaccine prior to meeting with them. With 
individuals expressing hesitancy, the participants generally described a poor ability to influence 
their acceptance of getting vaccinated. 
“I have not been able to convince any client who was hesitant or reluctant to take the 
vaccine.” PH15 
Interestingly, twice the number of respondents shared anecdotes about a negative vaccination 
outcome, wherein those expressing hesitancy chose not to receive the vaccine, compared to a 
positive vaccination outcome.  
4.4.4 Theme 4: Patient engagement on influenza vaccinations 
Passive engagement 
Often initiated by the patient, engagement on influenza vaccination at the pharmacy was 
primarily passive in nature. In contrast to assuming a proactive role in seeking and addressing 
VH, most participants described their engagement as primarily responding to questions asked by 
their patients.  
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“If they ask you about it [influenza vaccine], then it is important to engage in the 
conversation just like any other topic they raise, but it is not something you just randomly 
bring up with people.” PH21 
“I think that right now there is no promotion about vaccines, hesitancy or about asking 
questions. We are not being advocates; we are just responding to questions.” PH2 
For others, time and resource limitations further amplified this passive style of engagement. 
“I do not want to encourage everybody because I am already overwhelmed, I do not even 
want to promote the service because I am already overwhelmed and I cannot handle the 
workload without any extra help!” PH19 
Business implications of engagement 
Interestingly, some participants expressed friction between the ‘business’ and ‘health care 
delivery’ aspects of community pharmacy as a barrier further preventing active engagement. The 
fear of losing patients to other pharmacies by continuing to discuss vaccination upon an initial 
refusal was expressed by some owner-operator participants.  
“If we challenge their beliefs, they could go to another pharmacy where they are not 
going to be challenged, so we have to walk a fine line in terms of the services that we 
provide and what we do.” PH22 
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Process of patient engagement 
Consistent with the passive approach described earlier, most pharmacists described regular 
engagement on influenza vaccine as a brief conversation that happened after a degree of 
acceptance to receive the vaccine was expressed, such as while filling out the requisite 
paperwork or patients seeking reassurance right before vaccine administration. 
“I can say, it is more of a discussion just before you inject them.” PH17 
In contrast, two pharmacists described proactive engagement and utilizing other patient-facing 
opportunities such as medication reviews and non-prescription drug recommendations to initiate 
discussions on influenza vaccination. 
“If I’m called to counsel or if I am actually in the aisle giving advice or 
recommendations on cough and cold products or whatever else, I usually ask, ‘Do you 
normally get the flu shot?’…and that is when I try to address whatever concern they 
have.” PH13 
4.4.5 Theme 5: Addressing influenza VH in the community pharmacy 
Current strategies to address influenza VH 
Consistent with their own perceived role in VH, patient education was described as the choice 
strategy when engaging with those hesitant to receive the influenza vaccine.  
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“I think one on one discussion with the patient and just giving them the information, 
letting them make their own decision, so they do not feel pressured, is a good thing.” 
PH10 
To enhance the effectiveness of these conversations, participants underscored the importance of 
establishing rapport, capitalizing on existing relationships with their patients, and respecting 
patient autonomy over the eventual vaccination decision. Some participants also described the 
use of varying engagement styles such as use of humor and lighthearted tone when conversing 
with specific patients. Other arguments used were personal vaccination anecdotes and 
highlighting social/community protection benefits offered through vaccination.  
Barriers to engaging in VH conversations 
The most common barriers to engaging and addressing VH described were resource constraints, 
specifically related to personnel and time.  
“You tend to engage people if you have a quiet period, when you are not actually rushed 
off your feet and then you can suggest to them, ‘Would like to get a flu shot?’, ‘Have you 
had your flu shot this year?’ But if you are busy filling scripts and the phone is ringing 
that conversation does not happen because you do not have time.” PH21 
Resource burden was consistently emphasized as a barrier to not just engaging with those who 
may be hesitant to receive the influenza vaccine, but also to administering the vaccine in patients 
who have made a decision to receive it. 
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“Just with logistics and the workload of injecting people that want to be injected or need 
to be injected, I think is very challenging as a community pharmacist, so I do not think 
our main focus is on the patients who are reluctant to have a flu shot right now.” PH17 
Additionally, the current remuneration model for provision of influenza vaccine at the pharmacy, 
which includes a fee of CAD $7.50 for each completed vaccination, was criticized by the 
participants as being insufficient and not rewarding the additional time that may have been spent 
consulting with those expressing hesitancy, resulting in reduced motivation to engage in vaccine 
conversations.  
“We are not getting paid for the effort, we are getting paid for results and that is 
wrong…” PH8 
In addition to the aforementioned barriers, the participants also described the impact of pressures 
to increase vaccination volume, issues with obtaining adequate supply of vaccine, and paperwork 
relating to billing, communication, and record keeping as limiting time available for patient 
engagement on the influenza vaccine. 
Proposed strategies to support pharmacists in addressing influenza VH 
In addition to enhanced personnel and financial resources to enable vaccine discussions, the most 
frequently proposed strategies to promote influenza vaccination and address influenza VH 
revolved around equipping the pharmacist with knowledge and skills to counsel patients 
expressing hesitancy and answer frequently asked questions. 
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Other proposed strategies included: provision of fiscal incentives, improved access and 
availability to preservative-free vaccine products (i.e., pre-filled syringes rather than multi-dose 
vials), and ‘proactive’ engagement with patients on the influenza vaccine. Interestingly, only one 
participant described the need for specialized communication tools to handle VH conversations.  
“If we could find a way to make it easier to open the door to having a conversation about 
what it is that is preventing them from getting the flu shot, that might be handy.” PH22 
4.5 Discussion 
This study explores pharmacists’ experience with influenza VH and the nuances of their 
interactions with patients about the influenza vaccine. Our findings indicate that pharmacists 
primarily assume the role of educators, with knowledge provision and correction of 
misinformation being the strategy of choice when dealing with those expressing hesitancy. 
Pharmacists’ appeared to hold a binary perception of patient vaccination decisions, and the 
initiation of influenza vaccine conversations at the pharmacy was predominantly done by 
patients. Further, pharmacists’ capacity to engage in vaccine conversations appears to be limited 
by time and resource constraints.  
The association between healthcare provider recommendations and vaccine uptake by patients 
has been extensively documented.31,36,37,40,51,204 A trial evaluating the impact of personalized 
education on influenza vaccinations by pharmacists demonstrated an 8.7% increase in vaccine 
uptake among seniors.35 In a survey of pharmacy patrons conducted in Ontario, 62% of 
respondents expressed willingness to receive a vaccine if recommended by their health care 
professional.45 As such, encouraging active engagement between providers and patients on 
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vaccines is of great value towards maximizing the known association between provider 
recommendations and positive vaccination outcomes.  
Our results suggest that pharmacists’ engagement about influenza vaccine and with those 
expressing hesitancy is modulated through a complex and mutually reinforcing constellation of 
attitudes and behaviours. These include pharmacists’ perception of the phenomenon of VH as 
static and immutable, and the impact of prior experiences with individuals expressing hesitancy 
on their future behaviour. Based on our findings, we propose a model to illustrate the 
relationship between the various components modulating pharmacists’ engagement on influenza 
vaccines at the pharmacy (Figure 4-1). The model comprises three overarching components: 1) 
The passive engagement loop; 2) Practice consequences and missed opportunities; and 3) 
Extrinsic factors. 
Figure 4-1. Modulators of community pharmacists’ engagement with patients on 
influenza vaccine 
  76 
The passive engagement loop 
‘Passive engagement’, simply described as patient-led initiation of vaccine conversations, likely 
results in frequent interactions with individuals polarized about the vaccine, as those that are 
complacent or do not have strong opinions may not necessarily vocalize their concerns.102,132 
This experience is reflected through the pharmacists’ description of individuals expressing 
hesitancy as ‘adamant’ and ‘close-minded’ – expressions more commonly associated with those 
that are closer to the anti-vaxx end of the VH spectrum.  
A byproduct of this lived experience, pharmacists’ continued exposure to individuals who are 
polarized about vaccines further reinforces a binary outlook to patient vaccination decisions. 
This, in turn, enables a perception that all individuals merely accept or reject a vaccine, 
effectively negating the space on the spectrum for those that are hesitant. The resultant 
compression of the VH continuum and the misclassification of vaccine hesitants as anti-vaxxers 
essentially creates a ripple effect, dampening the pharmacists’ perceived ability to influence 
patient vaccination decisions, and further lowering their likelihood of engaging with individuals 
that express hesitancy. This therefore completes and sustains a positive feedback loop. 
Practice consequences and missed opportunities 
Despite being ideally placed to address VH due to frequent contact with patients and the public, 
easy accessibility, and convenient hours of service, our results describe a low frequency of 
community pharmacist encounters with those hesitant. A portion of this observation appears to 
be a direct consequence of the passive engagement loop. Such passive pharmacist engagement 
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on influenza vaccines at the pharmacy further results in missed opportunities, as a low rate of 
identification results in fewer opportunities to engage and positively nudge individuals along the 
VH continuum.  
Extrinsic factors 
Vaccinations in the pharmacy are nested within the context of constrained resources. Regular 
workload, limited time, and inadequate staffing, among others, were consistently identified as 
barriers to both vaccine administration and patient engagement on vaccinations. In combination 
with a binary outlook to vaccination decisions, insufficient fiscal incentives and a remuneration 
model tied to the act of administration further moderate pharmacists’ motivation to engage with 
those expressing hesitancy. 
A low influenza vaccine uptake rate in Ontario (~35%)91, coupled with evidence describing anti-
vaxxers as forming a small minority of the population3,98,205, leads us to believe that a vast 
majority of the population could be considered vaccine hesitant to some degree, either actively 
(by choice) or passively (through complacency). Pharmacists have an important role in 
addressing influenza VH within their communities; however, future research must explore 
strategies to break the loop of passive engagement and foster proactive pharmacist engagement 
on vaccines. The proposed model provides potential targets to address influenza VH in the 
community pharmacy with a focus on improved pharmacist engagement with patients on the 
influenza vaccine. However, future interventions must also explore means to alleviate resource 
constraints and other extrinsic barriers to support patient engagement and improve positive 
vaccination outcomes. 
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4.6 Limitations 
Only pharmacists who responded to a prior survey (n=885) conducted by the research team had 
the opportunity to participate in this research. As such, our results reflect the subjective 
experiences of the interview participants only, which may differ from those who did not 
participate in this study. While two independent researchers carried out the analysis, the effects 
of researcher biases cannot be ruled out.  
4.7 Conclusion 
Our research suggests that pharmacists’ engagement with patients on the influenza vaccine is 
modulated by a complex and mutually reinforcing constellation of attitudes and behaviours, 
including: a binary perception of patient vaccination decisions, a conflation of individuals 
expressing vaccine hesitancy with those that are anti-vaccine, and a passive approach to patient 
engagement on the influenza vaccine. While pharmacists hold the potential to effectively address 
influenza VH within their communities, future interventions must explore means to break the 
loop of passive patient engagement and enable proactive pharmacist-led discussions on the 
influenza vaccine.  
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Table 4-1. Participant demographics  
1 Gender  n %  
 Male 12 54.5  
 Female 10 45.5 
2 Authorized to administer injections  n % 
  Yes 20 90.9 
  No 2 9.1 
3 Location  n %  
 Small population centre (<29,999 individuals) 5 22.7  
 Medium population centre (30,000 – 99,999 individuals) 6 27.3  
 Large urban (>100,000 individuals) 11 50.0 
4 Pharmacy type n % 
  Independent 7 31.8 
  Mass merchandiser 6 27.3 
  Chain 5 22.7 
  Franchise 4 18.2 
5 Daily prescription volume  n§ %  
 < 100 7 33.3  
 101 – 200 4 19.0  
 201 – 300 7 33.3  
 > 300 3 14.3 
6 Position  n % 
  Full time: Staff pharmacist 8 36.4 
  Full time: Owner/Designated Manager 8 36.4 
  Part time/Relief 6 27.3 
7 Years in practice n %  
 < 5 years 1 4.5  
 6 to 10 years 1 4.5  
 11 to 15 years 1 4.5  
 16 to 20 years 3 13.6  
 > 20 years 16 72.7 
§Information not gathered from one respondent. 
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Table 4-2. Major themes and sub-themes identified 
 
  
Pharmacists and immunization 
services 
Degree of support for pharmacist’s role in influenza 
immunization 
Integration of vaccinations into pharmacy workflow 
Pharmacists’ attitudes towards 
influenza vaccine and VH 
Attitudes towards personal influenza immunization 
Perceived role in VH 
Attitudes towards VH and those expressing hesitancy 
Conflation of VH with binary vaccination decisions 
Pharmacists’ experiences with 
influenza VH 
Frequency of VH experiences 
Reasons for patient influenza VH 
Perceived influence on individuals expressing hesitancy 
Patient engagement on influenza 
vaccinations 
Passive engagement 
Business implications of engagement 
Process of patient engagement 
Addressing influenza VH in the 
community pharmacy 
Current strategies to address influenza VH 
Barriers to engaging in VH conversations 
Proposed strategies to support pharmacists in addressing 
influenza VH 
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 Chapter 5 
Cost-utility analysis of offering a novel remunerated community pharmacist 
consultation service on influenza vaccination for seniors in Ontario, Canada 
 
The contents of this chapter are reflective of an original manuscript published by the PhD 
candidate (Gokul Raj Pullagura) in the Journal of the American Pharmacists Association 
(JAPhA). The candidate was responsible for conception and design of the study, data collection, 
analysis and interpretation of data, drafting the manuscript and performing peer-requested 
revisions. 
Pullagura GR, Waite NM, Houle SKD, Violette R, Wong WWL. Cost-utility analysis of offering 
a novel remunerated community pharmacist consultation service on influenza vaccination for 
seniors in Ontario, Canada. J Am Pharm Assoc (2003). 2019;59(4):48-497.e1. doi: 
10.1016/j.japh.2019.02.011. 
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Prologue 
Having gained a better understanding of influenza vaccine hesitancy (VH) through the 
quantitative and qualitative studies (described in Chapters 3 and 4) in the community pharmacy 
setting, a natural progression for our research was to explore potential interventions that 
addressed this challenge. The implementation of evidence to practice often involves modifying 
or incorporating changes to individual and collective behaviours.206 Such change is best enabled 
through a thorough understanding of the ‘nature’ of the target behaviour, which in turn enables 
the selection of ideal intervention characteristics and components tailored to make the most of 
this understanding.206,207 Implementation science researchers therefore advocate the use of a 
systematic, theory driven approach to intervention design and evaluation.207-209 
Based on 19 theories, the behaviour change wheel (BCW)206 is a widely adopted meta-
framework to guide intervention design in a systematic and transparent manner. The application 
of this framework primarily involves: 1) An analysis of the target behaviour; 2) Determination of 
Figure.1. The Behaviour Change Wheel (BCW)1 
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appropriate intervention functions to bring about the desired change in behaviour; and 3) 
Identification of policy categories to enable and support the choice intervention.  
To best address influenza VH in the pharmacy setting, it is critical to first identify a central target 
behaviour, which when modified has the greatest potential to bring about the desired change in 
practice. A distillation of our research findings leads us to believe that breaking the loop of 
‘passive engagement’ (described in Chapter 4) has the most potential in this regard. More 
specifically, the ideal behavioural target would be to ensure that pharmacists utilize all available 
opportunities to proactively initiate and engage patients in influenza vaccine conversations. In 
addition to resolving existing patient concerns, such behaviour is expected to create space for 
issues of dormant hesitancy to be expressed and prevent passive VH through complacency.  
To facilitate an analysis of the target behaviour, the authors of BCW also present a behavioural 
model, (termed COM-B) that acts as a central ‘hub’ of the behaviour change ‘wheel’. This 
system proposes an individual’s physical and psychological Capability, their automatic and 
reflective Motivation, and the physical and social Opportunity to engage in the target behaviour, 
as the fundamental interacting components that generate and modulate Behaviour.206  
An assessment of the current behaviour of passive engagement through the COM-B lens hints at 
the need to target the ‘Motivation’ and ‘Opportunity’ components affecting this behaviour for 
most impact; as findings from our research (presented in Chapter 3) indicate that pharmacists’ 
already possess a high ‘Capability’ (i.e., knowledge, ability and confidence) to address influenza 
VH and; issues of time and remuneration appear to be the bigger challenges to optimal patient 
engagement. Interestingly, current approaches to address influenza VH such as the Canadian 
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Immunization Guide66 and, the ASK tool175 rely on the provision of knowledge, skills and/or 
information intended to augment the healthcare provider’s ‘Capability’. However, our analysis 
suggests that reorienting our efforts to target the ‘Motivation’ and ‘Opportunity’ components 
may be of increased benefit in the community pharmacy context.  
Based on the tenet of positive reinforcement, the use of incentives has been linked to improve 
both automatic (involving emotions, impulses and associative learning) and reflective (involving 
plans and evaluations) processes driving ‘Motivation’.206,207 In this chapter, we propose, design, 
and evaluate the cost-effectiveness of a novel incentive-based intervention targeting the 
pharmacists’ motivation to engage in influenza vaccine conversations. 
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“We are not getting paid for the effort, we are getting paid for results and that is 
wrong…” PH8 
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5.1 Overview 
Background: Despite the availability of free and accessible influenza vaccine to all Ontarians, 
uptake has remained suboptimal. While reasons to not receive the vaccine vary widely, 
healthcare provider recommendations remain the most effective strategy to positively influence 
vaccination decisions. 
Objective: This study aimed to predict the relative quality of life, costs and cost-effectiveness of 
introducing a remunerated community-pharmacist consultation service on influenza vaccination 
for Ontarians aged ≥65 years. 
Methods: A cost-utility analysis was performed from a third-party public-payer perspective over 
one-year. The delivery of consultation services by community-pharmacists on influenza 
vaccination, billable at CAD $15 was compared to current standard practices (absence of 
remunerated consultations). Model inputs were sourced primarily from existing literature. The 
impact of parameter uncertainties was assessed through deterministic and probabilistic sensitivity 
analyses. 
Results: The provision of influenza vaccine consultation services was predicted to prevent 2,407 
cases of mild-influenza and 3 influenza-related deaths at an additional cost of CAD $2.03/person 
over current practices. The incremental costs per quality-adjusted life-year (QALY) gained for 
the Enhanced Care strategy relative to Standard Care was CAD $2,087. The interpretation of the 
base-case result was found to be robust across all sensitivity analyses. The projected additional 
costs of implementing pharmacist consultations in Ontario was estimated at CAD $1.15 
million/year and the anticipated benefits included a gain of 507 QALYs/year. 
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Conclusion: Pharmacist delivered consultation services on influenza vaccination are cost-
effective and lead to improved clinical outcomes for Ontario seniors. Introduction of such 
services offers a promising strategy to address challenges related to poor vaccine uptake in this 
group. 
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5.2 Introduction 
Influenza is a vaccine preventable infectious disease of the respiratory system that affects 10-
20% of the world’s population annually.6 In Ontario alone, the 2016-17 influenza season 
resulted in 3,839 hospitalizations and 260 deaths.210 The national economic burden in Canada 
associated with the direct medical care costs of influenza was estimated to be CAD $60 
million.211 Through Ontario’s Universal Influenza Immunization Program, all residents can be 
vaccinated against influenza free of charge from a variety of healthcare providers including 
pharmacists,14 yet vaccination rates remain suboptimal.91 
While the entire population is susceptible to influenza, it is well recognized that individuals 
aged 65 years and over have higher morbidity and mortality.6 An analysis of 2005-2011 
health care data in the United States revealed that up to 85% of deaths and 70% of 
hospitalizations from seasonal influenza occurred in those that were aged ≥65 years.212 Other 
studies have also observed a longer hospital stay in this age group, ranging between 130-
200% relative to others.182,213 
From a socio-cultural perspective, a decision to vaccinate is not a simple dichotomy of accept 
or reject, but one that is complicated and influenced by multiple factors that vary across time, 
place, vaccine and context.3,58 As such, attitudes and behaviours towards vaccination are best 
perceived on a continuum, wherein individuals dynamically transition across a spectrum of 
possibilities.58 Therefore, a personalized approach specifically tailored around each 
individual’s questions and concerns may hold the most potential to improve vaccine 
uptake.214,215 
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Pharmacists are accessible sources of trustworthy information and education, who play a vital 
role in providing the community they serve with clear, factual information regarding 
influenza and its vaccine.43 In a 2014 survey of pharmacy patrons conducted in Ontario, 62% 
of respondents expressed willingness to receive a vaccine if recommended by their health care 
professional.45 Pharmacists in Ontario currently receive a fee of CAD $7.50 if a patient 
receives the vaccine, intended to only offset administration costs.216 As a result, any 
additional time spent providing education to patients who may be uncertain about their 
decision to receive the vaccine is not remunerated. In a busy community pharmacy 
environment, this lack of remuneration is an additional barrier which prevents these 
conversations from occurring.199 The introduction of standalone consultation services is 
anticipated to promote active patient engagement on influenza vaccine, provide means to 
address individual patient concerns, and exert positive influence on patient vaccination 
decisions. 
This study aimed to predict the relative quality of life changes, costs, and cost-effectiveness 
associated with the provision of a novel remunerated influenza vaccine consultation service 
by community pharmacists for Ontario seniors, when compared to current standard practices. 
5.3 Methods 
5.3.1 Type of economic evaluation 
The analysis was conducted using a cost-utility approach, wherein cost-effectiveness was 
assessed as the incremental cost per quality-adjusted life-year (QALY) gained. Such analysis 
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allows decision-makers to make comparisons across an array of conditions and interventions, 
facilitating the allocation of resources based on health gain maximization.217 
5.3.2 Study perspective and time horizon 
The analysis was conducted using a third-party public-payer perspective, specifically, the 
Ontario Ministry of Health and Long-Term Care (MOHLTC). The base-case analysis of the 
services was conducted over the duration of one year. 
5.3.3 Target population  
The Canadian National Advisory Committee on Immunization recommends the seasonal 
influenza vaccine to all individuals over the age of 6 months unless contraindicated, however, 
those aged ≥65 years are identified to be at a higher risk of influenza related complications and 
hospitalizations.15 The target population for this study therefore included all Ontarians aged ≥65 
years who accessed community-pharmacy services. Ontario cost-benefit projections were 
performed using a sample of 5,20,509 simulations, equivalent to the number of Ontarians aged 
≥65 years estimated to utilize immunization services in the Enhanced Care arm: 
Number of Ontario seniors estimated to receive their influenza vaccine at the 
community-pharmacy in the Enhanced Care arm = (Population of seniors in 
Ontario (2,424,818)234 X Proportion of seniors receiving the influenza vaccine 
in the Enhanced Care arm (0.7252) X Proportion of adults receiving their 
influenza vaccine at community-pharmacies (0.296)).260  
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5.4 Strategies assessed 
This study compared two different formats of influenza vaccination service delivery by 
community pharmacists: 1. Standard Care (SC) (status quo), and 2. Enhanced Care (EC). The SC 
strategy presented traditional means of influenza immunization delivery at the community 
pharmacy for Ontario seniors ≥65 years, which do not include the availability of remunerated 
influenza immunization consultations. The EC arm included the provision of all services 
available to those ≥65 years in the SC arm, with the additional availability of pharmacist 
delivered influenza immunization consultations. 
The provision of consultation services was considered to be at the professional discretion of the 
consulting pharmacist in response to an identified knowledge gap or questions around influenza 
vaccination from eligible individuals, or upon request from eligible individuals. The consultation 
service was considered to comprise a face-to-face, comprehensive and individualized assessment 
of the patient’s reservations surrounding influenza vaccination, followed by an appropriate 
resolution through the provision of high-quality tailored information. This interaction was 
expected to be conducted in a private counselling area housed within the pharmacy and was 
anticipated to take under 15 minutes of the pharmacists’ time including standard documentation 
requirements. 
5.4.1 Model description 
A decision-analytic model was implemented in TreeAge® Pro 2017 (TreeAge Software Inc., 
Williamstown, MA, USA). In this model, seniors utilizing pharmacy services chose to either 
receive the influenza vaccine or not. Based on their choice, the decision tree then explored 
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possible vaccination and disease related outcomes. Vaccination-specific outcomes included the 
presence or absence of an adverse event, which were further stratified into those that resulted in a 
cost to the health care system and those that did not. Disease-related outcomes included the 
occurrence of influenza, which was further stratified into mild [i.e., treated with non-prescription 
drugs, not resulting in physician office/emergency department (ED) visit], moderate [i.e., 
resulting in a physician office/ED visit], severe [i.e., admission to the hospital/ICU, not resulting 
in death] and death. The SC strategy was also considered to serve as an active control, as 
provision of no-cost annual influenza immunization constitutes the current standard of care for 
seniors (aged ≥65 years) in Ontario.218 The EC arm included the provision of all services 
available to those ≥65 years in the SC arm, with the additional availability of pharmacist 
delivered influenza immunization consultations.  
Based on the guidelines for economic evaluation of health technologies in Canada,217 
discounting of future events was not performed as the current analysis utilized a time-horizon of 
one year. In this study, a decision tree was selected as the choice decision analytic model due to 
the absence of recurring events, and a short time horizon. The decision tree is presented in Figure 
5-1. 
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Figure 5-1. The decision model schematic 
The Enhanced Care arm is identical in structure to the Standard Care arm. 
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5.4.2 Input data 
a. Efficacy, safety and transition probabilities 
The baseline estimate for the risk reduction offered by the influenza vaccine was obtained from a 
Cochrane meta-analysis that incorporated data from five randomized controlled trials.72 The 
vaccine uptake in the SC arm was estimated from the Canadian Community Health Survey data 
across seven influenza seasons (2007/08-2013/14).193 The impact of patient education and 
facilitation activities by pharmacists on influenza vaccine uptake has been studied previously 
with demonstrated gains in uptake ranging from 4% to 26.3%.36,219-221 The EC strategy assumed 
a relatively conservative 8.7% incremental gain in vaccine uptake, obtained from a sufficiently 
powered, controlled, cluster randomized controlled trial assessing the impact of personalized 
pharmacist education on influenza vaccine uptake among community dwelling seniors aged ≥65 
years in Tokyo, Japan.35 The decision to choose this study over other available literature was 
based on similarities in study and population characteristics. 
The probability of contracting influenza was obtained from the U.S. Centers for Disease Control 
and Prevention guidebook on influenza.6 The transition probabilities for severe influenza and 
death were estimated using data from Public Health Ontario’s influenza surveillance summaries 
spanning five seasons (2012/13-2016/17).222 The probabilities of developing moderate influenza 
and adverse drug reactions (ADRs) from the influenza vaccination were obtained from existing 
literature.223,224 Data on transition probabilities used in the analysis are presented in Table 5-1. 
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b. Costs 
Costs for all resources were adjusted to 2017 Canadian Dollars using Statistics Canada’s 
Consumer Price Index (health care component) for Ontario and Purchasing Power Parity where 
applicable.225 Costs for vaccination in the SC arm were calculated by adding the cost of vaccine 
and the professional fee for administration, available from existing literature.216,223 In addition, 
the EC arm included a consultation fee, which was set at CAD $15. Provision of influenza 
vaccine consultations were considered comparable in terms of time, effort and documentation 
requirements to that of the Pharmaceutical Opinion Program in Ontario, a service currently 
offered by pharmacists and reimbursed at a rate of CAD $15 by the Ontario MOHLTC.216 This 
assumption was established by reaching consensus with practicing pharmacists and pharmacy 
practice researchers. 
The EC arm also incorporated additional costs to account for: a) consultations that did not result 
in vaccinations (18.4% of all consultations)35, and b) individuals who may receive the vaccine 
irrespective of a consultation, but choose to receive the consult anyway upon its availability 
(10% of baseline vaccine uptake). Both the adjustments stated above resulted in increased costs 
without contributing to additional vaccinations. 
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Costs for vaccination: 
Standard Care arm = (Cost/dose + Professional fee for vaccine administration) 
Enhanced Care arm = (Cost/dose + Professional fee for vaccine administration + 
(Number of consultations X Consultation fee) + Additional costs (Consults not resulting 
in vaccinations and vaccinations occurring regardless of consultations).  
Costs for physician office visits, hospitalizations and ED visits were obtained from existing 
literature.79 Costs for influenza-related intensive care unit (ICU) admissions were obtained from 
the Canadian Institute for Health Information.226,227 Costs for influenza related deaths were 
assumed to be similar to the costs of ICU admissions, as death was considered to be a sequelae 
of severe influenza. Data on costs used in the analysis are presented in Table 5-1. 
c. Utilities 
Utility values were assigned for the occurrence of clinically relevant events (influenza and/or 
ADRs to the vaccination). Utility values were sourced from existing literature.79,228,229 Utility for 
severe influenza was assumed to be similar to the utility of community acquired pneumonia 
requiring hospitalization.230 Life expectancy was adjusted for baseline utility at a given age.79 
Minor ADRs included were transient, self-resolving, and did not require health professional 
intervention, such as fever, malaise, and soreness at the injection site. The utility score for minor 
ADRs was assumed to be 0.99, a value greater than mild/moderate influenza (0.9707),79 but less 
than 1 (perfect health). Data on utility scores used for the analysis are presented in Table 5-1. 
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Table 5-1. Input parameters 
Table 5-1. Input parameters   
Range used in sensitivity 
analysis 
  
Name Base-case 
estimate 
Low High Distribution 
used in PSA 
Reference(s) 
Age 65 65 110 ^ - 
Vaccine effectiveness 0.58 0.34 0.73 Normal 
72 
Costs† 
 Consultation fee $ 15 $ 10 $ 20 Gamma Assumed (based 
on 216) 
 Death $ 17918.97 $ 16127.073 $ 19710.867 Gamma Assumed (based 
on 226,227) 
 Mild Influenza $ 0 $ 0 $ 0 ^ NA (As defined) 
 Physician office visit $ 40.90 $ 21.03 $ 70.11 ^ 79 
 ED Visit $ 257.07 $ 213.8315 $ 433.5054 ^ 79 
 No Influenza $ 0 $ 0 $ 0 ^ NA (As defined) 
 Severe ADR $ 69349.77 $ 57,346.25 $ 81,353.29 Gamma 231 
 Severe Influenza $ 7499.293 $ 2424.592 $ 25178.37 Gamma 226,227 
 Influenza vaccine and  
 administration 
$ 12.93 $ 11.637 $ 14.223 Gamma 223 
Transition probabilities 
 Occurrence of influenza 0.15 0.10 0.20 Beta 6,232 
 Physician Visit 0.0022521 0.002027 0.002477 Beta 223 
 ED Visit 0.0010134 0.000912 0.001115 Beta 223 
 Severe Influenza 0.00100760 0.000423 0.001108 Beta 222 
 Death 0.000101 0.000037 0.000162 Beta 222 
 Minor ADR 0.12605 0.102345 0.149068 Beta 224 
 Severe ADR 1.02927E-06 9.26E-07 1.13E-06 Beta 233 
 Influenza vaccine received -  
 Standard Care arm 
0.6671 0.65 0.68 Beta 193 
 Incremental vaccine uptake -  
 Enhanced Care arm 
0.087 0.033 0.141 Beta 35,219 
Utilities 
 Death 0 0 0 ^ NA 
 Influenza 0.9707 0.9651 0.9767 ^ 79 
 Minor ADR 0.99 0.891 0.999 ^ Assumed (based 
on 79) 
 Severe ADR 0.5225 0.36 0.74 Beta 228 
 Severe influenza 0.7 0.63 0.77 Beta Assumed (based 
on 230) 
^Not included in PSA, †In 2017 Canadian dollars. 
Abbreviations: ADR, Adverse Drug Reaction; ED, Emergency Department; NA, Not Applicable; PSA, Probabilistic Sensitivity 
Analysis. 
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5.4.3 Analysis 
a. Validation 
Face validation of the model structure was performed by a health economist. Face validation of 
the hypothesis formulation and input parameters were performed by 4 clinical experts, including 
pharmacy practice researchers and practicing pharmacists. 
b. Base-case analysis and cost-benefit projections 
The estimation of base-case cost-effectiveness was performed by conducting eight age-stratified 
analyses in five-year intervals (65-70 years to 100-105 years), where each analysis accounted for 
age dependent changes in life expectancy and baseline health utility. The results were scaled 
using 2018 Ontario census data234 to obtain an aggregate incremental cost-effectiveness ratio for 
all Ontario residents aged ≥65 years. The cost projection for the provincial MOHLTC was made 
by multiplying the consultation fee with the number of individuals estimated to receive the 
consultation.  
c. Sensitivity analyses 
Extensive univariate sensitivity analyses were conducted to test the effects of changing 
individual underlying assumptions and parameter values within the model. In addition, 
probabilistic sensitivity analyses were performed by conducting 10,000 iterations of second order 
Monte Carlo simulation. The analysis incorporated distributions for uncertainties related to 
vaccine efficacy, transition probabilities, costs, and utilities. Estimates for incremental costs, and 
QALYs were obtained by running the model using parameter values derived from probability 
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distributions. In the absence of uncertainty information, the analysis adopted a 10% deviation 
around parameters.  
d.  Threshold analyses 
Multiple threshold analyses were conducted to determine the value of a parameter required to 
change the interpretation of the base-case result. This was based on the routinely employed 
willingness-to-pay (WTP) threshold in Canadian health technology assessments of CAD 
$50,000/QALY.235 
5.5 Results 
5.5.1 Base-case analysis 
The analysis modeled residents of Ontario, Canada aged 65 years to 105 years. The average costs 
in the SC arm was CAD $14.63, compared to the EC arm at CAD $16.66. The net additional 
costs of introducing the consultation service were CAD $2.03/person over current practices. The 
EC arm was found to be only slightly more effective at 12.3243 QALYs than the SC arm at 
12.3234 QALYs. The incremental cost per QALY gained for the EC arm relative to the SC arm 
was CAD $2,087.25. The base-case results are presented in Table 5-2. 
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Age group Population 
(Ontario, 2018)19 
Cost ($) QALY 
ICUR ($) 
EC arm SC arm EC arm SC arm 
65 to 69 years 757,793 16.67 14.63 17.2233 17.2246 1493.44 
70 to 74 years 613,928 16.67 14.63 13.7786 13.7797 1866.80 
75 to 79 years 426,449 16.67 14.63 10.6965 10.6974 2404.69 
80 to 84 years 302,369 16.67 14.63 7.6264 7.6270 3372.72 
85 to 89 years 198,414 16.67 14.63 5.4349 5.4354 4732.69 
90 to 94 years 94,793 16.67 14.63 3.6817 3.6820 6986.36 
95 to 99 years 27,614 16.67 14.63 2.5421 2.5423 10118.17 
100 to 105 years 3,458 16.67 14.63 1.7532 1.7533 14671.35 
Weighted average: 
65 to 105 years 2,424,818 16.67 14.63 12.3234 12.3243 2087.25 
Table 5-2. Base-case cost-effectiveness results 
The EC strategy was estimated to prevent 2,407 cases of mild influenza, 48 cases of moderate 
influenza requiring physician/ED visits, 24 cases of severe influenza requiring 
hospitalization/ICU admission, and 3 influenza-related deaths over the SC arm per influenza 
season. The results of the clinical outcomes analysis are presented in Table 5-3. The additional 
costs incurred to the provincial MOHLTC to implement remunerated community-pharmacist 
consultation services were estimated to be CAD $1.15million/year and the anticipated benefits 
included a cumulative gain of 507 QALYs/year. 
Table 5-3. Clinical outcomes analysis 
 Number of cases per season (#/season) 
 SC arm EC arm Net outcomes prevented 
Mild influenza 46603 44196 2407 
Moderate influenza  1038 990 48 
Severe influenza  350 318 24 
Death 24 21 3 
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5.5.2 Threshold analysis 
Threshold analysis was conducted assuming a WTP value of CAD $50,000 per QALY gained. 
The SC arm was found to be the cost-effective alternative when: a) the additional gain in vaccine 
uptake as a result of consultations fell below 0.27%, b) the vaccine effectiveness dropped below 
32.64%, c) the probability of contracting influenza was <7.68%, or d) when the cost of each 
consultation was over CAD $451. 
5.5.3 Deterministic sensitivity analysis 
Model results were most sensitive to the efficacy of the influenza vaccine followed by the age of 
the patients. The Incremental Cost Utility Ratio was not found to breach the WTP threshold of 
CAD $50,000/QALY in any of the tests. A tornado diagram summarizing results from the 
univariate sensitivity analysis is presented in Figure 5-2. 
 
Figure 5-2. Tornado diagram presenting the relative significance of variables 
EV: Expected value. 
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This summary of the 1-way sensitivity analysis describes the impact of modifying individual 
parameter values on the base incremental cost-effectiveness ratio of the EC arm relative to the 
SC arm. 
5.5.4 Probabilistic sensitivity analysis 
The EC strategy was the optimal choice in 81.23% replications at a WTP value of 
$5,000/QALY. At a WTP/QALY value of CAD $10,000 and more, the probability of the cost-
effectiveness of the two strategies compared plateaued. The cost-effectiveness acceptability 
curve is presented in Figure 5-3. 
 
Figure 5-3. Probabilistic sensitivity analysis 
Cost-effectiveness acceptability curve and scatter plot. 
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5.6 Discussion 
Offering a remunerated community-pharmacist consultation service on influenza vaccination for 
Ontario seniors is expected to be both cost-effective and clinically effective, preventing an 
estimated 20 cases of severe influenza requiring hospitalization/ICU admission and 3 influenza 
related deaths per influenza season. Cost-effectiveness of the EC strategy was found robust 
across all sensitivity analyses, adding confidence to the interpretation of the base-case result. The 
results were most sensitive to the efficacy of the influenza vaccine, followed by age, which is 
explained by the decline in life expectancy with increasing age. 
Currently, remuneration provided for publicly funded influenza immunizations in Ontario 
pharmacies is limited to a vaccine administration fee and does not include compensation to 
encourage engagement with those who may have questions about their decision to receive the 
vaccine. Ongoing research with community-pharmacists by our group suggests that despite 
having the knowledge, ability and confidence to impact a patient’s vaccination decision, this lack 
of payment for time discussing patient concerns on vaccination is a significant barrier preventing 
such discussions from being initiated more widely.199 
As this is the first published pharmacoeconomic study evaluating the potential impact of a 
remunerated pharmacist consultation service on influenza vaccination, we are unable to directly 
compare our findings to other works. However, systematic reviews of economic analyses 
evaluating professional pharmacy services, such as patient education and consultation across 
varying settings, populations and health conditions, found such services to be generally cost-
effective.236,237 A study evaluating the cost-effectiveness of pharmacist services (education, 
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consultation and/or prescribing) for managing hypertension in Canada determined the service as 
being simultaneously more effective and cost-saving relative to usual care.238 A 2011 cost-utility 
analysis in the United Kingdom identified one-on-one community pharmacist counselling as the 
choice strategy for smoking cessation when compared to group-based support or absence of 
additional external support.239 Consistent with our results, pharmacist delivered professional 
services in other contexts were routinely found to be cost-effective. 
The results of this study should be interpreted with consideration of several limitations. Owing to 
the novel nature of the proposed intervention, estimates for incremental vaccine uptake in the EC 
arm were based on a Cluster-RCT conducted in Tokyo, Japan. Despite potential differences in 
socio-geographical contexts, similarities in baseline vaccine uptake rates, study population 
(community dwelling elderly aged 65 years and older); intervention (community pharmacist 
delivered in-person education on influenza vaccination); control (current practices); outcome and 
duration (increase in influenza vaccination rates over one-year) most resemble our proposed 
study intervention compared to other available literature.36,219-221 Further, sensitivity analyses 
incorporating a broad range and distribution of vaccine uptake in the EC arm did not change the 
base result. However, effectiveness data obtained following a controlled pilot study of the 
proposed intervention in Ontario may provide better estimation of the intervention effectiveness.  
Although costs of some prescription medications for those ≥65 years in Ontario are covered by 
the provincial government, these costs were not incorporated into the analysis. Neuraminidase 
inhibitors Oseltamivir (Tamiflu®) and Zanamivir (Relenza®) used in the treatment of influenza 
are only covered for institutionalized seniors during confirmed outbreaks.240 Amantadine is 
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covered for all, but is not recommended for use due to high levels of resistance.240,241 Therefore, 
prescription drug costs borne by the provincial government excluded from this analysis are 
expected to be limited to drugs for symptomatic management and secondary bacterial infections. 
The exclusion of these costs is not expected to have a significant impact on the conclusions 
reached by this analysis, and only underestimates the cost-effectiveness of the EC strategy. 
Data on hospitalizations and deaths were obtained from Public Health Ontario’s influenza 
surveillance program. This data may not be complete as it primarily includes laboratory 
confirmed cases of influenza and cases that are coded specifically as influenza in patients’ 
electronic health records. Several cases of influenza may be missed as laboratory confirmation is 
not always performed. 
The complex and context specific nature of vaccine hesitancy, a prime contributor to poor 
vaccine uptake, necessitates the need to tailor messaging and communication to meet the specific 
needs of those expressing hesitancy. As such, the introduction of a standalone pharmacist-led 
consultation service on influenza vaccination would enable patients to freely discuss their 
concerns and receive information tailored specifically for them. Considering that healthcare 
professional recommendations are important predictors of vaccination decisions, the provision of 
a CAD $15 fee, consistent with fees offered in Ontario for other professional opinion services, 
may encourage pharmacists to increasingly engage in these discussions with patients. Such 
engagement is ultimately anticipated to improve the population vaccination rate, while remaining 
cost-effective from the payer’s perspective.  
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Expanding on this study, suitability of similar standalone fee-for-service consultations may be 
evaluated across other vaccines, target populations, providers or jurisdictions. Future research 
should consider the feasibility of implementing this service within the existing workflow of 
community pharmacies. 
5.7 Conclusion 
Community-pharmacist consultation services on influenza vaccination for Ontario seniors offers 
a cost-effective addition to current practices. Considering the positive impact of health 
professional recommendations on vaccination outcomes, policymakers should consider the 
humanistic and economic benefits achieved through the introduction of pharmacist-led 
consultation services on vaccination that are remunerated independent of any administration fees. 
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 Chapter 6 
Summary, implications, and conclusion 
6.1 Summary 
Vaccinations are easily amongst the greatest achievements of the 20th century, yet, inadequate 
uptake of vaccination services continues to burden population health. From a socio-cultural 
context, a decision to vaccinate is complex and influenced by multiple factors that vary across 
time, place, vaccine and context.3,123,183 VH challenges the traditional dichotomy of perceiving 
vaccination decisions as mere outcomes of vaccine-acceptance (pro-vaxx) or vaccine-refusal 
(anti-vaxx). Instead, the phenomenon of VH describes vaccine decision making as a dynamic 
process wherein individuals transition across a spectrum of possible attitudes and behaviours 
ranging from complete acceptance to absolute refusal of all vaccines.3,96 Therefore, a vast 
majority of the individuals, in fact, lie somewhere along the ‘continuum’; accepting, delaying, or 
refusing some or all vaccines. 
Despite such complexity in vaccine decision making, healthcare provider recommendations 
remain highly influential in positively swaying patient vaccine decisions.29-32,40,102 Their 
recommendations, education and advocacy form the current best predictor of positive vaccine 
outcomes.29-32,40,102 In addition to serving as a cue to action, provider recommendations can be 
acted upon immediately, bridging the behaviour-intention gap and sidestepping logistical barriers 
to immunization (ex. scheduling and making specific arrangements to get immunized).102 
Further, provider recommendations, and their personal immunization serve to establish social 
norms, construing vaccination as the default, which may be of particular benefit to those 
  108 
hesitant.102 As such, healthcare providers remain an indispensable asset in the global efforts to 
combat VH. 
Although recent years have witnessed a surge in VH research and an increasing prominence of 
pharmacists as immunizers,32,33,40,96,98,101,184,193,242-246 no work has been done to examine the 
community pharmacists’ preparedness or experiences with influenza VH. As such, our research 
presents some of the first work done on influenza VH in the community pharmacy space. 
6.2 Main findings 
The goal of this research was to establish a foundational understanding of community 
pharmacists’ experiences with influenza VH. To achieve this primary objective, we utilized a 
mixed-methods approach incorporating an exploratory cross-sectional survey, followed by in-
depth semi-structured interviews. Mixed-methods approach by virtue of its ability to gather 
robust data has been widely recommended,247-251 and extensively utilized68,252-255 in healthcare 
research. The combined findings from the quantitative and qualitative studies inform a better 
theoretical understanding of the phenomenon under study.256 Considering the relative naivety of 
research on influenza VH in the pharmacy space, the exploratory survey provided an overview of 
current practices and attitudes of pharmacists with regards to influenza VH, and the interview 
component allowed further investigation into distinct observations. 
In Chapter 3, we descriptively explored pharmacists’ self-perceived knowledge, current attitudes 
and practices relating to influenza VH. Our results illustrated that pharmacists’ self-rated 
knowledge of influenza disease and its vaccine, and their perceived confidence and ability to 
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identify, assess and address patient vaccine concerns were generally high. Interestingly, despite 
high prescription volumes, pharmacists’ encounters with individuals expressing hesitancy were 
relatively infrequent and pharmacist-patient engagement on influenza vaccination appeared to be 
passive in nature and patient-driven. However, overarching stressors of workload and poor 
perceived remuneration, limiting pharmacists’ engagement on influenza vaccine conversations 
do provide some context to understand this observation. 
In Chapter 4, we continued to build on our findings, and sought to gain an in-depth 
understanding of the pharmacists’ experiences with influenza VH and the modulators of their 
engagement with patients on the influenza vaccine. In addition to a passive style of engagement 
with patients, pharmacists appeared to hold a binary outlook to patient vaccination decisions, 
perceiving them as being static and an immutable dichotomy of either vaccine acceptors (pro-
vaccine) or rejectors (anti-vaccine). We believe these two findings are inter-related as passive 
engagement, through insufficient interactions with those expressing hesitancy, contributes to a 
binary perception of patient vaccination decisions and vice-versa; thereby, completing and 
sustaining a feedback loop. In the context of limited resources, this loop is further compounded 
as vaccinations and vaccine conversations compete for the pharmacists’ limited time. The 
implications of this ‘passive engagement loop’ includes infrequent interactions with those 
expressing hesitancy and thereby, fewer opportunities exist for pharmacists’ to positively engage 
and nudge those expressing hesitancy along the VH continuum. 
Having gained a better understanding of pharmacists’ current preparedness and experiences with 
influenza VH, a natural progression for our research was to explore potential interventions 
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tailored to the community pharmacy setting. As the translation of evidence to practice in 
healthcare often involves changing the behaviour of one or more individuals, we examined our 
results from Chapter 3 and 4 through an implementation science lens. Using the COM-B 
behavioural model and the behaviour change wheel (BCW)206, we identified that targeting 
pharmacists’ current behaviour of passive engagement and bolstering their motivation to 
proactively engage in vaccine conversations holds the most potential to address influenza VH in 
community pharmacies.  
Using these principles, we proposed and designed a remunerated pharmacist consultation service 
on influenza vaccination for Ontario seniors, and evaluated its cost-effectiveness from a third-
party public-payer perspective. The delivery of consultation services by community-pharmacists 
on influenza vaccination, billable at CAD $15 were compared to current standard practices 
(absence of remunerated consultations). Our results determined pharmacists’ influenza vaccine 
consultation services for seniors to be both cost-effective and clinically effective, preventing an 
estimated 2,407 cases of mild influenza, 20 cases of severe influenza requiring hospitalization 
and 3 influenza related deaths per influenza season, while only costing the public-payer an 
additional CAD $2.03 per person over current practices. The complex and context specific nature 
of VH limits a ‘one size fits all’ approach to address it. The introduction of standalone 
pharmacist consultation services on influenza vaccine would enable patients to freely discuss 
their concerns and receive tailored information, thereby, positively influencing their vaccination 
outcome. 
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6.3 Implications for practice, policy and research 
The work presented in this thesis provides data relevant to policymakers, healthcare providers, 
and the patients they care for. Community pharmacies offer an excellent proposition to identify 
and address influenza VH. The added convenience through the extended work hours, availability 
of walk-in immunization services, accessible locations and a high volume of patient foot-traffic 
provides multiple opportunities to identify, resolve and positively nudge those expressing 
hesitancy along the VH continuum. Existing research has described the demographic using 
Ontario pharmacy immunization services (younger, higher income quintile or non-immigrant) as 
being different from those immunized in physician offices (older, lower income quintile or those 
identifying as immigrant).257 As such, pharmacies can help target an important but difficult to 
reach group of healthy adults, who often tend to be caregivers for those at a higher risk. 
Therefore, community pharmacies provide a unique, yet complementary avenue for recognizing 
and addressing patient VH and positively impacting vaccine uptake.  
Capitalizing on this opportunity, however, requires pharmacists to let go of the binary outlook to 
patient vaccine decisions and proactively engage with all patients on the influenza vaccine. The 
important, albeit unintended practice consequences of holding such binary perceptions include: 
- Conflation of those hesitant with anti-vaxxers, thereby limiting engagement with patients 
who may in fact be influenced. Such conflation also leads to a diminished perception of 
pharmacists’ self-perceived ability to influence patient vaccine decisions. 
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- Framing engagement with patients in a binary context (ex. Would you like to get an influenza 
vaccine today?), limiting possible responses to either acceptance or refusal, essentially 
negating the scope for a fruitful engagement. 
Therefore, future research must explore means to improve the pharmacists’ awareness on the 
spectrum of hesitancy, break the loop of passive engagement, and explore tools to assist 
pharmacists engage in quick and productive interactions with patients on the influenza vaccine.  
In regard to VH, policymakers must recognize that while administration of vaccine may be the 
optimal outcome, it is not the only beneficial outcome. Positively nudging those expressing 
hesitancy along the VH continuum is arguably just as valuable. Recognizing and rewarding 
positive progress towards a goal has been established as important in other clinical areas such as 
weight loss, smoking cessation, and substance-abuse recovery, among others. However, the same 
approach has not been recognized for vaccine decisions.258,259 Perhaps, pharmacists’ binary 
outlook to patient vaccine decisions may stem from the fact that remuneration to pharmacies for 
influenza immunization is directly tied to the act of administration, devoid of any incentivization 
to consult with patients. From a policymaker’s perspective, the evidence on the cost-
effectiveness of incentivizing pharmacists’ time to consult with seniors on influenza vaccine 
supports the consideration of such services in Ontario. However, given the high heterogeneity 
between provinces in terms of legislation, pharmacists’ scope of practice, and remuneration 
models, the generalizability of our findings remains unclear.93,258,259  
‘In face of rising hesitancy and an increasingly interprofessional milieu of healthcare delivery, 
patient receipt of the vaccine is paramount, regardless of the provider.’ 
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6.4 Conclusion 
A key challenge of immunization lies not with the small vocal minority of outright vaccine 
refusers, but rather with those who are hesitant to vaccinate. When engaging with those hesitant, 
it is important for community pharmacists to move beyond the traditional assumption of binary 
vaccination outcomes, and instead focus on positively nudging those hesitant along the VH 
continuum. Facilitating optimal practice scope for pharmacists, and capitalizing the additional 
convenience and accessibility offered through the community pharmacy setting presents a 
promising means to address influenza VH. However, efforts must be reoriented to enhance 
pharmacists’ motivation and opportunity to proactively engage with patients in one-on-one 
influenza vaccine conversations to best address influenza VH in the pharmacy. 
  
  114 
 References 
1. Ten great public health achievements --- worldwide, 2001--2010. 
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6024a4.htm. Updated 2011. Accessed July 
31, 2019. 
2. Andre FE, Booy R, Bock HL, et al. Vaccination greatly reduces disease, disability, death and 
inequity worldwide. Bull World Health Organ. 2008;86(2):140-146. 
3. MacDonald NE, SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, 
scope and determinants. Vaccine. 2015;33(34):4161-4164. doi: 10.1016/j.vaccine.2015.04.036. 
4. Ten threats to global health in 2019. https://www.who.int/emergencies/ten-threats-to-global-
health-in-2019. Accessed July 30, 2019. 
5. Measles cases and outbreaks. https://www.cdc.gov/measles/cases-outbreaks.html. Updated 
2019. Accessed October 8, 2019. 
6. Influenza - epidemiology and prevention of vaccine-preventable disease. 
http://www.cdc.gov/vaccines/pubs/pinkbook/flu.html. Updated April 15, 2019. Accessed July, 
2019. 
7. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines 
for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2014;3:CD001269. doi: 
10.1002/14651858.CD001269.pub4. 
8. Schanzer DL, Sevenhuysen C, Winchester B, Mersereau T. Estimating influenza deaths in 
Canada, 1992-2009. PLoS One. 2013;8(11):e80481. doi: 10.1371/journal.pone.0080481. 
9. Schanzer DL, McGeer A, Morris K. Statistical estimates of respiratory admissions attributable 
to seasonal and pandemic influenza for Canada. Influenza Other Respir Viruses. 2013;7(5):799-
808. doi: 10.1111/irv.12011. 
  115 
10. Statistics Canada - leading causes of death, total population, by age group. 
https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310039401. Accessed September 12, 
2019. 
11. O'Reilly DJ, Blackhouse G, Burns S, et al. Economic analysis of pharmacist-administered 
influenza vaccines in Ontario, Canada. Clinicoecon Outcomes Res. 2018;10:655-663. doi: 
10.2147/CEOR.S167500. 
12. Putri, Wayan C. W. S., Muscatello DJ, Stockwell MS, Newall AT. Economic burden of 
seasonal influenza in the United States. Vaccine. 1983;36(27):3960-3966. doi: 
10.1016/j.vaccine.2018.05.057. 
13. Ontario respiratory virus bulletin. 
http://www.publichealthontario.ca/en/DataAndAnalytics/Documents/Ontario_Respiratory_Virus
_Bulletin-2013-2014_Season_Summary.pdf. Updated 2014. Accessed October 15, 2017. 
14. Universal influenza immunization program (UIIP). 
https://www.opatoday.com/professional/resources/for-pharmacists/programs/uiip. Updated 2016. 
Accessed March, 2017. 
15. Statement on seasonal influenza vaccine for 2014-2015. http://www.phac-aspc.gc.ca/naci-
ccni/flu-grippe-eng.php. Updated 2014. Accessed March, 2017. 
16. Talbot TR, Talbot HK. Influenza prevention update: Examining common arguments against 
influenza vaccination. JAMA. 2013;309(9):881-882. doi: 10.1001/jama.2013.453. 
17. Glezen WP. Clinical practice. prevention and treatment of seasonal influenza. N Engl J Med. 
2008;359(24):2579-2585. doi: 10.1056/NEJMcp0807498. 
18. Demicheli V, Jefferson T, Ferroni E, Rivetti A, Pietrantonj CD. Vaccines for preventing 
influenza in healthy adults. Cochrane Database Syst Rev. 2018(2). doi: 
10.1002/14651858.CD001269.pub6 
  116 
19. Hickler B, Guirguis S, Obregon R. Editorial - Vaccine special issue on vaccine hesitancy. 
Vaccine. 2015;33(34):4155-4156. doi: 10.1016/j.vaccine.2015.04.034. 
20. Dube E, MacDonald NE. Managing the risks of vaccine hesitancy and refusals. Lancet Infect 
Dis. 2016. doi: 10.1016/S1473-3099(16)00028-1. 
21. Report of the SAGE working group on vaccine hesitancy. 
http://www.who.int/immunization/sage/meetings/2014/october/SAGE_working_group_revised_r
eport_vaccine_hesitancy.pdf?ua=1. Updated November 2014. Accessed March, 2017. 
22. Kane MA. Commentary: Public perception and the safety of immunization. Vaccine. 1998;16 
Suppl:73. doi: 10.1016/s0264-410x(98)00302-8. 
23. Jarrett C, Wilson R, O'Leary M, Eckersberger E, Larson HJ, SAGE Working Group on 
Vaccine Hesitancy. Strategies for addressing vaccine hesitancy - A systematic review. Vaccine. 
2015;33(34):4180-4190. doi: 10.1016/j.vaccine.2015.04.040. 
24. Larson HJ, Jarrett C, Schulz WS, et al. Measuring vaccine hesitancy: The development of a 
survey tool. Vaccine. 2015;33(34):4165-4175. doi: 10.1016/j.vaccine.2015.04.037. 
25. Eskola J, Duclos P, Schuster M, MacDonald NE, SAGE Working Group on Vaccine 
Hesitancy. How to deal with vaccine hesitancy? Vaccine. 2015;33(34):4215-4217. doi: 
10.1016/j.vaccine.2015.04.043. 
26. Year in review: Measles linked to Disneyland | CDC. 2015. 
https://blogs.cdc.gov/publichealthmatters/2015/12/year-in-review-measles-linked-to-disneyland/. 
Accessed October 8, 2019. 
27. Press release - Potential public exposures to international measles case. https://us4.campaign-
archive.com/?e=&u=2f2593b644c191a74f2a4d25a&id=7da8021e24. Updated 2019. Accessed 
October 8, 2019. 
  117 
28. Dube E, Gagnon D, MacDonald NE, SAGE Working Group on Vaccine Hesitancy. 
Strategies intended to address vaccine hesitancy: Review of published reviews. Vaccine. 
2015;33(34):4191-4203. doi: 10.1016/j.vaccine.2015.04.041. 
29. Polisena J, Chen Y, Manuel D. The proportion of influenza vaccination in Ontario, Canada in 
2007/2008 compared with other provinces. Vaccine. 2012;30(11):1981-1985. doi: 
10.1016/j.vaccine.2012.01.009. 
30. Wu S, Su J, Yang P, et al. Factors associated with the uptake of seasonal influenza 
vaccination in older and younger adults: A large, population-based survey in Beijing, China. 
BMJ Open. 2017;7(9):e017459. doi: 10.1136/bmjopen-2017-017459. 
31. Gargano LM, Painter JE, Sales JM, et al. Seasonal and 2009 H1N1 influenza vaccine uptake, 
predictors of vaccination, and self-reported barriers to vaccination among secondary school 
teachers and staff. Human Vaccin. 2011;7(1):89-95. doi: 10.4161/hv.7.1.13460. 
32. Schmid P, Rauber D, Betsch C, Lidolt G, Denker ML. Barriers of influenza vaccination 
intention and behavior - A systematic review of influenza vaccine hesitancy, 2005 - 2016. PLoS 
One. 2017;12(1):e0170550. doi: 10.1371/journal.pone.0170550. 
33. Alsabbagh MW, Church D, Wenger L, et al. Pharmacy patron perspectives of community 
pharmacist administered influenza vaccinations. Res Social Adm Pharm. 2019;15(2):202-206. 
doi: 10.1016/j.sapharm.2018.04.015. 
34. Wade GH. Nurses as primary advocates for immunization adherence. MCN Am J Matern 
Child Nurs. 2014;39(6):351. doi: 10.1097/NMC.0000000000000083. 
35. Usami T, Hashiguchi M, Kouhara T, Ishii A, Nagata T, Mochizuki M. Impact of community 
pharmacists advocating immunization on influenza vaccination rates among the elderly. 
Yakugaku Zasshi. 2009;129(9):1063-1068. doi: 10.1248/yakushi.129.1063. 
  118 
36. Van Amburgh JA, Waite NM, Hobson EH, Migden H. Improved influenza vaccination rates 
in a rural population as a result of a pharmacist-managed immunization campaign. 
Pharmacotherapy. 2001;21(9):1115-1122. doi: 10.1592/phco.21.13.1115.34624. 
37. Leung KC, Mui C, Chiu WY, et al. Impact of patient education on influenza vaccine uptake 
among community-dwelling elderly: A randomized controlled trial. Health Educ Res. 
2017;32(5):455-464. doi: 10.1093/her/cyx053. 
38. Smith PJ, Kennedy AM, Wooten K, Gust DA, Pickering LK. Association between health 
care providers' influence on parents who have concerns about vaccine safety and vaccination 
coverage. Pediatrics. 2006;118(5):1287. doi: 10.1542/peds.2006-0923. 
39. Rosenthal SL, Weiss TW, Zimet GD, Ma L, Good MB, Vichnin MD. Predictors of HPV 
vaccine uptake among women aged 19-26: Importance of a physician's recommendation. 
Vaccine. 2011;29(5):890-895. doi: 10.1016/j.vaccine.2009.12.063. 
40. Paterson P, Meurice F, Stanberry LR, Glismann S, Rosenthal SL, Larson HJ. Vaccine 
hesitancy and healthcare providers. Vaccine. 2016;34(52):6700-6706. doi: 
10.1016/j.vaccine.2016.10.042. 
41. Pandolfi E, Marino MG, Carloni E, et al. The effect of physician's recommendation on 
seasonal influenza immunization in children with chronic diseases. BMC Public Health. 
2012;12:98-984. doi: 10.1186/1471-2458-12-984. 
42. Pharmacists' scope of practice in Canada. https://www.pharmacists.ca/pharmacy-in-
Canada/scope-of-practice-Canada/. Updated 2016. Accessed May 1, 2017. 
43. Steyer TE, Ragucci KR, Pearson WS, Mainous AG,3rd. The role of pharmacists in the 
delivery of influenza vaccinations. Vaccine. 2004;22(8):1001-1006. doi: 
10.1016/j.vaccine.2003.08.045. 
44. Gardner JS. A practical guide to establishing vaccine administration services in community 
pharmacies. J Am Pharm Assoc (Wash). 1997;NS37(6):68-3. 
  119 
45. Papastergiou J, Folkins C, Li W, Zervas J. Community pharmacist-administered influenza 
immunization improves patient access to vaccination. Can Pharm J (Ott). 2014;147(6):359-365. 
doi: 10.1177/1715163514552557. 
46. Lynas K. Professionals you can trust: Pharmacists top the list again in ipsos reid survey. Can 
Pharm J (Ott). 2012;145(2):55. doi: 10.3821/145.2.cpj55c. 
47. Tsuyuki RT, Beahm NP, Okada H, Al Hamarneh YN. Pharmacists as accessible primary 
health care providers: Review of the evidence. Can Pharm J (Ott). 2018;151(1):4-5. doi: 
10.1177/1715163517745517. 
48. Manolakis PG, Skelton JB. Pharmacists' contributions to primary care in the united states 
collaborating to address unmet patient care needs: The emerging role for pharmacists to address 
the shortage of primary care providers. Am J Pharm Educ. 2010;74(10). doi:10.5688/aj7410s7. 
49. Public Health Agency of Canada. Seasonal influenza vaccine coverage in Canada, 2017–
2018. http://publications.gc.ca/collections/collection_2019/aspc-phac/HP40-198-2018-eng.pdf. 
Updated 2019. Accessed August 27, 2019. 
50. Offeddu V, Tam CC, Yong TT, et al. Coverage and determinants of influenza vaccine among 
pregnant women: A cross-sectional study. BMC Public Health. 2019;19(1):890. doi: 
10.1186/s12889-019-7172-8. 
51. Andrew MK, Gilca V, Waite N, Pereira JA. EXamining the knowledge, attitudes and 
experiences of Canadian seniors towards influenza (the EXACT survey). BMC Geriatr. 
2019;19(1):178. doi: 10.1186/s12877-019-1180-5. 
52. Kunze U, Böhm G, Prager B, Groman E. Influenza vaccination in austria: Persistent 
resistance and ignorance to influenza prevention and control. Cent Eur J Public Health. 
2019;27(2):127-130. doi: 10.21101/cejph.a5010. 
  120 
53. Bertoldo G, Pesce A, Pepe A, Pelullo CP, Di Giuseppe G. Seasonal influenza: Knowledge, 
attitude and vaccine uptake among adults with chronic conditions in italy. PLoS ONE. 
2019;14(5):e0215978. doi: 10.1371/journal.pone.0215978. 
54. Freeman VA, Freed GL. Parental knowledge, attitudes, and demand regarding a vaccine to 
prevent varicella. Am J Prev Med. 1999;17(2):153-155. doi: 10.1016/S0749-3797(99)00063-X. 
55. Kennedy AM, Brown CJ, Gust DA. Vaccine beliefs of parents who oppose compulsory 
vaccination. Public Health Rep. 2005;120(3):252-258. doi: 10.1177/003335490512000306. 
56. Quadri-Sheriff M, Hendrix KS, Downs SM, Sturm LA, Zimet GD, Finnell SM. The role of 
herd immunity in parents' decision to vaccinate children: A systematic review. Pediatrics. 
2012;130(3):522-530. doi: 10.1542/peds.2012-0140. 
57. Taddio A, Ipp M, Thivakaran S, et al. Survey of the prevalence of immunization non-
compliance due to needle fears in children and adults. Vaccine. 2012;30(32):4807-4812. doi: 
10.1016/j.vaccine.2012.05.011. 
58. Dube E, Gagnon D, Ouakki M, et al. Understanding vaccine hesitancy in Canada: Results of 
a consultation study by the Canadian immunization research network. PLoS One. 
2016;11(6):e0156118. doi: 10.1371/journal.pone.0156118. 
59. Lee T, Saskin R, McArthur M, McGeer A. Beliefs and practices of Ontario midwives about 
influenza immunization. Vaccine. 2005;23(13):1574-1578. doi: 10.1016/j.vaccine.2004.09.024. 
60. Dube E, Gilca V, Sauvageau C, et al. Acute otitis media and its prevention by immunization: 
A survey of Canadian pediatricians' knowledge, attitudes and beliefs. Hum Vaccin. 
2011;7(4):429-435. doi: 10.4161/hv.7.4.14141. 
61. Dube E, Gilca V, Sauvageau C, et al. Canadian paediatricians' opinions on rotavirus 
vaccination. Vaccine. 2011;29(17):3177-3182. doi: 10.1016/j.vaccine.2011.02.044. 
  121 
62. Herzog R, Álvarez-Pasquin MJ, Díaz C, Del Barrio JL, Estrada JM, Gil Á. Are healthcare 
workers' intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic 
review. BMC Public Health. 2013;13:154. doi: 10.1186/1471-2458-13-154. 
63. Gilca V, Boulianne N, Dubé E, Sauvageau C, Ouakki M. Attitudes of nurses toward current 
and proposed vaccines for public programs: A questionnaire survey. Int J Nurs Stud. 
2009;46(9):1219-1235. doi: 10.1016/j.ijnurstu.2009.02.013.  
64. Taubenberger JK, Morens DM. The pathology of influenza virus infections. Annu Rev 
Pathol. 2008;3(1):499-522. doi: 10.1146/annurev.pathmechdis.3.121806.154316. 
65. CDC Pinkbook - Epidemiology and prevention of vaccine-preventable diseases - Influenza. 
https://www.cdc.gov/vaccines/pubs/pinkbook/flu.html. Updated 2019. Accessed Sep 19, 2019. 
66. Public Health Agency of Canada. Canadian immunization guide chapter on influenza and 
statement on seasonal influenza vaccine for 2019–2020. https://www.Canada.ca/en/public-
health/services/publications/vaccines-immunization/canadian-immunization-guide-statement-
seasonal-influenza-vaccine-2019-2020.html. Updated 2019. Accessed Aug 6, 2019. 
67. Girard MP, Tam JS, Assossou OM, Kieny MP. The 2009 A (H1N1) influenza virus 
pandemic: A review. Vaccine. 2010;28(31):4895-4902. doi: 10.1016/j.vaccine.2010.05.031. 
68. Fischer WA, Gong M, Bhagwanjee S, Sevransky J. Global burden of influenza: 
Contributions from resource limited and low-income settings. Global heart. 2014;9(3):325-336. 
doi: 10.1016/j.gheart.2014.08.004. 
69. Shrestha SS, Swerdlow DL, Borse RH, et al. Estimating the burden of 2009 pandemic 
influenza A (H1N1) in the United States (April 2009–April 2010). Clin Infect Dis. 
2011;52(suppl_1):S75-S82. doi: 10.1093/cid/ciq012. 
70. Belongia EA, Kieke BA, Donahue JG, et al. Effectiveness of inactivated influenza vaccines 
varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J 
Infect Dis. 2009;199(2):159-167. doi: 10.1086/595861. 
  122 
71. Lee JKH, Lam GKL, Shin T, et al. Efficacy and effectiveness of high-dose versus standard-
dose influenza vaccination for older adults: A systematic review and meta-analysis. Expert 
Review of Vaccines. 2018;17(5):435-443. doi: 10.1080/14760584.2018.1471989. 
72. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines 
for preventing influenza in the elderly. Cochrane Database Syst Rev. 2010;(2):CD004876. 
doi(2):CD004876. 
73. Demicheli V, Jefferson T, Ferroni E, Rivetti A, Pietrantonj CD. Vaccines for preventing 
influenza in healthy adults. Cochrane Database Syst Rev. 2018(2). doi: 
10.1002/14651858.CD001269.pub6. 
74. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza 
vaccines: A systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36-44. doi: 
10.1016/S1473-3099(11)70295-X. 
75. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza 
vaccination of healthy working adults: A randomized controlled trial. JAMA. 
2000;284(13):1655-1663. doi: 10.1001/jama.284.13.1655. 
76. Muennig PA, Khan K. Cost-effectiveness of vaccination versus treatment of influenza in 
healthy adolescents and adults. Clin Infect Dis. 2001;33(11):1879-1885. doi: 10.1086/324491. 
77. Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: A 
cost-effectiveness analysis. Am J Med. 2005;118(1):68-77. doi: 10.1016/j.amjmed.2004.03.044. 
78. Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination programs for elderly 
persons: Cost-effectiveness in a health maintenance organization. Ann Intern Med. 
1994;121(12):947-952. doi: 10.7326/0003-4819-121-12-199412150-00008. 
79. Sander B, Kwong JC, Bauch CT, et al. Economic appraisal of Ontario's universal influenza 
immunization program: A cost-utility analysis. PLoS Med. 2010;7(4):e1000256. doi: 
10.1371/journal.pmed.1000256. 
  123 
80. Pearson ML, Bridges CB, Harper SA, Healthcare Infection Control Practices Advisory 
Committee, (HICPAC), Advisory Committee on Immunization Practices, (ACIP). Influenza 
vaccination of health-care personnel: Recommendations of the healthcare infection control 
practices advisory committee (HICPAC) and the advisory committee on immunization practices 
(ACIP). MMWR Recomm Rep. 2006;55(RR-2):1-16. 
81. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: 
Recommendations of the advisory committee on immunization practices (ACIP), 2010. MMWR 
Recomm Rep. 2010;59(RR-8):1-62. 
82. National advisory committee on immunization - statement on thiomersal. http://www.phac-
aspc.gc.ca/publicat/ccdr-rmtc/07vol33/acs-06/index-eng.php. Updated 2007. Accessed March, 
2018. 
83. Gerber JS, Offit PA. Vaccines and autism: A tale of shifting hypotheses. Clin Infect Dis. 
2009;48(4):456-461.doi: 10.1086/596476. 
84. Haber P, DeStefano F, Angulo FJ, et al. Guillain-barre syndrome following influenza 
vaccination. JAMA. 2004;292(20):2478-2481. doi: 10.1001/jama.292.20.2478. 
85. Juurlink DN, Stukel TA, Kwong J, et al. Guillain-barre syndrome after influenza vaccination 
in adults: A population-based study. Arch Intern Med. 2006;166(20):2217-2221. doi: 
10.1001/archinte.166.20.2217. 
86. Skowronski DM, Strauss B, De Serres G, et al. Oculo-respiratory syndrome: A new influenza 
vaccine-associated adverse event? Clin Infect Dis. 2003;36(6):705-713. doi: 10.1086/367667. 
87. 2019/20 Universal influenza immunization program (UIIP). 
http://www.health.gov.on.ca/en/pro/programs/publichealth/flu/uiip/. Updated 2019. Accessed 
September 15, 2019. 
  124 
88. What is the universal influenza immunization program? 
http://www.peelregion.ca/health/professionals/vaccine-storage/pdf/CDS-0277-RS-7.pdf. 
Updated 2015. Accessed March, 2017. 
89. Flu consult toolkit. 
http://www.health.gov.on.ca/en/pro/programs/publichealth/flu/resources.aspx. Updated 2015. 
Accessed March, 2016. 
90. Kwong JC, Stukel TA, Lim J, et al. The effect of universal influenza immunization on 
mortality and health care use. PLoS Med. 2008;5(10):e211. 
91. Gionet L. Flu vaccination rates in Canada. https://www.statcan.gc.ca/pub/82-624-
x/2015001/article/14218-eng.htm. Updated 2015. Accessed September 12, 2019. 
92. Crouse BJ, Nichol K, Peterson DC, Grimm MB. Hospital-based strategies for improving 
influenza vaccination rates. J Fam Pract. 1994;38(3):258-261. 
93. Canadian Pharmacists Association. Pharmacists' scope of practice in Canada. 
https://www.pharmacists.ca/pharmacy-in-Canada/scope-of-practice-Canada/. Updated 2019. 
Accessed Sep 15, 2019. 
94. Grabenstein JD. Pharmacists as vaccine advocates: Roles in community pharmacies, nursing 
homes, and hospitals. Vaccine. 1998;16(18):1705-1710. doi: 10.1016/s0264-410x(98)00131-5. 
95. Andrawis MA, Rehm SJ. Health-system pharmacists' role in improving immunization rates. 
Am J Health Syst Pharm. 2012;69(1):74-76. doi: 10.2146/ajhp110257. 
96. Peretti-Watel P, Larson HJ, Ward JK, Schulz WS, Verger P. Vaccine hesitancy: Clarifying a 
theoretical framework for an ambiguous notion. PLoS Curr. 2015;7:10.1371. doi: 
10.1371/currents.outbreaks.6844c80ff9f5b273f34c91f71b7fc289. 
97. Buttenheim AM, Asch DA. Making vaccine refusal less of a free ride. Hum Vaccin 
Immunother. 2013;9(12):2674-2675. doi: 10.4161/hv.26676. 
  125 
98. Dube E, Vivion M, MacDonald NE. Vaccine hesitancy, vaccine refusal and the anti-vaccine 
movement: Influence, impact and implications. Expert Rev Vaccines. 2015;14(1):99-117. doi: 
10.1586/14760584.2015.964212. 
99. Yaqub O, Castle-Clarke S, Sevdalis N, Chataway J. Attitudes to vaccination: A critical 
review. Soc Sci Med. 2014;112:1-11. doi: 10.1016/j.socscimed.2014.04.018. 
100. Robbins SCC, Bernard D, McCaffery K, Brotherton JML, Skinner SR. "I just signed": 
Factors influencing decision-making for school-based HPV vaccination of adolescent girls. 
Health Psychol. 2010;29(6):618-625. doi: 10.1037/a0021449. 
101. Betsch C, Schmid P, Heinemeier D, Korn L, Holtmann C, et al. Beyond confidence: 
Development of a measure assessing the 5C psychological antecedents of vaccination. PLoS 
One. 2018;13(12):e0208601. doi: 10.1371/journal.pone.0208601. 
102. Brewer NT, Chapman GB, Rothman AJ, Leask J, Kempe A. Increasing vaccination: Putting 
psychological science into action. Psychol Sci Public Interest. 2017;18(3):149-207. doi: 
10.1177/1529100618760521. 
103. Benin AL, Wisler-Scher DJ, Colson E, Shapiro ED, Holmboe ES. Qualitative analysis of 
mothers' decision-making about vaccines for infants: The importance of trust. Pediatrics. 
2006;117(5):1532-1541. doi: 10.1542/peds.2005-1728. 
104. Larson HJ, Jarrett C, Eckersberger E, Smith DM, Paterson P. Understanding vaccine 
hesitancy around vaccines and vaccination from a global perspective: A systematic review of 
published literature, 2007-2012. Vaccine. 2014;32(19):2150-2159. doi: 
10.1016/j.vaccine.2014.01.081. 
105. Dube E, Gagnon D, Nickels E, Jeram S, Schuster M. Mapping vaccine hesitancy--country-
specific characteristics of a global phenomenon. Vaccine. 2014;32(49):6649-6654. doi: 
10.1016/j.vaccine.2014.09.039. 
  126 
106. Zhang S, Yin Z, Suraratdecha C, et al. Knowledge, attitudes and practices of caregivers 
regarding Japanese encephalitis in Shaanxi province, China. Public Health. 2011;125(2):79-83. 
doi: 10.1016/j.puhe.2010.10.011 
107. Sinno DD, Shoaib HA, Musharrafieh UM, Hamadeh GN. Prevalence and predictors of 
immunization in a health insurance plan in a developing country. Pediatr Int. 2009;51(4):520-
525. doi: 10.1111/j.1442-200X.2008.02769.x. 
108. Muhsen K, Abed El-Hai R, Amit-Aharon A, et al. Risk factors of underutilization of 
childhood immunizations in ultraorthodox Jewish communities in Israel despite high access to 
health care services. Vaccine. 2012;30(12):2109-2115. doi: 10.1016/j.vaccine.2012.01.044. 
109. Rahman M, Obaida-Nasrin S. Factors affecting acceptance of complete immunization 
coverage of children under five years in rural Bangladesh. Salud Publica Mex. 2010;52(2):134-
140. 
110. Wei F, Mullooly JP, Goodman M, et al. Identification and characteristics of vaccine 
refusers. BMC Pediatr. 2009;9:1-18. doi: 10.1186/1471-2431-9-18. 
111. Danis K, Georgakopoulou T, Stavrou T, Laggas D, Panagiotopoulos T. Socioeconomic 
factors play a more important role in childhood vaccination coverage than parental perceptions: 
A cross-sectional study in Greece. Vaccine. 2010;28(7):1861-1869. doi: 
10.1016/j.vaccine.2009.11.078. 
112. Uwemedimo OT, Findley SE, Andres R, Irigoyen M, Stockwell MS. Determinants of 
influenza vaccination among young children in an inner-city community. J Community Health. 
2012;37(3):663-672. doi: 10.1007/s10900-011-9497-9. 
113. Oladokun RE, Lawoyin TO, Adedokun BO. Immunization status and its determinants 
among children of female traders in Ibadan, south-western Nigeria. Afr J Med Med Sci. 
2009;38(1):9-15. 
  127 
114. Siddiqi N, Siddiqi AE, Nisar N, Khan A. Mothers' knowledge about EPI and its relation 
with age-appropriate vaccination of infants in peri-urban Karachi. J Pak Med Assoc. 
2010;60(11):940-944. 
115. Mitchell S, Andersson N, Ansari NM, Omer K, Soberanis JL, Cockcroft A. Equity and 
vaccine uptake: A cross-sectional study of measles vaccination in Lasbela district, Pakistan. 
BMC Int Health Hum Rights. 2009;9 Suppl 1:S-S7. doi: 10.1186/1472-698X-9-S1-S7. 
116. Vikram K, Vanneman R, Desai S. Linkages between maternal education and childhood 
immunization in India. Soc Sci Med. 2012;75(2):331-339. doi: 10.1016/j.socscimed.2012.02.043. 
117. Casiday RE. Children's health and the social theory of risk: Insights from the British 
measles, mumps and rubella (MMR) controversy. Soc Sci Med. 2007;65(5):1059-1070. doi: 
10.1016/j.socscimed.2007.04.023. 
118.Poltorak M, Leach M, Fairhead J, Cassell J. 'MMR talk' and vaccination choices: An 
ethnographic study in Brighton. Soc Sci Med. 2005;61(3):709-719. doi: 
10.1016/j.socscimed.2004.12.014. 
119. Poland GA, Spier R. Fear, misinformation, and innumerates: How the Wakefield paper, the 
press, and advocacy groups damaged the public health. Vaccine. 2010;28(12):2361-2362. doi: 
10.1016/j.vaccine.2010.02.052. 
120. Spier RE. Perception of risk of vaccine adverse events: A historical perspective. Vaccine. 
2001;20 Suppl 1:S7-7. doi: 10.1016/s0264-410x(01)00306-1. 
121. Burki T. The many shades of vaccine hesitancy. Lancet Infect Dis. 2015;15(10):1138-1139. 
doi: 10.1016/S1473-3099(15)00311-4. 
122. Mason BW, Donnelly PD. Impact of a local newspaper campaign on the uptake of the 
measles mumps and rubella vaccine. J Epidemiol Community Health. 2000;54(6):473-474. doi: 
10.1136/jech.54.6.473. 
  128 
123. Dube E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J. Vaccine hesitancy: An 
overview. Hum Vaccin Immunother. 2013;9(8):1763-1773. doi: 10.4161/hv.24657. 
124. Morin A, Lemaitre T, Farrands A, Carrier N, Gagneur A. Maternal knowledge, attitudes and 
beliefs regarding gastroenteritis and rotavirus vaccine before implementing vaccination program: 
Which key messages in light of a new immunization program? Vaccine. 2012;30(41):5921-5927. 
doi: 10.1016/j.vaccine.2012.07.050. 
125. Agyeman P, Desgrandchamps D, Vaudaux B, et al. Interpretation of primary care 
physicians' attitude regarding rotavirus immunisation using diffusion of innovation theories. 
Vaccine. 2009;27(35):4771-4775. doi: 10.1016/j.vaccine.2009.05.097. 
126. Davies P, Chapman S, Leask J. Antivaccination activists on the world wide web. Arch Dis 
Child. 2002;87(1):22-25. doi: 10.1136/adc.87.1.22. 
127. Zimmerman RK, Wolfe RM, Fox DE, et al. Vaccine criticism on the World Wide Web. J 
Med Internet Res. 2005;7(2):e17. doi: 10.2196/jmir.7.2.e17. 
128. Betsch C, Renkewitz F, Betsch T, Ulshofer C. The influence of vaccine-critical websites on 
perceiving vaccination risks. J Health Psychol. 2010;15(3):446-455. doi: 
10.1177/1359105309353647. 
129. Salathé M, Khandelwal S. Assessing vaccination sentiments with online social media: 
Implications for infectious disease dynamics and control. PLoS Comput Biol. 
2011;7(10):e1002199. doi: 10.1371/journal.pcbi.1002199. 
130. McPherson M, Smith-Lovin L, Cook JM. Birds of a feather: Homophily in social networks. 
Annu Rev Sociol. 2001;27(1):415-444. https://doi.org/10.1146/annurev.soc.27.1.415. doi: 
10.1146/annurev.soc.27.1.415. 
131. Christakis NA, Fowler JH. Social contagion theory: Examining dynamic social networks 
and human behavior. Stat Med. 2011;32(4). doi: 10.1002/sim.5408. 
  129 
132. Meyer SB, Violette R, Aggarwal R, Simeoni M, MacDougall H, Waite N. Vaccine 
hesitancy and web 2.0: Exploring how attitudes and beliefs about influenza vaccination are 
exchanged in online threaded user comments. Vaccine. 2019;37(13):1769-1774. doi: 
10.1016/j.vaccine.2019.02.028. 
133. Dittmann S. Vaccine safety: Risk communication--a global perspective. Vaccine. 
2001;19(17-19):2446-2456. doi: 10.1016/s0264-410x(00)00470-9. 
134. Plotkin SA. Lessons learned concerning vaccine safety. Vaccine. 2001;20 Suppl 1:S1-9; 
discussion S1. doi: 10.1016/s0264-410x(01)00303-6. 
135. Briss PA, Rodewald LE, Hinman AR, et al. Reviews of evidence regarding interventions to 
improve vaccination coverage in children, adolescents, and adults. The Task Force on 
Community Preventive Services. Am J Prev Med. ;18(1):97-140. doi: 10.1016/S0749-
3797(99)00118-X 
136. Reyna VF. Risk perception and communication in vaccination decisions: A fuzzy-trace 
theory approach. Vaccine. 2012;30(25):3790-3797. doi: 10.1016/j.vaccine.2011.11.070. 
137. Downs JS, de Bruin WB, Fischhoff B. Parents' vaccination comprehension and decisions. 
Vaccine. 2008;26(12):1595-1607. doi: 10.1016/j.vaccine.2008.01.011. 
138. Leask J. Target the fence-sitters. Nature. 2011;473(7348):443-445. doi: 10.1038/473443a. 
139. Lantos JD, Jackson MA, Opel DJ, Marcuse EK, Myers AL, Connelly BL. Controversies in 
vaccine mandates. Curr Probl Pediatr Adolesc Health Care. 2010;40(3):38-58. doi: 
10.1016/j.cppeds.2010.01.003. 
140. Salmon DA, MacIntyre CR, Omer SB. Making mandatory vaccination truly compulsory: 
Well intentioned but ill conceived. The Lancet Infectious Diseases. 2015;15(8):872-873. doi: 
10.1016/S1473-3099(15)00156-5. 
  130 
141. Huynh S, Poduska P, Mallozzi T, Culler F. American journal of infection control. Am J 
Infect Control. 2009;37(8):A14. doi: 10.1016/S0196-6553(09)00726-3. 
142. Currie D, Malow J. Successful implementation of a mandatory influenza vaccination 
program across a 12 hospital system. Am J Infect Control. 2012;40(5):e98-e99. doi: 
10.1016/j.ajic.2012.04.171. 
143. Babcock HM, Gemeinhart N, Jones M, Dunagan WC, Woeltje KF. Mandatory influenza 
vaccination of health care workers: Translating policy to practice. Clin Infect Dis. 
2010;50(4):459-464. doi: 10.1086/650752. 
144. Miller BL, Ahmed F, Lindley MC, Wortley PM. Increases in vaccination coverage of 
healthcare personnel following institutional requirements for influenza vaccination: A national 
survey of US hospitals. Vaccine. 2011;29(50):9398-9403. doi: 10.1016/j.vaccine.2011.09.047. 
145. Gruben V, Siemieniuk RA, McGeer A. Health care workers, mandatory influenza 
vaccination policies and the law. CMAJ. 2014;186(14):1076-1080. doi: 10.1503/cmaj.140035. 
146. Galanakis E, Jansen A, Lopalco PL, Giesecke J. Ethics of mandatory vaccination for 
healthcare workers. Euro Surveill. 2013;18(45):20627. doi: 10.2807/1560-
7917.ES2013.18.45.20627. 
147. Burton-Jeangros C, Golay M, Sudre P. Compliance and resistance to child vaccination: A 
study among swiss mothers. Rev Epidemiol Sante Publique. 2005;53(4):341-350. doi: S0398-
7620(05)84616-4. 
148. Streefland P, Chowdhury AM, Ramos-Jimenez P. Patterns of vaccination acceptance. Soc 
Sci Med. 1999;49(12):1705-1716. doi: 10.1016/s0277-9536(99)00239-7. 
149. Bish A, Yardley L, Nicoll A, Michie S. Factors associated with uptake of vaccination 
against pandemic influenza: A systematic review. Vaccine. 2011;29(38):6472-6484. doi: 
10.1016/j.vaccine.2011.06.107. 
  131 
150. Norton SP, Scheifele DW, Bettinger JA, West RM. Influenza vaccination in paediatric 
nurses: Cross-sectional study of coverage, refusal, and factors in acceptance. Vaccine. 
2008;26(23):2942-2948. doi: 10.1016/j.vaccine.2008.03.033. 
151. Hollmeyer HG, Hayden F, Poland G, Buchholz U. Influenza vaccination of health care 
workers in hospitals--a review of studies on attitudes and predictors. Vaccine. 2009;27(30):3935-
3944. doi: 10.1016/j.vaccine.2009.03.056 
152. Verger P, Fressard L, Collange F, et al. Vaccine hesitancy among general practitioners and 
its determinants during controversies: A national cross-sectional survey in France. 
EBioMedicine. 2015;2(8):889-895. doi: 10.1016/j.ebiom.2015.06.018. 
153. Zhang J, While AE, Norman IJ. Seasonal influenza vaccination knowledge, risk perception, 
health beliefs and vaccination behaviours of nurses. Epidemiol Infect. 2012;140(9):1569-1577. 
doi: 10.1017/S0950268811002214. 
154. Opel DJ, Heritage J, Taylor JA, et al. The architecture of provider-parent vaccine 
discussions at health supervision visits. Pediatrics. 2013;132(6):1037-1046. doi: 
10.1542/peds.2013-2037 
155. Macdonald L, Cairns G, Angus K, de Andrade M. Promotional communications for 
influenza vaccination: A systematic review. J Health Commun. 2013;18(12):1523-1549. doi: 
10.1080/10810730.2013.840697. 
156. Brewer NT, Chapman GB, Gibbons FX, Gerrard M, McCaul KD, Weinstein ND. Meta-
analysis of the relationship between risk perception and health behavior: The example of 
vaccination. Health Psychol. 2007;26(2):136-145. doi: 10.1037/0278-6133.26.2.136. 
157. Suk JE, Lopalco P, Pastore Celentano L. Hesitancy, trust and individualism in vaccination 
decision-making. PLoS Curr. 
2015;7:10.1371/currents.outbreaks.49dba84ad4146de33706b1f131d7caa3. doi: 
10.1371/currents.outbreaks.49dba84ad4146de33706b1f131d7caa3. 
  132 
158. Healy CM, Pickering LK. How to communicate with vaccine-hesitant parents. Pediatrics. 
2011;127 Suppl 1:127. doi: 10.1542/peds.2010-1722S. 
159. Brownlie J, Howson A. ‘Leaps of faith’ and MMR: An empirical study of trust. Sociology. 
2005;39(2):221-239. doi: 10.1177/0038038505050536. 
160. Blackwell T. Debate over HPV vaccine flares up in Alberta after catholic leaders warn shots 
encourage pre-marital sex. http://news.nationalpost.com/health/debate-over-hpv-vaccine-flares-
up-in-alberta-after-catholic-leaders-warn-shots-encourage-pre-marital-sex. Updated 2016. 
Accessed March, 2017. 
161. Opinion: Bishop Fred Henry defends church stand on HPV vaccine. 
http://news.nationalpost.com/holy-post/opinion-bishop-fred-henry-defends-church-stand-on-hpv-
vaccine. Updated 2012. Accessed March, 2017. 
162. McRee AL, Gilkey MB, Dempsey AF. HPV vaccine hesitancy: Findings from a statewide 
survey of health care providers. J Pediatr Health Care. 2014;28(6):541-549. doi: 
10.1016/j.pedhc.2014.05.003. 
163. Bloom BR, Marcuse E, Mnookin S. Addressing vaccine hesitancy. Science. 
2014;344(6182):339. doi: 10.1126/science.1254834. 
164. Butler R, MacDonald NE, SAGE Working Group on Vaccine Hesitancy. Diagnosing the 
determinants of vaccine hesitancy in specific subgroups: The guide to tailoring immunization 
programmes (TIP). Vaccine. 2015;33(34):4176-4179. doi: 10.1016/j.vaccine.2015.04.038. 
165. Omer SB, Salmon DA, Orenstein WA, deHart MP, Halsey N. Vaccine refusal, mandatory 
immunization, and the risks of vaccine-preventable diseases. N Engl J Med. 2009;360(19):1981-
1988. doi: 10.1056/NEJMsa0806477. 
166. Tailoring immunization programmes for seasonal influenza (TIP FLU). A guide for 
increasing health care workers' uptake of seasonal influenza vaccination (2015). 
  133 
http://www.euro.who.int/__data/assets/pdf_file/0007/290851/TIPGUIDEFINAL.pdf?ua=1. 
Updated 2016. Accessed March, 2017. 
167. WHO - improving vaccination demand and addressing hesitancy. 
http://www.who.int/immunization/programmes_systems/vaccine_hesitancy/en/. Updated 2019. 
Accessed Sep 21, 2019. 
168. Hobson-West P. Understanding vaccination resistance: Moving beyond risk. Health Risk 
Soc. 2003;5(3):273-283. doi: 10.1080/13698570310001606978. 
169. Witteman HO. Addressing vaccine hesitancy with values. Pediatrics. 2015;136(2):215-217. 
doi: 10.1542/peds.2015-0949. 
170. Blue CL, Valley JM. Predictors of influenza vaccine. acceptance among healthy adult 
workers. AAOHN J. 2002;50(5):227-233. 
171. Leighton L, Williams M, Aubery D, Parker SH. Sickness absence following a campaign of 
vaccination against influenza in the workplace. Occup Med (Lond). 1996;46(2):146-150. 
doi: 10.1093/occmed/46.2.146. 
172. Doebbeling BN, Edmond MB, Davis CS, Woodin JR, Zeitler RR. Influenza vaccination of 
health care workers: Evaluation of factors that are important in acceptance. Prev Med. 
1997;26(1):68-77. 
173. Kempe A, Patel MM, Daley MF, et al. Adoption of rotavirus vaccination by pediatricians 
and family medicine physicians in the United States. Pediatrics. 2009;124(5):809. doi: 
10.1542/peds.2008-3832. 
174. Let's get fluless. 
http://www.health.gov.on.ca/en/pro/programs/publichealth/flu/healthcareworkers.aspx.Updated 
2015, Accessed May 25, 2017. 
  134 
175. Immunization communication tool - immunize BC. http://www.bccdc.ca/resource-
gallery/Documents/Guidelines%20and%20Forms/Guidelines%20and%20Manuals/Immunization
/Vaccine%20Safety/BCCDCICT_300315.pdf. Updated 2015. Accessed May 25, 2017. 
176. Schuster M, Eskola J, Duclos P, SAGE Working Group on Vaccine Hesitancy. Review of 
vaccine hesitancy: Rationale, remit and methods. Vaccine. 2015;33(34):4157-4160. doi: 
10.1016/j.vaccine.2015.04.035.  
177. Talbot HK, Zhu Y, Chen Q, Williams JV, Thompson MG, Griffin MR. Effectiveness of 
influenza vaccine for preventing laboratory-confirmed influenza hospitalizations in adults, 2011-
2012 influenza season. Clin Infect Dis. 2013;56(12):1774-1777. doi: 10.1093/cid/cit124. 
178. Campbell DS, Rumley MH. Cost-effectiveness of the influenza vaccine in a healthy, 
working-age population. J Occup Environ Med. 1997;39(5):408-414. doi: 10.1097/00043764-
199705000-00006. 
179. Ciancio BC, Rezza G. Costs and benefits of influenza vaccination: More evidence, same 
challenges. BMC Public Health. 2014;14:81-818. doi: 10.1186/1471-2458-14-818. 
180. O'Reilly DJ, Blackhouse G, Burns S, et al. Economic analysis of pharmacist-administered 
influenza vaccines in Ontario, Canada. Clinicoecon Outcomes Res. 2018;10:655-663. doi: 
10.2147/CEOR.S167500. 
181. Herrera GA, Iwane MK, Cortese M, et al. Influenza vaccine effectiveness among 50-64-
year-old persons during a season of poor antigenic match between vaccine and circulating 
influenza virus strains: Colorado, United States, 2003-2004. Vaccine. 2007;25(1):154-160. doi: 
10.1016/j.vaccine.2006.05.129. 
182. Nordin J, Mullooly J, Poblete S, et al. Influenza vaccine effectiveness in preventing 
hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: 
Data from 3 health plans. J Infect Dis. 2001;184(6):665-670. doi: 10.1086/323085. 
  135 
183. Dube E, MacDonald NE. Addressing vaccine hesitancy and refusal in Canada. CMAJ. 
2016;188(1):17. doi: 10.1503/cmaj.150707. 
184. Meyer SB, Lum R. Explanations for not receiving the seasonal influenza vaccine: An 
Ontario Canada based survey. J Health Commun. 2017;22(6):506-514. Accessed July 31, 2019. 
doi: 10.1080/10810730.2017.1312720. 
185. Godin G, Vézina-Im L, Naccache H. Determinants of influenza vaccination among 
healthcare workers. Infect Control Hosp Epidemiol. 2010;31(7):689-693. doi: 10.1086/653614. 
186. Corace K, Prematunge C, McCarthy A, et al. Predicting influenza vaccination uptake 
among health care workers: What are the key motivators? Am J Infect Control. 2013;41(8):679-
684. doi: 10.1016/j.ajic.2013.01.014. 
187. Prematunge C, Corace K, McCarthy A, et al. Qualitative motivators and barriers to 
pandemic vs. seasonal influenza vaccination among healthcare workers: A content analysis. 
Vaccine. 2014;32(52):7128-7134. doi: 10.1016/j.vaccine.2014.10.023. 
188. Warwick DP. The KAP survey: Dictates of mission versus demands of science. M.Bulmer 
und DP Warwick (Hg.): Social research in developing countries.Surveys and censuses in the 
Third World. 1993;1:349-364. 
189. Patel T, Chang F, Mohammed HT, et al. Knowledge, perceptions and attitudes toward 
chronic pain and its management: A cross-sectional survey of frontline pharmacists in Ontario, 
Canada. PloS one. 2016;11(6):e0157151. doi: 10.1371/journal.pone.0157151. 
190. Muliira JK, D'Souza MS, Ahmed SM, Al-Dhahli SN, Al-Jahwari FRM. Barriers to 
colorectal cancer screening in primary care settings: Attitudes and knowledge of nurses and 
physicians. Asia Pac J Oncol Nurs. 2016;3(1):98-107. doi: 10.4103/2347-5625.177391. 
191. Lalonde L, Leroux-Lapointe V, Choinière M, et al. Knowledge, attitudes and beliefs about 
chronic noncancer pain in primary care: A Canadian survey of physicians and pharmacists. Pain 
Res Manag. 2014;19(5):241-250.doi: 10.1155/2014/760145. 
  136 
192. Tavakol M, Dennick R. Making sense of Cronbach's alpha. Int J Med Educ. 2011;2:53-55. 
doi: 10.5116/ijme.4dfb.8dfd. 
193. Buchan SA, Kwong JC. Trends in influenza vaccine coverage and vaccine hesitancy in 
Canada, 2006/07 to 2013/14: Results from cross-sectional survey data. CMAJ Open. 
2016;4(3):E45-E462. doi: 10.9778/cmajo.20160050. 
194. Kizawa Y, Morita T, Miyashita M, et al. Improvements in physicians' knowledge, 
difficulties, and self-reported practice after a regional palliative care program. J Pain Symptom 
Manage. 2015;50(2):232-240. doi: 10.1016/j.jpainsymman.2015.02.025. 
195. Karpel JP, Peters JI, Szema AM, Smith B, Anderson PJ. Differences in physicians’ self-
reported knowledge of, attitudes toward, and responses to the black box warning on long-acting 
β-agonists. Ann Allergy Asthma Immunol. 2009;103(4):304-310. doi: 10.1016/S1081-
1206(10)60529-7. 
196. Stafford S, Sedlak T, Fok MC, Wong RY. Evaluation of resident attitudes and self-reported 
competencies in health advocacy. BMC Med Educ. 2010;10:82. Accessed August 28, 2019. doi: 
10.1186/1472-6920-10-82. 
197. Ginsburg LR, Tregunno D, Norton PG. Self-reported patient safety competence among new 
graduates in medicine, nursing and pharmacy. BMJ Qual Saf. 2013;22(2):147-154. doi: 
10.1136/bmjqs-2012-001308. 
198. Doyle P, VanDenKerkhof EG, Edge DS, Ginsburg L, Goldstein DH. Self-reported patient 
safety competence among Canadian medical students and postgraduate trainees: A cross-
sectional survey. BMJ Qual Saf. 2015;24(2):135-141. doi: 10.1136/bmjqs-2014-003142. 
199. Pullagura GR, Waite N, Violette R, Houle S. Assessment of practicing community 
pharmacists’ knowledge, attitudes and behaviour towards influenza vaccine hesitancy in Ontario: 
An exploratory study. Can Pharm J (Ott). 2017;150(4):S55. 
  137 
200. Dubé E, Gagnon D, Kiely M, et al. Seasonal influenza vaccination uptake in Quebec, 
Canada, 2 years after the influenza A (H1N1) pandemic. Am J Infect Control. 2014;42(5):55. 
doi: 10.1016/j.ajic.2014.01.006. 
201. Buchan SA, Rosella LC, Finkelstein M, et al. Impact of pharmacist administration of 
influenza vaccines on uptake in Canada. CMAJ. 2017;189(4):E146-E152. Accessed August 12, 
2019. doi: 10.1503/cmaj.151027. 
202. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psych. 2006;3(2):77-
101. doi: 10.1191/1478088706qp063oa. 
203. Fereday J, Muir-Cochrane E. Demonstrating rigor using thematic analysis: A hybrid 
approach of inductive and deductive coding and theme development. Int J Qual Methods. 
2006;5(1):80-92. doi: 10.1177/160940690600500107. 
204. Wiley KE, Massey PD, Cooper SC, Wood N, Quinn HE, Leask J. Pregnant women's 
intention to take up a post-partum pertussis vaccine, and their willingness to take up the vaccine 
while pregnant: A cross sectional survey. Vaccine. 2013;31(37):3972-3978. doi: 
10.1016/j.vaccine.2013.06.015. 
205. Seither R. Vaccination coverage for selected vaccines, exemption rates, and provisional 
enrollment among children in kindergarten — United States, 2016–17 school year. MMWR Morb 
Mortal Wkly Rep. 2017;66(40):1073-1080. doi: 10.15585/mmwr.mm6640a3. 
206. Michie S, van Stralen M, West R. The behaviour change wheel: A new method for 
characterising and designing behaviour change interventions. Implement Sci. 2011;6:42. doi: 
10.1186/1748-5908-6-42. 
207. Cane J, O'Connor D, Michie S. Validation of the theoretical domains framework for use in 
behaviour change and implementation research. Implement Sci. 2012;7(1):37. doi: 10.1186/1748-
5908-7-37. 
  138 
208. Atkins L, Francis J, Islam R, et al. A guide to using the theoretical domains framework of 
behaviour change to investigate implementation problems. Implement Sci. 2017;12(1):77. 
Accessed August 26, 2019. doi: 10.1186/s13012-017-0605-9. 
209. Barker F, Atkins L, Lusignan SD. Applying the COM-B behaviour model and behaviour 
change wheel to develop an intervention to improve hearing-aid use in adult auditory 
rehabilitation. Int. J Audiol. 2016;55(sup3):S90-S98. 
https://doi.org/10.3109/14992027.2015.1120894.  
210. Ontario respiratory pathogen bulletin, 2016-2017. 
https://www.publichealthOntario.ca/en/DataAndAnalytics/Documents/Ontario%20Respiratory%
20Pathogen%20Bulletin%20-Season%20Summary%20-%202016-17.pdf. Updated 2017. 
Accessed January 18, 2018. 
211. Economic burden of illness in Canada. https://www.Canada.ca/en/public-
health/services/chronic-diseases/chronic-disease-knowledge-development-exchange/economic-
burden-illness-Canada.html. Updated 2018. Accessed January 5, 2018. 
212. Kostova D, Reed C, Finelli L, et al. Influenza illness and hospitalizations averted by 
influenza vaccination in the United States, 2005-2011. PLoS One. 2013;8(6):e66312. doi: 
10.1371/journal.pone.0066312. 
213. McBean AM, Babish JD, Warren JL. The impact and cost of influenza in the elderly. Arch 
Intern Med. 1993;153(18):2105-2111. doi:10.1001/archinte.1993.00410180051005. 
214. MacDougall DM, Halperin BA, MacKinnon-Cameron D, et al. The challenge of 
vaccinating adults: Attitudes and beliefs of the Canadian public and healthcare providers. BMJ 
Open. 2015;5(9). doi: 10.1136/bmjopen-2015-009062. 
215. Eilers R, Krabbe PF, de Melker HE. Factors affecting the uptake of vaccination by the 
elderly in western society. Prev Med. 2014;69:224-234. doi: 10.1016/j.ypmed.2014.10.017. 
  139 
216. Fees and claims data for government-sponsored pharmacist services, by province. 
http://www.pharmacists.ca/cpha-ca/assets/File/pharmacy-in-
Canada/CFP_prov_chart_june_2014.pdf. Updated 2014. Accessed December 5, 2017. 
217. Guidelines for the economic evaluation of health technologies: Canada — 4th edition. 
https://www.cadth.ca/dv/guidelines-economic-evaluation-health-technologies-Canada-4th-
edition. Updated 2017. Accessed January 18, 2018. 
218. Public funding for influenza vaccination by province/territory. 
https://www.Canada.ca/en/public-health/services/provincial-territorial-immunization-
information/public-funding-influenza-vaccination-province-territory.html. Updated 2017. 
Accessed January 24, 2018. 
219. Isenor JE, Edwards NT, Alia TA, et al. Impact of pharmacists as immunizers on vaccination 
rates: A systematic review and meta-analysis. Vaccine. 2016;34(47):5708-5723. doi: 
10.1016/j.vaccine.2016.08.085. 
220. Marra F, Kaczorowski J, Gastonguay L, Marra CA, Lynd LD, Kendall P. Pharmacy-based 
immunization in rural communities strategy (PhICS): A community cluster-randomized trial. 
Can Pharm J (Ott). 2014;147(1):33-44. doi: 10.1177/1715163513514020. 
221. Bourdet SV, Kelley M, Rublein J, Williams DM. Effect of a pharmacist-managed program 
of pneumococcal and influenza immunization on vaccination rates among adult inpatients. Am J 
Health Syst Pharm. 2003;60(17):1767-1771. doi: 10.1093/ajhp/60.17.1767. 
222. Ontario respiratory pathogen bulletin. 
https://www.publichealthOntario.ca/en/ServicesAndTools/SurveillanceServices/Pages/Ontario-
Respiratory-Virus-Bulletin.aspx. Updated 2018. Accessed May 16, 2018. 
223. O'Reilly DJ, Blackhouse G, Burns S, et al. Economic analysis of pharmacist-administered 
influenza vaccines in Ontario, Canada. Clinicoecon Outcomes Res. 2018;10:655-663. doi: 
10.2147/CEOR.S167500. 
  140 
224. Product monograph - AGRIFLU. 
http://www.seqirus.ca/docs/851/102/2017%2018%20Agriflu%20Product%20Monograph,0.pdf. 
Updated 2017. Accessed December 5, 2017. 
225. Consumer price index, by province (Ontario). https://www.statcan.gc.ca/tables-
tableaux/sum-som/l01/cst01/econ09g-eng.htm. Updated 2018. Accessed March 10, 2017. 
226. Care in Canadian ICUs - CIHI. https://secure.cihi.ca/free_products/ICU_Report_EN.pdf. 
Updated 2016. Accessed December 2, 2017. 
227. Cost of a standard hospital stay details for Ontario - CIHI. 
http://yourhealthsystem.cihi.ca/hsp/indepth?lang=en#/indicator/015/2/C5001/. Updated 2017. 
Accessed November 27, 2017. 
228. Jivraj F, Dranitsaris G, Nicolle M. Cost utility analysis of immunoglobulins (IVIG) versus 
plasma exchange (PE) for the treatment of Guillain-Barre syndrome (GBS). 
http://www.augmentium.com/pdfs/professional/GBS-Presentation.pdf. Accessed November 28, 
2017. 
229. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care. 
2000;38(6):583-637. doi: 10.1097/00005650-200006000-00004. 
230. Andrade LF, Saba G, Ricard JD, et al. Health related quality of life in patients with 
community-acquired pneumococcal pneumonia in France. Health Qual Life Outcomes. 
2018;16:6. doi: 10.1186/s12955-018-0854-6. 
231. Frenzen PD. Economic cost of Guillain-Barre syndrome in the United States. Neurology. 
2008;71(1):21-27. doi: 10.1212/01.wnl.0000316393.54258.d1. 
232. Canadian immunization guide. http://www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php. 
Updated 2017. Accessed May 03, 2017. 
  141 
233. Kwong JC, Vasa PP, Campitelli MA, et al. Risk of Guillain-Barre syndrome after seasonal 
influenza vaccination and influenza health-care encounters: A self-controlled study. Lancet 
Infect Dis. 2013;13(9):769-776. 
234. Statistics Canada - Population estimates on July 1st, by age and sex. 
http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo31a-eng.htm. Updated 2019. 
Accessed January 27, 2019. 
235. CADTH policy guidance - Hip protectors in long term care. https://www.cadth.ca/policy-
guidance. Updated 2010. Accessed January 18, 2018. 
236. Malet-Larrea A, Garcia-Cardenas V, Saez-Benito L, Benrimoj SI, Calvo B, Goyenechea E. 
Cost-effectiveness of professional pharmacy services in community pharmacy: A systematic 
review. Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):747-758. doi: 
10.1080/14737167.2016.1259071. 
237. Touchette DR, Doloresco F, Suda KJ, et al. Economic evaluations of clinical pharmacy 
services: 2006-2010. Pharmacotherapy. 2014;34(8):771-793. doi: 10.1002/phar.1414. 
238. Marra C, Johnston K, Santschi V, Tsuyuki RT. Cost-effectiveness of pharmacist care for 
managing hypertension in Canada. Can Pharm J (Ott). 2017;150(3):184-197. 
doi: 10.1177/1715163517701109. 
239. Bauld L, Boyd KA, Briggs AH, et al. One-year outcomes and a cost-effectiveness analysis 
for smokers accessing group-based and pharmacy-led cessation services. Nicotine Tob Res. 
2011;13(2):135-145. doi: 10.1093/ntr/ntq222. 
240. Ontario drug benefit formulary. https://www.formulary.health.gov.on.ca/formulary/. 
Updated 2016. Accessed February 5, 2018. 
241. Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of 
influenza - Recommendations of the advisory committee on immunization practices (ACIP). 
MMWR Recomm Rep. 2011;60(1):1-24.  
  142 
242. Odone A, Signorelli C. When vaccine hesitancy makes headlines. Vaccine. 2015. doi: 
10.1016/j.vaccine.2015.11.051. 
243. Kumar D, Chandra R, Mathur M, Samdariya S, Kapoor N. Vaccine hesitancy: 
Understanding better to address better. Isr J Health Policy Res. 2016;5:y. eCollection 2016. doi: 
10.1186/s13584-016-0062-y. 
244. Salmon DA, Dudley MZ, Glanz JM, Omer SB. Vaccine hesitancy: Causes, consequences, 
and a call to action. Am J Prev Med. 2015. doi: 10.1016/j.amepre.2015.06.009. 
245. Ramanadhan S, Galarce E, Xuan Z, Alexander-Molloy J, Viswanath K. Addressing the 
vaccine hesitancy continuum: An audience segmentation analysis of American adults who did 
not receive the 2009 H1N1 vaccine. Vaccines (Basel). 2015;3(3):556-578. doi: 
10.3390/vaccines3030556. 
246. Public Health Agency of Canada. Canadian immunization guide chapter on influenza and 
statement on seasonal influenza vaccine for 2019–2020. https://www.canada.ca/en/public-
health/services/publications/vaccines-immunization/canadian-immunization-guide-statement-
seasonal-influenza-vaccine-2019-2020.html. Updated 2019. Accessed Oct 17, 2019. 
247. Regnault A, Willgoss T, Barbic S. Towards the use of mixed methods inquiry as best 
practice in health outcomes research. J Patient Rep Outcomes. 2018;2(1):1-4. doi: 
10.1186/s41687-018-0043-8. 
248. Tariq S, Woodman J. Using mixed methods in health research. JRSM Short Reports. 
2013;4(6):2042533313479197. doi: 10.1177/2042533313479197. 
249. Borkan JM. Mixed methods studies: A foundation for primary care research. Ann Fam Med. 
2004;2(1):4-6. doi: 10.1370/afm.111. 
250. Yardley L, Bishop FL. Using mixed methods in health research: Benefits and challenges. Br 
J Health Psychol. 2015;20(1):1-4. doi: 10.1111/bjhp.12126. 
  143 
251. Bishop FL. Using mixed methods research designs in health psychology: An illustrated 
discussion from a pragmatist perspective. Br J Health Psychol. 2015;20(1):5-20. doi: 
10.1111/bjhp.12122. 
252. Bradbury K, Dennison L, Little P, Yardley L. Using mixed methods to develop and evaluate 
an online weight management intervention. Br J Health Psychol. 2015;20(1):45-55. doi: 
10.1111/bjhp.12125. 
253. Doornekamp L, de Jong W, Wagener MN, Goeijenbier M, van Gorp, E. C. M. Dutch 
healthcare professionals' opinion on vaccination and education to prevent infections in 
immunocompromised patients: A mixed-method study with recommendations for daily practice. 
Vaccine. 2019;37(11):1476-1483. doi: 10.1016/j.vaccine.2019.01.075. 
254. Wilcox CR, Bottrell K, Paterson P, et al. Influenza and pertussis vaccination in pregnancy: 
Portrayal in online media articles and perceptions of pregnant women and healthcare 
professionals. Vaccine. 2018;36(50):7625-7631. doi: 10.1016/j.vaccine.2018.10.092. 
255. Bazán M, Villacorta E, Barbagelatta G, et al. Health workers' attitudes, perceptions and 
knowledge of influenza immunization in Lima, Peru: A mixed methods study. Vaccine. 
2017;35(22):2930-2936. doi: 10.1016/j.vaccine.2017.04.021. 
256. Tashakkori A, Teddlie C. Sage handbook of mixed methods in social and behavioral 
research. Thousand Oaks, CA: Sage; 2010. 
257. Waite NM, Cadarette SM, Campitelli MA, Consiglio GP, Houle SKD, Kwong JC. 
Characteristics of patients vaccinated against influenza in physician offices versus pharmacies 
and predictors of vaccination location: A cross-sectional study. CMAJ Open. 2019;7(2):E421-
E429. doi: 10.9778/cmajo.20180189. 
258. Houle SKD, Grindrod KA, Chatterley T, Tsuyuki RT. Publicly funded remuneration for the 
administration of injections by pharmacists: An international review. Can Pharm J (Ott). 
2013;146(6):353-364. doi: 10.1177/1715163513506369. 
  144 
259. Houle SKD, Carter CA, Tsuyuki RT, Grindrod KA. Remunerated patient care services and 
injections by pharmacists: An international update. J Am Pharm Assoc (2003). 2019;59(1):89-
107. doi: 10.1016/j.japh.2018.07.002. 
260. Influenza vaccine uptake: Results from the 2015/16 national influenza immunization 
coverage survey in Canada. https://www.canada.ca/en/public-
health/services/publications/healthy-living/vaccine-uptake-results-2015-16-national-influenza-
immunization-coverage-survey.html. Updated 2017. Accessed September 6, 2019. 
 
 
  
  145 
Appendix A 
Survey - Ontario community pharmacists’ knowledge, attitude and behaviour 
towards influenza vaccine hesitancy – An exploratory study 
 
1. Do you currently practice at a community pharmacy in Ontario? 
 Yes  
 No  
 
2. What degrees/certificates have you completed?  
[Select all that apply] 
❑ BSc Pharmacy  
❑ Post-baccalaureate PharmD  
❑ Entry-to-practice PharmD  
❑ Masters in Pharmacy  
❑ PhD in Pharmacy  
❑ Residency  
❑ Fellowship  
❑ Other (please specify): ____________________ 
 
3. How many years have you practiced as a pharmacist in Ontario? 
 Less than 5 years  
 5-10 years  
 11-15 years 
 16-20 years  
 More than 20 years 
 
4. Which of the following best describes you? 
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 Man  
 Woman 
 Other (e.g. Trans-gender): ____________________ 
 
5. What type of community pharmacy is your primary place of practice? 
 Chain (more than 6 stores with one owner, e.g. PharmaPlus, Medical Pharmacy)  
 Independent (one owner up to 6 stores)  
 Franchise (e.g. Rexall, Medicine Shoppe)  
 Banner (e.g. IDA, Guardian, Pharmasave) 
 Mass merchandiser/Food store (e.g. Loblaws, Walmart) 
 Other (please specify): ____________________ 
 
6. What is your current position at your primary place of practice?  
[Select all that apply] 
❑ Pharmacist - Manager  
❑ Staff pharmacist - Full time (30 hours/week or more) 
❑ Staff pharmacist - Part time (Less than 30 hours/week) 
❑ Pharmacy owner 
❑ Freelance/Relief pharmacist  
❑ Other (please specify): ____________________ 
 
7. What are the first three digits of the postal code of your primary place of practice? 
 
8. Which of the following best describes the area where your primary place of practice is 
located?  
 Rural (population <1000 individuals) 
 Small population centre (1000 to 29,999 individuals) 
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 Medium population centre (30,000 to 99,000 individuals)  
 Large urban population centre (>100,000 individuals)  
 
9. What is the average number of pharmacists that work in your primary place of practice during 
peak times? 
 One  
 Two  
 Three 
 Four or more 
 
10. On average, how many prescriptions are filled at your pharmacy per day? 
______ Prescriptions filled per day 
 
11. Is your community pharmacy currently involved with influenza immunizations? 
 Yes, pharmacist(s) administer the vaccine 
 Yes, nurses/nursing agencies contracted by the pharmacy administer the vaccine  
 No current involvement, but planning to participate in the future  
 No current involvement and no immediate plans for involvement in the future  
 
12. Are you currently certified to administer vaccines? 
 Yes  
 No 
 
[If certified to administer vaccines] 
13. To how many individuals did YOU PERSONALLY ADMINISTER the influenza vaccine 
during the 2015-16 influenza season? 
 
[If NOT certified to administer vaccines] 
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14. Are you planning to become certified to administer the influenza vaccine in Ontario? 
 Yes  
 No  
 Not sure 
 
15. In which of the following influenza seasons did YOU PERSONALLY RECEIVE the 
influenza vaccine? [Select all that apply] 
❑ 2015-16  
❑ 2014-15  
❑ 2013-14  
❑ I did not receive the influenza vaccine in any of the above seasons  
 
[If influenza vaccine was received at least once in the preceding three seasons] 
16. Please specify, which of the following best describe YOUR MOTIVATION(S) TO 
RECEIVE the influenza vaccine:  
[Select all that apply] 
❑ I am afraid of contracting influenza  
❑ I have suffered from influenza in the past  
❑ I believe influenza is a serious disease  
❑ I believe that influenza vaccine will protect me from influenza  
❑ I do not wish to transmit influenza to the patients I come in contact with  
❑ I do not wish to transmit influenza to my family and friends  
❑ I wish to protect my community by contributing to herd immunity  
❑ It was encouraged by my employer  
❑ It was required by my employer  
❑ It was encouraged by my environment (e.g. colleagues, family, friends)  
❑ It was influenced by media  
  149 
❑ Any other reason (please specify): ____________________ 
 
[If influenza vaccine was NOT received in the preceding three seasons] 
17. Please specify, which of the following best describe YOUR RATIONALE FOR NOT 
RECEIVING the influenza vaccine: 
[Select all that apply] 
❑ I have never had seasonal influenza before  
❑ I believe that seasonal influenza is not a serious disease  
❑ My religious beliefs are against vaccinations  
❑ I believe that acquiring immunity by contracting the disease is better than getting vaccinated  
❑ I don't believe I am at risk for seasonal influenza  
❑ I am concerned about vaccine side effects  
❑ I am concerned about getting influenza from the vaccine  
❑ I am skeptical about the effectiveness of the influenza vaccine  
❑ I have suffered from vaccine related side effects in the past  
❑ I have allergies to the influenza vaccine or components of the vaccine  
❑ I believe I have acquired immunity due to the nature of my work  
❑ I am afraid of needles  
❑ I am skeptical about the long-term health effects of the vaccine  
❑ Getting the vaccine is inconvenient  
❑ I've had negative experience with immunizations before  
❑ I have not thought about getting it  
❑ Any other reason (please specify): ____________________ 
❑ I do not wish to specify  
 
18. On a scale of 1 to 5, 1 being limited and 5 being expert, how would you rate your knowledge 
in each of the following: 
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 1  2  3  4  5  
Pathophysiology            
Pharmacotherapy           
Dosing and indications           
Formulations            
Composition            
Interactions            
Pharmacology           
Adverse reactions           
Contraindications            
[If certified to administer vaccines] 
Management of allergic reactions and adverse effects 
          
Vaccines and autism            
Vaccine hesitancy            
Annual influenza vaccine updates (e.g. strain match, new 
formulations, safety updates etc.)  
          
Communication frameworks to promote vaccinations           
 
19. What does 'Vaccine hesitancy' mean to you? Someone is vaccine-hesitant when:  
[Select all that apply] 
❑ They do not trust the vaccine and immunization services  
❑ They are accepting a vaccine while not being entirely convinced of its benefits  
❑ They delay receiving the vaccine  
❑ They refuse a vaccine  
❑ They cannot get the vaccine due to an Insufficient vaccine supply and/or lack of trained 
personnel to administer the vaccine  
❑ They've had negative experiences with immunizations in past  
❑ They believe they have a low risk of contracting a vaccine preventable disease  
❑ They've had an uncomfortable and/or inconvenient vaccination experience  
❑ Others (please specify): ____________________ 
Comments: ____________________ 
 
20. In your experience, what percent of individuals make their decision to receive the influenza 
vaccine prior to meeting their health care professionals? 
  151 
______%  
 
21. Think back to a typical week during the 2015-16 influenza season. How often did you 
recommend the influenza vaccine? 
 Never 
 Rarely (1-24% of eligible individuals)  
 Sometimes (25-49% of individuals)  
 Frequently (50-74% of individuals)  
 Always (75-100% of individuals)  
 
22. Think back to a typical week during the 2015-16 influenza season. What percentage of your 
total vaccine recommendations were aimed at individuals with high risk of influenza-
related complications (e.g. age ≥ 65 years, individuals with cardiac/pulmonary disorders etc.)? 
______ % total recommendations  
 
[If certified to administer vaccines] 
23. Based on your experience, what percentage of individuals getting the influenza vaccine at 
your community pharmacy come in asking for the service? 
______ % of individuals actively requesting vaccination at your pharmacy 
 
24. On a scale from low to high, how would you rate your ability to influence an individual's 
decision to vaccinate?  
 
25. Vaccine hesitancy as defined by the World Health Organization:   
‘[a] delay in acceptance or refusal of vaccines despite availability of vaccination services. 
Vaccine hesitancy is complex and context specific, varying across time, place and 
vaccines. It is influenced by factors such as complacency, convenience and confidence’  
MacDonald NE, SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: 
Definition, scope and determinants. Vaccine. 2015;33(34):4161 
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To what degree does this definition align with your experience of vaccine hesitancy in the 
community pharmacy?  
______  
 
26. Drawing from your professional experience, how frequently do the following factors form 
the basis of vaccine hesitancy among individuals visiting your community pharmacy?  
 1  2  3  4  5  
Negative media coverage about vaccines           
Anti-vaccination movements            
Religion/culture            
Politics/policies            
Negative perception about the pharmaceutical industry            
Bad personal experience with vaccination            
Negative experience of family, friends and 
acquaintances with the vaccine(s).  
          
Concerns of pain with vaccine administration            
Personal beliefs and attitudes about health and 
prevention (e.g. maintenance of personal hygiene 
negates the need for vaccine)  
          
Insufficient knowledge or misinformation            
Lack of trust or poor personal experience with the health 
system  
          
Poor perceived risk/benefit to the influenza vaccine            
Poor viral strain match            
Concerns of insufficient data on new vaccines and 
formulations  
          
Fear of vaccine associated adverse effects            
Negative perception of pharmacist as the immunizer            
Negative perception of pharmacy as a health care 
delivery setting  
          
Need for annual re-vaccination with the influenza 
vaccine  
          
Long wait or inconvenient times to get the vaccine            
Others (please specify): _______________            
 
27. Now that you are acquainted with the idea of vaccine hesitancy, how many vaccine-hesitant 
individuals did you come across during a typical week of the 2015-16 influenza season? 
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[If certified to administer vaccines] 
28. Upon engaging, what percent of vaccine-hesitant individuals received the influenza vaccine 
at your pharmacy? 
______ % of hesitant individuals receiving the vaccine at your pharmacy  
 
[If NOT certified to administer vaccines] 
29. Upon your encouragement, what percent of vaccine-hesitant individuals do you think, 
received the influenza vaccine? 
______ % of hesitant individuals receiving the vaccine 
 
30. As a pharmacist, how important do you perceive your role in engaging with individuals 
hesitant about getting the influenza vaccine?  
 
 Not important 
at all  
Slightly 
important  
Moderately 
important  
Very 
important  
Extremely 
important  
Your role in engaging 
with vaccine hesitant 
individuals is  
          
 
31. Which of the following have you used to address influenza vaccine hesitancy at your practice 
site? How effective are they? 
[Grade their effectiveness from 1-5. 1 being not very effective and 5 being very effective] 
 Utilization Effectiveness 
 Yes  No  1  2 3 4 5 
Provide information on safety of the 
influenza vaccine  
              
Provide information on efficacy of the 
influenza vaccine  
              
Use emotional appeal (e.g. protecting 
family, loved ones etc.)  
              
Use the appeal of social responsibility 
(e.g. herd immunity, protecting those 
vulnerable etc.)  
              
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Remind the benefits of vaccination and 
point out the risks of not immunizing  
              
Correct vaccine related misinformation                
Communication frameworks (e.g. ASK 
tool, NACI guidelines)  
              
Promotional material including fact 
sheets, websites and other vaccination 
resources  
              
Shared decision making                
Refer patient to other health 
professionals  
              
Authoritative directions (e.g. strong 
professional recommendation)  
              
Motivational interviewing                
Provide personal examples (own 
vaccination/ examples of vaccination-
preventable diseases in practice)  
              
 
[If certified to administer vaccines] 
32. Have any of the following ever deterred you from making a vaccine recommendation? If yes, 
how often? 
 Never  Rarely  Sometimes  Frequently  Always  
Elderly patients with multiple co-
morbidities  
          
Pregnant women            
Risk of ADRs from the influenza vaccine            
Insufficient information when 
recommending new formulations of the 
influenza vaccine  
          
Personal beliefs on the safety, efficacy or 
need for vaccine  
          
Lack of confidence in ability to provide 
vaccinations  
          
Lack of tools to promote influenza 
vaccinations  
          
Risk of anaphylaxis            
 
[If NOT certified to administer vaccines] 
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33. Have any of the following ever deterred you from making a vaccine recommendation? If yes, 
how often? 
 Never  Rarely  Sometimes  Frequently  Always  
Elderly patients with 
multiple co-
morbidities  
          
Pregnant women            
Risk of ADRs from 
the influenza vaccine  
          
Insufficient 
information when 
recommending new 
formulations of the 
influenza vaccine  
          
Personal beliefs on 
the safety, efficacy or 
need for vaccine  
          
Lack of tools to 
promote influenza 
vaccinations  
          
 
34. From which of the following resources do you obtain most of the information you use when 
answering vaccine-related questions? 
[Rank the options in decreasing order of preference, 1 being the most used source of information 
and 10 the least. Drag and drop the options to re-arrange. Click and move an option to begin 
ranking] 
 
______ Peer reviewed articles  
______ Print media  
______ Social media and pharmacy blogs  
______ Pharmacist listservs (e.g. Pharmacy Immunization-Net, CANAPS-L, APhA-ASP)  
______ Colleagues  
______ Compendium of Pharmaceuticals and Specialties (CPS)  
______ Annual influenza guides (from PHAC, CDC WHO etc.)  
______ Regulatory and professional body websites and newsletters (e.g. OPA, OCP)  
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______ Online drug information resources (e.g. RxTx, UptoDate, Micromedex)  
______ Others (please specify):  
 
35. How confident do you feel answering patron’s questions about:  
 1  2  3  4  5  
Efficacy of the influenza vaccine            
Safety of the influenza vaccine            
Risk of contracting influenza            
Anti-vaccine positions            
Vaccines causing autism            
[If certified to administer vaccines] 
Your professional competence in providing the vaccine  
          
[If certified to administer vaccines] 
Ability to manage adverse reactions  
          
Pharmacy being a retail space where vaccinations are promoted for 
financial gains  
          
Collusion between government and pharmaceutical companies            
Other conspiracy theories            
 
[If certified to administer vaccines] 
36. Thinking back to the previous influenza seasons, rate your ability in each of the following: 
 1 2 3 4 5 
Identify a vaccine hesitant individual            
Determine the cause of hesitancy in such individuals           
Engage in hesitancy related conversations            
Respond to patrons’ vaccine hesitancy related concerns 
and beliefs  
          
Administer the influenza vaccine in healthy adults           
Administer the influenza vaccine in special populations 
(e.g. pregnant women, elderly etc.)  
          
Manage anaphylactic reactions following vaccination            
 
[If NOT certified to administer vaccines] 
37. Thinking back to the previous influenza seasons, rate your ability in each of the following: 
 1 2 3 4 5 
Identify a vaccine hesitant individual            
Determine the cause of hesitancy in such individuals            
Engage in hesitancy related conversations            
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Respond to patrons’ vaccine hesitancy related concerns 
and beliefs  
          
 
[If certified to administer vaccines] 
38. To what extent do each of the following form barriers to effective immunization service 
delivery in your community pharmacy? 
 1 2 3 4 5 
Time            
Lack of compensation to the immunizer            
Regular workflow            
Privacy for patrons           
Space            
Current pharmacy staffing            
Confidence in ability to administer vaccinations            
Quality of available immunization training            
Lack of vaccine hesitancy support resources           
 
39. If we were to design an initiative targeted at practicing community pharmacists to support 
them in effectively managing vaccine hesitancy, which of the following would best suit their 
needs?  
[Rank the options in decreasing order of preference, 1 being the most preferred and 9 the 
least. Drag and drop the options to re-arrange. Click and move an option to begin ranking] 
 
______ Communication frameworks  
______ Online continuing education program  
______ In-person regional workshop  
______ E-game based learning  
______ Promotional materials (e.g. vignettes, posters) for display in work-place  
______ Education resources for the health care professional  
______ Additional training on vaccine hesitancy incorporated into existing programs  
______ Simulation based training  
______ Others 
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Appendix B  
Participant demographics in relation to the Ontario pharmacist population at large 
Characteristics  Survey respondents 
n = 885 
n (%) 
Ontario pharmacists in 2016  
N = 14,952 
n (%) 
Sex 
Male 
Female 
 
190 (48.5%) 
202 (51.5%) 
 
6,299 (42.1%) 
8,653 (57.9%) 
Location 
Rural  
Urban  
 
25 (2.9%) 
841 (97.1%) 
 
969 (6.9%) 
13,106 (93.1%) 
Position 
Pharmacy Owner/Manger 
Staff pharmacist 
Other 
 
422 (48.2%) 
447 (51.1) 
 
 
4,232 (29.6%) 
9,128 (63.9%) 
919 (6.4%) 
Years of Practice 
0-10 
11-20 
>20 
 
107 (27.3%) 
84 (21.4%) 
201 (51.3%) 
 
4,450 (29.8%) 
3,625 (24.2%) 
6,877 (46.0%) 
 
Reference: 
1. Canadian Institute for Health Information. Pharmacists in Canada, 2016. December 2017. 
Available from https://secure.cihi.ca/free_products/PHARM-2016-data-tables-en-
web.xlsx. Accessed December 6, 2019. 
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Appendix C 
Semi structured interview guide 
- Welcome and introduction 
- Brief description of the purpose of study 
- Guidance on questions and how to respond to them: open dialogue, no judgement on what is 
said. 
- Assurance on data management: anonymity/confidentiality, data analysis and reporting. 
- Consent (written or recorded) 
- Respondent shares demographic data 
Demographics  
City/Town/Village of practice (name): 
Gender:  Male  Female Gender queer 
Injection trained? 
  Yes   No 
Received the influenza vaccine in 2015-16 influenza season? 
Yes   No 
Volume of prescriptions filled at primary site of practice? 
______Rx/day 
Workplace setup: 
 Chain  
 Independent  
 Franchise  
 Banner  
 Mass merchandiser/Food store  
 Other, please specify ___________________ 
 
 
Confirm for any additional queries before starting 
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Thank you for agreeing to this interview and completing the consent forms. As a reminder, the 
information that you share will remain confidential, there are no right answers and there shall be 
no judgement on what you say. Unless there are any questions, let’s begin. 
[Provide VH definition as a primer] 
1. In general, thinking of vaccine hesitancy and your work-place, what are the first thoughts that 
come to your mind? 
2. Do you come across vaccine hesitant individuals in your practice? 
 - Do you think it is important for the pharmacist to be concerned about vaccine 
hesitancy? (Why / Why not) 
 How involved are the pharmacists in the space of vaccine hesitancy? (Is it sufficient – 
Why/Why not) 
3. What approaches that you have utilized to manage vaccine hesitant individuals? 
 - Are they effective? 
4. Can you describe your most vivid experience with a vaccine hesitant individual at the 
pharmacy? 
 - Reasons stated 
 - Assessment of the individual? 
 - Approach taken 
 - Outcome 
5. In your opinion what could be the role of the pharmacist when engaging with a hesitant 
individual at his/her workplace?  
 - What is working? 
 - What’s not working? 
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6. If there were one or two key things (tools/approaches/resources/techniques/modifications) that 
could lead to improvement in your ability to better handle those hesitant, what would they be? 
Closing 
A. Is there anything you would like to add regarding the topics we have just discussed? 
B. Any last questions regarding this research? 
Debrief 
 Summarize the interview – provide chance for clarification/revision. 
 Reiterate use of data and anonymity. 
 Explain ways to access the final report, if interested. 
 Thank the pharmacist for time and consideration. 
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Appendix D  
Semi structured interviews 
Coding table 
# Name 
1 Pharmacists in vaccination 
1.1 Advocates of pharmacist administered injection service 
1.1.1 Additional vaccinations 
1.1.2 Convenience 
1.1.3 Enhanced Rx-Pt. relationship 
1.1.4 Pandemic preparedness 
1.1.5 Win-win 
1.2 Critical of pharmacists' administered injection service 
1.2.1 Conflict of interest 
1.2.2 Critical of UIIP 
1.2.3 Inefficient 
1.2.4 Poor implementation 
1.2.5 Technical task 
1.3 Perceived role in immunizations 
1.3.1 Education 
1.3.2 Enhancing public health 
1.3.3 Increasing accessibility 
1.3.4 Pandemic preparedness 
1.4 Vaccination delivery process 
2 Pharmacists' attitudes to influenza vaccine and vaccine hesitancy 
2.1 Attitudes towards vaccine hesitancy and those hesitant 
2.1.1 Dead end 
2.1.2 Patient autonomy 
2.1.3 Perceived severity 
2.2 Conflation of binary vaccine decision making 
2.3 Meaning of hesitancy 
2.4 Perceived impact on a hesitant individual’s vaccination decision 
2.4.1 Open mind 
2.4.2 Outcome 
 
Poor outcome 
 
Positive outcome 
 
Pre-made decision 
2.5 Perceived role in vaccine hesitancy 
2.5.1 Opportunity 
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2.5.2 Patient education 
2.5.3 Self-preparedness 
2.6 Perception of vaccine hesitancy continuum 
2.6.1 Continuum in practice 
2.6.2 Outcome 
2.6.3 Role of multiple HCPs 
2.6.4 Types of vaccination decisions 
2.7 Personal influenza vaccine attitudes 
2.7.1 Vaccine adopters 
2.7.2 Vaccine hesitant 
 
Credibility of information 
3 Pharmacists' experience of influenza vaccine hesitancy 
3.1 Description of a vaccine hesitant 
3.2 Experience anecdotes  
3.2.1 Anecdote - Negative outcome 
3.2.2 Anecdote - Positive outcome 
3.3 Frequency of vaccine hesitancy 
3.4 Pharmacists’ experience of vaccine hesitancy 
3.5 Reasons for vaccine hesitancy 
3.5.1 Reasons for vaccine hesitancy - Other HCPs 
3.5.2 Reasons for vaccine hesitancy - Patrons 
 
Complacency 
 
Fear of needles 
 
Foreign agents 
 
Misinformation 
 
Influenza from vaccine 
 
Religion 
 
Seeking info. 
 
Willingness to pay - NOT INFLUENZA 
4 Patient engagement on influenza vaccinations 
4.1 Business aspect 
4.2 Engagement style 
4.3 Passive engagement 
4.4 Rx-Pt relationship 
4.5 Technicality of engagement 
5 Addressing influenza vaccine hesitancy at the community pharmacy 
5.1 Barriers 
5.1.1 Barrier - Impact of corporates 
 
Push for 'walk-in' 
 
Volume 
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5.1.2 Barrier - Pharmacy specific 
 
Competing with other HCPs 
 
Existing workflow 
 
Manpower 
 
Not barriers - Space and Privacy 
 
Space 
 
Time 
5.1.3 Barrier - Remuneration 
 
Compared to other HCPs 
 
Immunization - Loss maker 
 
Pay for pharmacist 
5.1.4 Barriers - System, policy or regulatory 
 
Contradicting info. 
 
Paperwork 
 
Stock 
5.2 Current strategies 
5.2.1   Engagement 
5.2.2   Patient education 
5.2.5   Personal anecdote 
5.2.4   Promotional communication 
5.2.5   Self-reflection 
5.2.6   Social protection - Guilt 
5.3 Proposed strategies 
5.3.1   Communication tools 
5.3.2   Education for pharmacist 
5.3.3   Fiscal incentive 
5.3.4   Improved product access - Pre-filled syringes 
5.3.5   Proactive patient engagement 
5.3.6   Resource provision - Manpower 
5.3.7   Vaccine info. & promotion material 
5.4 Promoters for engagement in vaccinations 
5.4.1 Additional training 
5.4.2 Manpower 
5.4.3 Patient satisfaction 
5.4.4 Remuneration 
5.4.5 Time 
5.4.6 Tools 
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Appendix E 
Survey - Participant recruitment mail 
 
Dear Pharmacist, 
You are being contacted as you have previously indicated interest in participation in research purposes to OCP. The 
Ontario Pharmacist Research Collaboration (OPEN) is conducting a study to understand the knowledge, attitude and 
behaviour of community pharmacists towards influenza vaccine hesitancy in Ontario. OPEN has signed a data use 
agreement with OCP that enables researchers to contact potential participants through e-mail. The information from 
this study will help the investigators to provide recommendations and inform the development of tailored tools to 
address influenza vaccine hesitancy in the community pharmacy. 
In order to accomplish this, we are requesting your participation in an anonymous online survey, wherein you will 
not be asked for your name or any identifying information. This survey, intended for practicing community 
pharmacists of Ontario will take approximately 15-20 minutes to complete. It will contain questions of general 
demographics (your professional/site of practice characteristics), followed by your experience of influenza vaccine 
hesitancy at the community pharmacy. 
By clicking the link below, you will find a document that will inform you of your rights as a participant. Upon 
reviewing this information and providing consent, you will be redirected to the survey. 
*Survey link* 
Should you have any questions concerning the study, or have any problems accessing or completing it, please feel free 
to contact Gokul Raj Pullagura at 519-573-4040 (ext. 21371); grpullag@uwaterloo.ca or Nancy Waite at 519-888-
4484; nmwaite@uwaterloo.ca. 
We sincerely thank you for considering participation and appreciate the value of your time. 
Warm regards, 
Study investigators: 
 
 
Dr. Nancy Waite, PharmD, FCCP 
Professor,  
Co-lead OPEN program, 
School of Pharmacy,  
University of Waterloo 
Gokul Raj Pullagura, PharmD 
MSc. Candidate, 
Ontario Pharmacy Research Collaboration (OPEN), 
School of Pharmacy,  
University of Waterloo 
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Appendix F 
Survey - Participant information and consent letter 
 
Title of the study: 
Ontario community pharmacists’ knowledge, attitude and behaviour towards influenza vaccine 
hesitancy – An exploratory study 
You are invited to participate in a research study conducted by Gokul Raj Pullagura for a Master’s degree 
through the Ontario Pharmacist Research Collaboration (OPEN). OPEN is a multi-institutional research 
program funded by the government of Ontario that spans 4 universities and one research institution. The 
objectives of this research study are to explore Ontario pharmacist’s experience of influenza vaccine 
hesitancy at the community pharmacy.  
This survey, intended for practicing community pharmacists of Ontario will take approximately 15-20 
minutes to complete. Your participation is voluntary and you may decline to answer any questions or 
withdraw your participation at any time. There are no known or anticipated risks from participating in this 
study. The survey begins with demographic questions including details of your qualifications, and 
location of practice. The subsequent sections focus on your experience with influenza vaccine hesitancy 
at the community pharmacy. 
It is important for you to know that any information that you provide will be confidential and 
anonymous  ¸such that no name or identifying information shall be collected. All of the data will be 
summarized and no individual responses will be identifiable from these aggregate results.  
Although all efforts will be maintained, confidentiality may not be guaranteed when information is 
transmitted over the internet. University of Waterloo practices are to turn off functions that collect 
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machine identifiers such as IP addresses. The host of the system collecting the data such as Qualtrics™ 
may collect this information without our knowledge and make it accessible to us. Such information will 
not be used or saved without your consent. If you prefer not to submit your survey responses through this 
host, please contact one of the researchers (information provided below) so you can participate using an 
alternative method such as an e-mail or paper-based questionnaire. The alternate method may decrease 
anonymity but confidentiality will be maintained. 
The data collected from this study will be maintained on a password-protected computer database in a 
restricted access area of the university. As well, the data will be electronically archived after completion 
of the study and maintained for seven years and then erased. 
Should you have any questions about the study, please contact either Gokul Raj Pullagura 
(grpullag@uwaterloo.ca) or Nancy Waite (nmwaite@uwaterloo.ca). Further, if you would like to receive 
a copy of the results of this study, please contact either investigator.  
I would like to assure you that this study has been reviewed and received ethics clearance through a 
University of Waterloo Research Ethics Committee. However, the final decision about participation is 
yours. If you have any comments or concerns resulting from your participation in this study, please 
contact the Chief Ethics Officer, Office of Research Ethics, at 1-519-888-4567, ext. 36005 or ore-
ceo@uwaterloo.ca. 
Thank you for considering participation in this study.  
With full knowledge of all foregoing, I agree, of my own free will, to participate in this study. 
 
o I agree to participate 
 
o I do not wish to participate (you may close your web browser now) 
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Appendix G 
Survey - Participant thank you letter 
 
Dear Pharmacist, 
We would like to thank you for your participation in this study titled Ontario community pharmacists’ knowledge, 
attitude and behaviour towards influenza vaccine hesitancy – An exploratory study. 
As a reminder, the purpose of this study is to investigate the community pharmacists’ experience and perception of 
influenza vaccine hesitancy in regular practice. 
The data collected during the survey will contribute to a better understanding of the manifestation of vaccine 
hesitancy in the community pharmacy and shall help comprehend your needs to better address this issue in regular 
practice. Thereby, enabling a better and practical immunization service delivery that meets your requirements. 
Please remember that any data pertaining to you as an individual participant is anonymous and kept confidential. 
Once data is collected and analyzed, the aggregate information will be shared with the research community through 
seminar(s), conference(s), presentation(s), and journal article(s). If you are interested in receiving more information 
regarding the results of this study, or would like a summary of the results, please reach out to a study investigator 
and when the results become available (anticipated by Spring 2017), the information shall be sent to you. In the 
meanwhile, if you have any questions about the study, please do not hesitate to contact the researcher by email or 
telephone (contact information provided below). As with all University of Waterloo projects involving human 
participants, this project was reviewed by, and received ethics clearance through a University of Waterloo Research 
Ethics Committee. Should you have any comments or concerns resulting from your participation in this study, 
please contact the Chief Ethics Officer, Office of Research Ethics, at 1-519-888-4567, ext. 36005 or ore-
ceo@uwaterloo.ca. 
Regards, 
Dr. Nancy Waite, PharmD, FCCP 
Professor, 
School of Pharmacy,  
University of Waterloo, 
nmwaite@uwaterloo.ca 
(519)-888-4485  
Gokul Raj Pullagura, PharmD 
MSc. Candidate, 
School of Pharmacy,  
University of Waterloo, 
grpullag@uwaterloo.ca;  
(519)-888-4567 Ext. 21371 
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Appendix H 
Interview - Interest form 
 
Interview interest form 
Ontario community pharmacists’ knowledge, attitude and behaviour towards influenza 
vaccine hesitancy – An exploratory study 
All responses on this form are completely detached and cannot be linked back to your survey 
Name: 
E-mail address: 
Telephone number: 
 
A study researcher will contact you soon to confirm your interest and set-up the interview 
date, time and location.  
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Appendix I 
Survey – Reminder email 
 
 
Dear Pharmacist, 
This is a gentle reminder requesting your participation in a research study being conducted by the Ontario 
Pharmacy Research Collaboration (OPEN) that aims to explore your experience with influenza vaccine 
hesitancy at the community pharmacy and identify your requirements for the development of tailored tools 
to address this issue. 
[Please note: If you have already started the survey, you may resume it from the point of last complete 
response by clicking the link below]  
You are being contacted as you have previously indicated interest in participation in research purposes 
to OCP. OPEN has signed a data use agreement with OCP that enables researchers to contact potential 
participants through e-mail. The information from this study will help us to provide recommendations and 
inform the development of tailored tools to address influenza vaccine hesitancy in the community 
pharmacy. 
In order to accomplish this, we are requesting your participation in an anonymous online survey, wherein 
you will not be asked for your name or any identifying information. This survey, intended for practicing 
community pharmacists of Ontario will take approximately 10-15 minutes to complete. It will contain 
questions on general demographics (your professional/site of practice characteristics), followed by your 
experience of influenza vaccine hesitancy at the community pharmacy. 
By clicking the link below, you will find a document that will inform you of your rights as a participant. 
Upon reviewing this information and providing consent, you will be redirected to the survey. 
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Follow this link to the Survey: 
Or copy and paste the URL below into your internet browser:  
*Survey link* 
Should you have any questions concerning the study, or have any problems accessing or completing it, 
please feel free to contact Gokul Raj Pullagura at 519-573-4040 (ext. 21371); grpullag@uwaterloo.ca or 
Nancy Waite at 519-888-4484; nmwaite@uwaterloo.ca. 
We sincerely thank you for considering participation and appreciate the value of your time. 
Warm regards, 
Nancy Waite, PharmD, FCCP 
Associate Director, Clinical Education, 
Ontario College of Pharmacists Professor in Pharmacy Innovation,  
Professor, School of Pharmacy, 
University of Waterloo  
 
Gokul Raj Pullagura, PharmD 
MSc. Candidate, 
Ontario Pharmacy Research Collaboration (OPEN), 
School of Pharmacy, 
University of Waterloo 
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Appendix J 
Interview - Participant information package 
 
Title of the study: Ontario community pharmacists’ knowledge, attitude and behaviour towards 
influenza vaccine hesitancy – An exploratory study 
Dear Pharmacist, 
We at the Ontario Pharmacist Research Collaboration (OPEN) are conducting a research to understand 
influenza vaccine hesitancy at the community pharmacy. The goal of the study is to comprehend 
influenza vaccine hesitancy from the community pharmacists’ perspective and identify their requirements 
for the development of tailored tools to address this issue.  
Despite provision of free and accessible influenza vaccine to the public of Ontario, vaccine coverage has 
remained below target. Vaccine hesitancy has been identified as a barrier to vaccine uptake, however, 
very little is known about its manifestation in a community pharmacy. This study will try to explore and 
understand the factors that drive and differentiate influenza vaccine hesitancy at a community pharmacy 
setting. Researchers will produce recommendations that could potentially, utilizing the participants' input 
result in an improved pharmacist-patient engagement and outcomes on influenza vaccine hesitancy at the 
community pharmacy. 
If you agree, you will be asked to participate in a one-time interview that will take approximately 25-30 
minutes of your time. However, you should feel free to end the interview at any time you choose. As well, 
you may not feel obligated to answer any question that you prefer not to and may indicate that you do not 
wish to respond to a question at any time. If you choose to answer, brief demographic information such as 
location of practice, gender, workplace setup etc. shall be collected alongside the interview. With your 
permission, the interview will be digitally audio recorded to facilitate collection of information, and 
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transcription at a later stage for analysis. All information you provide is considered completely 
confidential. Your name will not appear in any reports resulting from this study, however, with your 
permission anonymous quotations may be used. The digital audio file of your interview will be in a 
password protected computer accessible only to authorized personnel. If you would like to receive a copy 
of the report, please indicate this to the researcher and you will be forwarded one upon completion of the 
study. 
This project has been reviewed by, and received ethics clearance through a University of Waterloo 
Research Ethics Committee. If you have any comments or concerns resulting from your participation in 
this study, please contact the Chief Ethics Officer, Office of Research Ethics, at 1-519-888-4567, ext. 
36005 or ore-ceo@uwaterloo.ca.  
Thank you for your willingness to share your experience and expertise. Your inputs help us learn more 
about influenza vaccine hesitancy at community pharmacies in Ontario. If you have further questions or 
concerns about the present research assignment, please feel free to contact Gokul Raj Pullagura 
(grpullag@uwaterloo.ca) or Nancy Waite (nmwaite.uwaterloo.ca).  
Sincerely, 
 
 
 
 
  
Dr. Nancy Waite, PharmD, FCCP 
Professor,  
Co-lead OPEN program, 
School of Pharmacy,  
University of Waterloo 
Gokul Raj Pullagura, PharmD 
MSc. Candidate, 
Ontario Pharmacy Research Collaboration (OPEN), 
School of Pharmacy,  
University of Waterloo 
 
 
  174 
Appendix K 
Interview – Consent forms 
 
Written consent of participation 
By signing this consent form, you are not waiving your legal rights or releasing the investigator(s) or involved 
institution(s) from their legal and professional responsibilities. 
I have read the information presented in the information letter about a research study titled ‘Ontario community 
pharmacists knowledge, attitude and behaviour towards influenza vaccine hesitancy – An exploratory study’, being 
conducted by Gokul Raj Pullagura under the supervision of Dr. Nancy Waite of the School of Pharmacy at the 
University of Waterloo. I have had the opportunity to ask any questions related to this study, to receive satisfactory 
answers to my questions related to this study, to receive satisfactory answers to my questions, and any additional 
details I wanted. I am aware that I may withdraw from the study without penalty at any time by advising the 
researchers of this decision. 
I am aware that I have the option of allowing my interview to be audio recorded to ensure an accurate recording of 
my responses. 
I am also aware that excerpts from the interview may be included in the thesis and/or publications to come from this 
research, with the understanding that the quotations will be anonymous. 
I was informed that I may withdraw my consent at any time without penalty by advising the researcher. 
This project has been reviewed by, and received ethics clearance through a University of Waterloo research ethics 
committee. I was informed that any comments or concerns resulting from my participation in this study can be 
directed to the Chief Ethics Officer, Office of Research Ethics, at 1-519-888-4567, ext. 36005 or ore-
ceo@uwaterloo.ca 
With full knowledge of all foregoing: 
Do you agree, of your own free will, to participate in this study? 
          YES  NO 
Do you agree to have your interview audio recorded? 
          YES  NO 
Do you agree to the use of anonymous quotations in any academic poster, presentation or publication that comes out 
of this research? 
          YES  NO 
 
_____________________          _____________________ 
Print name           Signature of the participant 
Date and location: _________________    Witnessed: _________________ 
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Verbal consent of participation 
By indicating your consent, you are not waiving your legal rights or releasing the investigator(s) or involved 
institution(s) from their legal and professional responsibilities. 
I have been presented with information about a research study titled ‘Ontario community pharmacists knowledge, 
attitude and behaviour towards influenza vaccine hesitancy – An exploratory study’, being conducted by Gokul Raj 
Pullagura under the supervision of Dr. Nancy Waite of the School of Pharmacy at the University of Waterloo. I have 
had the opportunity to ask any questions related to this study, to receive satisfactory answers to my questions related 
to this study, to receive satisfactory answers to my questions, and any additional details I wanted. I am aware that I 
may withdraw from the study without penalty at any time by advising the researchers of this decision. 
I am aware that I have the option of allowing my interview to be audio recorded to ensure an accurate recording of 
my responses. 
I have been informed that excerpts from the interview may be included in the thesis and/or publications to come 
from this research, with the understanding that the quotations will be anonymous. 
I have been informed that I may withdraw my consent at any time without penalty by advising the researcher. 
I have been informed that this project has been reviewed by, and received ethics clearance through a University of 
Waterloo research ethics committee. I have also been informed that any comments or concerns resulting from my 
participation in this study can be directed to the Chief Ethics Officer, Office of Research Ethics, at 1-519-888-4567, 
ext. 36005 or ore-ceo@uwaterloo.ca 
With full knowledge of all foregoing: 
Do you agree, of your own free will, to participate in this study? 
          YES  NO 
Do you agree to have your interview audio recorded? 
          YES  NO 
Do you agree to the use of anonymous quotations in any academic poster, presentation or publication that comes out 
of this research? 
          YES  NO 
Please state the following: 
 
_____________________            _____________________ 
First and last name          Signature of the person obtaining consent  
Date and location: _________________ 
Time: _________________  
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Appendix L 
Interview - Participant thank you letter 
 
Dear Pharmacist, 
We would like to thank you for your participation in this study titled Ontario community pharmacists’ knowledge, 
attitude and behaviour towards influenza vaccine hesitancy – An exploratory study. 
As a reminder, the purpose of this study is to investigate the community pharmacists’ experience and perception of 
influenza vaccine hesitancy in regular practice. 
The data collected during the interview will contribute to a better understanding of the manifestation of vaccine 
hesitancy in the community pharmacy and shall help comprehend your needs to better address this issue in regular 
practice. Thereby, enabling a better and practical immunization service delivery that meets your requirements. 
Please remember that any data pertaining to you as an individual participant will be kept confidential. Once data is 
collected and analyzed, the information will be shared with the research community through seminar(s), 
conference(s), presentation(s), and journal article(s). If you are interested in receiving more information regarding 
the results of this study, or would like a summary of the results, please reach out to a study investigator and when 
the results become available (anticipated by Spring 2017), the information shall be sent to you. In the meanwhile, if 
you have any questions about the study, please do not hesitate to contact the researcher by email or telephone 
(contact information provided below). As with all University of Waterloo projects involving human participants, this 
project was reviewed by, and received ethics clearance through a University of Waterloo Research Ethics 
Committee. If you have any comments or concerns resulting from your participation in this study, please contact the 
Chief Ethics Officer, Office of Research Ethics, at 1-519-888-4567, ext. 36005 or ore-ceo@uwaterloo.ca.  
Regards, 
 
 
Dr. Nancy Waite, PharmD, FCCP 
Professor, 
School of Pharmacy,  
University of Waterloo 
nmwaite@uwaterloo.ca 
(519)-888-4485  
 
 
Gokul Raj Pullagura, PharmD 
MSc. Candidate, 
School of Pharmacy,  
University of Waterloo 
grpullag@uwaterloo.ca 
(519)-888-4567 Ext21371 
 
 
